Updated on 2025/08/22

写真a

 
SOMEYA Masanori
 
Organization
School of Medicine Department of Radiology Professor
Title
Professor
ORCID ID
0000-0001-8821-7754
External link

Degree

  • 医学博士 ( 2005.3   札幌医科大学 大学院医学研究科 )

Research Interests

  • DNA損傷修復

  • 腫瘍免疫と放射線治療

  • 放射線腫瘍学

  • リキッドバイオプシー

Research Areas

  • Life Science / Radiological sciences

Education

  • Sapporo Medical University   Graduate School of Medicine

    2001.4 - 2005.3

      More details

    Country: Japan

    researchmap

  • Sapporo Medical University

    1991.4 - 1997.3

      More details

    Country: Japan

    researchmap

Research History

  • Department of Radiology, Sapporo Medical University   Professor

    2025.7

      More details

  • Sapporo Medical University   Associate Professor

    2020.10 - 2025.6

      More details

  • Sapporo Medical University   Lecturer

    2011.4 - 2020.9

      More details

    Country:Japan

    researchmap

  • Sapporo Medical University   Assistant Professor

    2007.4 - 2011.3

      More details

  • Sapporo Medical University   Research Assistant

    2005.8 - 2007.3

      More details

  • 札幌医科大学附属病院   放射線科   診療医

    1999.4 - 2005.7

      More details

    Country:Japan

    researchmap

  • 国立函館病院   放射線科   研修医

    1998.4 - 1999.3

      More details

  • 札幌医科大学附属病院   放射線科   研修医

    1997.4 - 1998.3

      More details

▼display all

Professional Memberships

▼display all

Committee Memberships

  • 日本放射線腫瘍学会生物部会   幹事  

    2023.6   

      More details

  • 日本バイオセラピィ学会   評議員  

    2022.6   

      More details

    Committee type:Academic society

    researchmap

  • 日本免疫治療学会   運営委員ジュニア  

    2022.4   

      More details

  • 日本膵臓学会   膵癌治療ガイドライン改訂委員  

    2017.9   

      More details

    Committee type:Academic society

    researchmap

  • 日本放射線腫瘍学会   JASTRO代議員  

    2010.10   

      More details

    Committee type:Academic society

    researchmap

Papers

  • Association between cancer immunity and treatment results in uterine cervical cancer patients treated with radiotherapy. Reviewed International journal

    Masanori Someya, Takaaki Tsuchiya, Yuki Fukushima, Tomokazu Hasegawa, Yu Takada, Masakazu Hori, Katsutoshi Miura, Mio Kitagawa, Toshio Gocho, Yoshihiko Hirohashi, Toshihiko Torigoe, Masahiro Iwasaki, Motoki Matsuura, Tsuyoshi Saito, Koh-Ichi Sakata

    Japanese journal of clinical oncology   50 ( 11 )   1290 - 1297   2020.10

     More details

    Authorship:Lead author, Corresponding author   Language:English   Publishing type:Research paper (scientific journal)   Publisher:Oxford University Press (OUP)  

    OBJECTIVE: To evaluate proteins related to tumor immune response and treatment outcome from radiotherapy for uterine cervical cancer patients. METHODS: We performed a retrospective immunohistochemical staining of 81 patients with uterine cervical cancer who underwent definitive radiotherapy. We examined the expression of programmed death ligand 1, human leukocyte antigen class I, tumor-infiltrating CD8+, and forkhead box P3+ (FoxP3+) T cells in tumor tissues. RESULTS: In biopsy specimen, patients with a higher number of CD8+ T cells and FoxP3+ T cells had a better disease-specific survival than patients with a lower number of CD8+ T cells and FoxP3+ cells (P = 0.018 and P = 0.009). Multivariate analysis showed that equivalent dose in 2 Gy fractions (EQD2) of the minimum dose to 90% of the high-risk clinical target volume, FoxP3+ T cells and expression of human leukocyte antigen class I were significant prognostic factors. When the EQD2 is 70 Gy or more, a higher local control rate is obtained regardless of the number of CD8- or FoxP3-positive cells. When EQD2 is <70 Gy, the number of CD8-positive cells has a significant impact on treatment outcome: the recurrence rate (local recurrence rate + distant metastasis rate) was 46.2% in the group with a CD8 value of 230 or higher, whereas the recurrence rate was 75.7% in the group with a CD8 value of less than 230. CONCLUSION: The combination of CD8 or FoxP3 with EQD2 can be potentially useful to predict the treatment results of radiotherapy for cervical cancer, leading to individualized optimal selection of treatment for cervical cancer.

    DOI: 10.1093/jjco/hyaa149

    PubMed

    researchmap

  • Retrospective DVH analysis of point A based intracavitary brachytherapy for uterine cervical cancer. Reviewed International journal

    Masanori Someya, Tomokazu Hasegawa, Takaaki Tsuchiya, Mio Kitagawa, Toshio Gocho, Yuuki Fukushima, Masakazu Hori, Katsutoshi Miura, Yu Takada, Kensei Nakata, Koh-Ichi Sakata

    Journal of radiation research   61 ( 2 )   265 - 274   2020.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Combining external beam radiotherapy (EBRT) with intracavitary brachytherapy (ICBT) is important for definitive treatment of cervical cancer. In cervical cancer patients receiving radiotherapy, we evaluated treatment outcomes in relation to dose-volume histogram parameters, including the computed tomography (CT)-based high-risk clinical target volume (HR-CTV) for ICBT. Between 2010 and 2015, 89 consecutive cervical cancer patients were mostly treated with 40 Gy of EBRT in 20 fractions and 18 Gy of ICBT prescribed to point A in 3 fractions. CT scans were obtained during ICBT. The HR-CTV D90 was calculated and the total doses of ICBT and EBRT were converted to the equivalent dose in 2 Gy fractions (EQD2). When the patients were divided into four groups according to EQD2 of the HR-CTV D90, the 3-year local recurrence-free survival rates were 95.2, 78.4, 52.7 and 42.9% for patients receiving >80 , 70-80 , 60-70 and <60 Gy, respectively. There was a significant negative correlation between EQD2 of the HR-CTV D90 and the HR-CTV volume at first ICBT (r = -0.713). Local recurrence was more frequent when the HR-CTV volume was ≥22 cc and EQD2 of the HR-CTV D90 was <70 Gy. Multivariate analysis showed that EQD2 of the HR-CTV D90 and concurrent chemotherapy (≥4 cycles) were significant determinants of overall survival. HR-CTV D90 was an important prognostic indicator for local recurrence. HR-CTV D90 >70 Gy is required for the better local control, especially in patients with a larger HR-CTV (≥22 cc at initial ICBT).

    DOI: 10.1093/jrr/rrz099

    PubMed

    researchmap

  • Prediction of acute gastrointestinal and genitourinary radiation toxicity in prostate cancer patients using lymphocyte microRNA. Reviewed International journal

    Masanori Someya, Masakazu Hori, Toshio Gocho, Kensei Nakata, Takaaki Tsuchiya, Mio Kitagawa, Tomokazu Hasegawa, Yuuki Fukushima, Koh-Ichi Sakata

    Japanese journal of clinical oncology   48 ( 2 )   167 - 174   2018.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Background: To search for novel biomarkers that can predict acute radiation toxicity, we conducted microRNA expression analysis of peripheral blood lymphocytes (PBLs). Methods: The discovery cohort was 69 patients with localized adenocarcinoma of the prostate who received intensity-modulated radiation therapy between October 2007 and October 2010. The validation cohort was 72 patients treated with low-dose-rate brachytherapy between May 2008 and March 2014. After13 microRNAs were selected by TaqMan® Array analysis in a preliminary experiment, expression of these microRNAs in all samples was analyzed by RT-PCR. Results: In the discovery cohort, the average prostate volume, the rectal volume receiving 70 Gy, and expression of miR-410 and miR-221 were significant risk factors for Grade 1-2 gastrointestinal toxicity. Receiver operating characteristic analysis showed that the area under the curve (AUC) was 0.807. The maximum dose to the urinary bladder, prostate volume, pretreatment urinary function score, and miR-99a and miR-221 expression were risk factors for Grade 2 genitourinary toxicity. The corresponding AUC was 0.796. In the validation cohort, reproducibility of these markers was confirmed for gastrointestinal toxicity, but not for genitourinary toxicity. Conclusion: Combining radiation dose parameters with microRNA expression in PBLs may be useful for predicting acute gastrointestinal toxicity of radiation therapy, thus contributing to personalized treatment of prostate cancer.

    DOI: 10.1093/jjco/hyx181

    PubMed

    researchmap

  • Local tumor control and DNA-PK activity of peripheral blood lymphocytes in prostate cancer patients receiving radiotherapy. Reviewed International journal

    Masanori Someya, Tomokazu Hasegawa, Masakazu Hori, Yoshihisa Matsumoto, Kensei Nakata, Naoya Masumori, Koh-Ichi Sakata

    Journal of radiation research   58 ( 2 )   225 - 231   2017.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Repair of DNA damage is critical for genomic stability, and DNA-dependent protein kinase (DNA-PK) has an important role in repairing double-strand breaks. We examined whether the DNA-PK activity of peripheral blood lymphocytes (PBLs) was related to biochemical (prostate-specific antigen: PSA) relapse and radiation toxicity in prostate cancer patients who have received radiotherapy. A total of 69 patients with localized adenocarcinoma of the prostate participated in this study. Peripheral blood was collected 2 years or later after radiotherapy and centrifuged, then DNA-PK activity was measured by a filter binding assay. The high DNA-PK activity group had a significantly higher PSA relapse-free survival rate than the low DNA-PK activity group. The 10-year PSA relapse-free survival was 87.0% in the high DNA-PK activity group, whereas it was 52.7% in the low DNA-PK activity group. Multivariate analysis showed the Gleason score and the level of DNA-PK activity were significant predictors of PSA relapse after radiotherapy. In addition, the low DNA-PK activity group tended to have a higher incidence of Grade 1-2 urinary toxicity than the high DNA-PK activity group. Prostate cancer patients with low DNA-PK activity had a higher rate of PSA relapse and a higher incidence of urinary toxicity. DNA-PK activity in PBLs might be a useful marker for predicting PSA relapse and urinary toxicity, possibly contributing to personalized treatment of prostate cancer.

    DOI: 10.1093/jrr/rrw099

    PubMed

    researchmap

  • Relation between Ku80 and microRNA-99a expression and late rectal bleeding after radiotherapy for prostate cancer. Reviewed International journal

    Masanori Someya, Hiroyuki Yamamoto, Masanori Nojima, Masakazu Hori, Kunihiko Tateoka, Kensei Nakata, Masaru Takagi, Masato Saito, Naoki Hirokawa, Takashi Tokino, Koh-Ichi Sakata

    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology   115 ( 2 )   235 - 9   2015.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.radonc.2015.04.008

    PubMed

    Web of Science

    researchmap

  • Results and DVH analysis of late rectal bleeding in patients treated with 3D-CRT or IMRT for localized prostate cancer. Reviewed International journal

    Masanori Someya, Masakazu Hori, Kunihiko Tateoka, Kensei Nakata, Masaru Takagi, Masato Saito, Naoki Hirokawa, Masato Hareyama, Koh-Ichi Sakata

    Journal of radiation research   56 ( 1 )   122 - 7   2015.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    In patients undergoing radiotherapy for localized prostate cancer, dose-volume histograms and clinical variables were examined to search for correlations between radiation treatment planning parameters and late rectal bleeding. We analyzed 129 patients with localized prostate cancer who were managed from 2002 to 2010 at our institution. They were treated with 3D conformal radiation therapy (3D-CRT, 70 Gy/35 fractions, 55 patients) or intensity-modulated radiation therapy (IMRT, 76 Gy/38 fractions, 74 patients). All radiation treatment plans were retrospectively reconstructed, dose-volume histograms of the rectum were generated, and the doses delivered to the rectum were calculated. Time to rectal bleeding ranged from 9-53 months, with a median of 18.7 months. Of the 129 patients, 33 patients had Grade 1 bleeding and were treated with steroid suppositories, while 25 patients with Grade 2 bleeding received argon plasma laser coagulation therapy (APC). Three patients with Grade 3 bleeding required both APC and blood transfusion. The 5-year incidence rate of Grade 2 or 3 rectal bleeding was 21.8% for the 3D-CRT group and 21.6% for the IMRT group. Univariate analysis showed significant differences in the average values from V65 to V10 between Grades 0-1 and Grades 2-3. Multivariate analysis demonstrated that patients with V65 ≥ 17% had a significantly increased risk (P = 0.032) of Grade 2 or 3 rectal bleeding. Of the 28 patients of Grade 2 or 3 rectal bleeding, 17 patients (60.7%) were cured by a single session of APC, while the other 11 patients required two sessions. Thus, none of the patients had any further rectal bleeding after the second APC session.

    DOI: 10.1093/jrr/rru080

    PubMed

    researchmap

  • Effects of depletion of dihydropyrimidine dehydrogenase on focus formation and RPA phosphorylation. Reviewed International journal

    Masanori Someya, Koh-ichi Sakata, Yoshihisa Matsumoto, Hiroshi Tauchi, Masahiro Kai, Masato Hareyama, Masakazu Fukushima

    Journal of radiation research   53 ( 2 )   250 - 6   2012

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase (DPYD), partially inhibits homologous recombination (HR) repair and has a radiosensitizing effect as well as enhanced sensitivity to Camptothecin (CPT). DPYD is the target protein for radiosensitization by Gimeracil. We investigated the mechanisms of sensitization of radiation and CPT by DPYD inhibition using DLD-1 cells treated with siRNA for DPYD. We investigated the focus formation of various kinds of proteins involved in HR and examined the phosphorylation of RPA by irradiation using Western blot analysis. DPYD depletion by siRNA significantly restrained the formation of radiation-induced foci of Rad51 and RPA, whereas it increased the number of foci of NBS1. The numbers of colocalization of NBS1 and RPA foci in DPYD-depleted cells after radiation were significantly smaller than in the control cells. These results suggest that DPYD depletion is attributable to decreased single-stranded DNA generated by the Mre11/Rad50/NBS1 complex-dependent resection of DNA double-strand break ends. The phosphorylation of RPA by irradiation was partially suppressed in DPYD-depleted cells, suggesting that DPYD depletion may partially inhibit DNA repair with HR by suppressing phosphorylation of RPA. DPYD depletion showed a radiosensitizing effect as well as enhanced sensitivity to CPT. The radiosensitizing effect of DPYD depletion plus CPT was the additive effect of DPYD depletion and CPT. DPYD depletion did not have a cell-killing effect, suggesting that DPYD depletion may not be so toxic. Considering these results, the combination of CPT and drugs that inhibit DPYD may prove useful for radiotherapy as a method of radiosensitization.

    PubMed

    researchmap

  • Immunohistochemical analysis of Ku70/86 expression of breast cancer tissues. Reviewed International journal

    Masanori Someya, Koh-ichi Sakata, Yoshihisa Matsumoto, Masaaki Satoh, Hideaki Narimatsu, Masato Hareyama

    Oncology reports   18 ( 6 )   1483 - 7   2007.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DNA-dependent protein kinase (DNA-PK) has an important role in DNA double-strand break repair. We previously demonstrated the association of DNA-PK activity in peripheral blood lymphocytes (PBL) with incidence of chromosomal aberrations and risk of cancer. In this study, we examined the expression of Ku70 and Ku86 in breast cancer tissue and normal breast tissue with immunohistochemistry. We also measured the DNA-PK activity in PBL of the same patient. One hundred and ten breast cancer patients were included in this study. The expression of Ku70, and Ku86 in normal mammary epithelial cells and breast cancer cells obtained from surgical specimens was immunohistochemically examined. DNA-PK activity of PBL was measured by DNA-pull-down assay. The expression of Ku70 and that of Ku86 tended to parallel each other in normal and cancer tissues. There was also a relationship in the expression of Ku70 and Ku86 between cancer tissues and normal tissues in the same samples. Lower expression of Ku70 or Ku86 tended to be associated with higher malignant nuclear grade of cancer cells and higher frequency of axillary lymph node metastasis. The staining score of Ku70 or Ku86 of normal mammary epithelial cells or breast cancer cells had no significant relationship with DNA-PK activity of PBL. In conclusion, breast cancer cells inherited the characteristics of expression of Ku proteins from original mammary epithelial cells. The staining score of Ku70 or Ku86 of normal or cancer cells had no significant relationship with DNA-PK activity of PBL. This may be due to limitations in the assay sensitivity of immunohistochemistry.

    PubMed

    researchmap

  • Association of DNA-PK activity and radiation-induced NBS1 foci formation in lymphocytes with clinical malignancy in breast cancer patients. Reviewed International journal

    Masanori Someya, Koh-Ichi Sakata, Yoshihisa Matsumoto, Hiroshi Tauchi, Hideaki Narimatsu, Masato Hareyama

    Oncology reports   18 ( 4 )   873 - 8   2007.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DNA double-strand break (DSB) is one of the most deleterious lesions induced by DNA damaging agents. DSB repair pathway is implicated in maintaining genomic integrity via suppression of genetic instability and neoplastic transformation. DNA-dependent protein kinase (DNA-PK) has a pivotal role in DNA DSB repair. The Nijmegen breakage syndrome protein (NBS1), essential for DSB repair, re-localizes into subnuclear structures upon induction of DNA damage by ionizing radiation, forming so-called ionizing radiation-induced foci (IRIF), which is visualized by immunostaining. We measured DNA-PK activity and the number of persistent NBS1 IRIF per nucleus 24 h after irradiation of peripheral blood lymphocytes (PBL) from patients with sporadic breast cancer. Chromosomal aberrations were examined by cytogenetic methods. We examined the relationship between these measurements and clinical characteristics of patients such as tumor size, lymph node metastasis and nuclear grade of cancer cells. A higher number of NBS1 IRIF or lower DNA-PK activity correlated with higher chromosome instability. Patients whose PBL had lower DNA-PK or higher NBS1 IRIF had aggressive cancer phenotypes such as a larger tumor, higher nuclear grade and positive axillary lymph node metastasis. The combination of DNA-PK activity and NBS1 IRIF were useful for predicting lymph node metastasis. The ability of DSB repair in PBL is related to aggressive breast cancer phenotypes. Axillary lymph node dissection can be avoided by examining DNA-PK activity and NBS1 IRIF of PBL, which can contribute to improving the quality of life of breast cancer patients.

    PubMed

    researchmap

  • Association of ionizing radiation-induced foci of NBS1 with chromosomal instability and breast cancer susceptibility. Reviewed International journal

    Masanori Someya, Koh-ichi Sakata, Hiroshi Tauchi, Yoshihisa Matsumoto, Asako Nakamura, Kenshi Komatsu, Masato Hareyama

    Radiation research   166 ( 4 )   575 - 82   2006.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    NBS1, a protein essential for DNA double-strand break repair, relocalizes into subnuclear structures upon induction of DNA damage by ionizing radiation, forming ionizing radiation-induced foci. We compared radiation-induced NBS1 foci in peripheral blood lymphocytes (PBLs) from 46 sporadic breast cancer patients and 30 healthy cancer-free volunteers. The number of persistent radiation-induced NBS1 foci per nucleus at 24 h after irradiation for patients with invasive cancer was significantly higher than for normal healthy volunteers. The frequency of spontaneous chromosome aberration increased as the number of persistent radiation-induced NBS1 foci increased, indicating that the number of persistent radiation-induced NBS1 foci might be associated with chromosome instability. There was also an inverse correlation between the number of radiation-induced NBS1 foci and the activity of DNA-dependent protein kinase (DNA-PK), which plays an important role in the nonhomologous end-joining (NHEJ) pathway, another mechanism of DNA DSB repair, indicating a close interrelationship between homologous recombination (HR) and NHEJ in DNA DSB repair. In conclusion, the number of persistent radiation-induced NBS1 foci is associated with chromosomal instability and risk of sporadic breast cancer and hence might be used to select individuals for whom a detailed examination is necessary because of their increased susceptibility to breast cancer, although refinement of the techniques for technical simplicity and accuracy will be required for clinical use.

    PubMed

    researchmap

  • The changes in irradiated salivary gland function of patients with head and neck tumors treated with radiotherapy. Reviewed International journal

    Masanori Someya, Koh-ichi Sakata, Hisayasu Nagakura, Kensei Nakata, Atsushi Oouchi, Masato Hareyama

    Japanese journal of clinical oncology   33 ( 7 )   336 - 40   2003.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: To investigate and analyze changes in irradiated salivary gland function of patients with head and neck tumors treated with radiotherapy. METHODS: Thirty-seven patients with head and neck tumors, who received 40-70 Gy of irradiation to all major salivary glands, were analyzed. The weights of saliva secreted for 10 minutes at rest, and for 5 minutes with vitamin C stimulation, were measured. The salivary gland function was defined by the weight of saliva. RESULTS: With vitamin C stimulation, the weight of saliva in patients whose doses were < or =50 Gy, was significantly higher than that of patients whose doses were > or = 58 Gy (2.48 +/- 0.33 g vs. 0.73 +/- 0.18 g, P = 0.0003). When doses administered to salivary glands were < or =50 Gy, the stimulated saliva secretion recovered over time, after irradiation. However, when the doses of irradiation were > or = 58 Gy, there was no recovery in saliva secretion even after a few years. Multiple regression analysis showed that age and chemotherapy may not affect salivary gland function even years after radiotherapy. CONCLUSION: When salivary glands were irradiated with doses < or =50 Gy, gradual recovery of salivary gland function was observed over time, whereas there was no significant recovery when the irradiation dose was >58 Gy.

    PubMed

    researchmap

  • Results of external irradiation and low-dose-rate intraluminal brachytherapy for esophageal cancer. Reviewed International journal

    Masanori Someya, Koh-ichi Sakata, Akio Saito, Hisayasu Nagakura, Atsushi Oouchi, Masato Hareyama

    Acta oncologica (Stockholm, Sweden)   41 ( 1 )   63 - 8   2002

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The results of definitive radiotherapy to elucidate the optimal doses of external irradiation (ERT) and low-dose-rate intraluminal brachytherapy (ILBT) were analyzed. Between 1979 and 1998, 100 patients with esophageal cancer were treated with ERT and ILBT. ERT was given at a dose of 40-65 Gy/25-32 fractions and ILBT at 10-24.3 Gy/2-3 fractions. The 5-year actuarial survival rate for all cases was 13% and that for patients with tumors of 5 cm or less in length was 22.64%, while for patients with tumors longer than 5 cm the rate was 5% (p < 0.005). In patients with tumors of 5 cm or less in length, the local control rate of those whose ILBT dose was 20 Gy or more was 83%, and for those with an ILBT dose of less than 20 Gy the control rate was 26.5% (p = 0.014). In patients with tumors of 5 cm or less in length, the results of treatment with 60 Gy ERT and 20 Gy ILBT were promising and did not cause severe late complications.

    PubMed

    researchmap

  • Japanese version of the MD Anderson Symptom Inventory for Head and Neck Tumor module: Validation study. International journal

    Hiroto Sawaguchi, Masanori Someya, Kensei Nakata, Yu Takada, Keiko Danzuka, Mitsunori Miyashita, Mikiko Kawamura

    Asia-Pacific journal of oncology nursing   12   100711 - 100711   2025.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: This study aimed to examine the reliability and validity of the Japanese version of the MD Anderson Symptom Inventory Head and Neck Tumor module (MDASI-HN), a patient-reported outcome measure for head and neck cancer. METHODS: The MDASI-HN was translated into Japanese, and cognitive debriefing was conducted. A cross-sectional study was administered to patients with head and neck cancer who were recruited within 5 years of receiving surgery, chemotherapy, or radiotherapy at three cancer treatment centers. The reliability and validity of the Japanese version were confirmed through structural equation modeling, internal consistency, test-retest reliability, convergent validity, known-groups validity. RESULTS: The Japanese translation of the MDASI-HN was revised with developer feedback. Cognitive debriefing with five patients provided positive feedback regarding the ease of completion and understanding. A cross-sectional sample of 147 patients completed the questionnaire. Structural equation modeling showed a Confirmatory Fit Index of 0.975 and Root Mean Square Error of Approximation of 0.059. The Cronbach's alpha coefficient was 0.88 for head and neck cancer-specific items and 0.96 for all symptom items. The Intraclass Correlation Coefficients (2,1) were 0.72 for HNC-specific items and 0.74 for all items. The convergent validity with the EORTC QLQ-H&N module was r ​= ​0.79. The known-groups validity showed small to moderate effect sizes for all subitems, based on the comparison of mean ECOG Performance Status Scale scores between the two groups. CONCLUSIONS: The results showed that the translated MSASI-HN was reliable, valid, and feasible for use in Japanese-speaking patients with head and neck cancer.

    DOI: 10.1016/j.apjon.2025.100711

    PubMed

    researchmap

  • Autoantibody spark response predicts treatment outcome in patients receiving chemoradiation followed by durvalumab therapy. International journal

    Takeru Mori, Mio Kitagawa, Tomokazu Hasegawa, Masanori Someya, Takaaki Tsuchiya, Toshio Gocho, Tomoko Honjo, Mirei Date, Mariko Morii, Ai Miyamoto, Junichiro Futami

    Scientific reports   15 ( 1 )   27502 - 27502   2025.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The PACIFIC regimen, comprising chemoradiotherapy (CRT) followed by maintenance with the immune checkpoint inhibitor (ICI) durvalumab, has become the standard of care for patients with unresectable non-small cell lung cancer (NSCLC). Although ICI is used to prevent recurrence by targeting residual microtumors, biomarkers capable of monitoring immune activity during this phase remain lacking. Here, we evaluated whether temporal changes in serum autoantibody levels can predict treatment efficacy. This retrospective study included 20 patients with unresectable stage II or III NSCLC who received the PACIFIC regimen. Serum autoantibodies against 130 antigens were quantified before CRT, after CRT, and two weeks after the first ICI dose. The primary outcome was progression-free survival (PFS), and its association with autoantibody dynamics was examined. We observed an immediate and strong autoantibody response (spark response [SR]) after ICI initiation in patients with favorable treatment outcomes. Patients with SR and programmed death ligand 1 (PD-L1) expression ≥ 50% showed better PFS (two-year PFS; 72.9% vs. 18.2%, p = 0.0021). These findings suggest that serial monitoring of serum autoantibodies can provide a noninvasive approach to assess immune activity and predict treatment outcomes in patients receiving CRT or ICI therapy.

    DOI: 10.1038/s41598-025-12069-5

    PubMed

    researchmap

  • Cisplatin intra-arterial chemotherapy for recurrent maxillary gingival cancer and metastatic lymph nodes without radiation or surgery: A case report International journal

    Akemi Ohtani, Masato Saito, Naoki Hirokawa, Hiroki Okuda, Hiroki Sato, Kenichiro Nitta, Shoh Mafune, Akihiro Miyazaki, Hironari Dehari, Masanori Someya

    Radiology Case Reports   20 ( 1 )   560 - 565   2025.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Most patients with head and neck cancers struggle with their treatment, particularly those with recurrent cancer. However, there is no consensus on effective treatments for recurrent head and neck cancer. Recurrent cases are often challenging to treat because performing both reirradiation and surgical intervention can occasionally be difficult. This report describes the effective cisplatin intra-arterial chemotherapy with oral S-1 for a recurrent case of maxillary gingival cancer (rT4bN1M0, rStage ⅣB). The patient who had undergone chemoradiotherapy 13 years ago and achieved complete response (CR) was referred to us due to recurrence. His recurrent lesions were located on the left maxillary bone, and a metastatic cervical lymph node was detected. We approached the feeder of the locoregional recurrence site using Seldinger's technique and repeated the cisplatin intra-arterial chemotherapy 5 times. As a result, we achieved a complete response, including the regional metastatic lymph node, without radiation or surgery. Notably, although we infused the anticancer drug into the feeder of the locoregional metastatic area, we noticed its effect on the metastatic cervical lymph node. Initially, neck dissection following intra-arterial chemotherapy had been planned; however, owing to the high effectiveness of the treatment, the subsequent surgery was deemed unnecessary. No evidence of recurrence has been observed during the 2.5-year follow-up period. In the future, intra-arterial chemotherapy can be an alternative option for patients with recurrent head and neck cancers, and our result seems to be enough to indicate that possibility.

    DOI: 10.1016/j.radcr.2024.10.081

    PubMed

    researchmap

  • A Japanese multi-institutional phase II study of moderate hypofractionated intensity-modulated radiotherapy with image-guided technique for prostate cancer.

    Katsumasa Nakamura, Keiji Nihei, Yoshihiro Saito, Naoto Shikama, Shin-Ei Noda, Ryusuke Hara, Toshiyuki Imagumbai, Takashi Mizowaki, Takeshi Akiba, Etsuo Kunieda, Masanori Someya, Saiji Ohga, Jiro Kawamori, Takuyo Kozuka, Yosuke Ota, Koji Inaba, Takeshi Kodaira, Yoshiyuki Itoh, Kouta Funakoshi, Yoshikazu Kagami

    International journal of clinical oncology   29 ( 6 )   847 - 852   2024.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: The aim of this multi-institutional phase II study was to confirm the safety and the potential efficacy of moderately hypofractionated intensity-modulated radiotherapy (IMRT) with prostate-based image-guidance for Japanese patients. METHODS: Patients with low- or intermediate-risk localized prostate cancer were eligible. Patients with a part of high risk (having only one of the following factors, cT3a, 20 < PSA ≤ 30, or GS = 8 or 9) were also included. Hypofractionated IMRT using daily image-guided technique with prostate matching was performed with a total dose of 70 Gy in 28 fractions. Neoadjuvant hormonal therapy for 4-8 months was mandatory for patients with intermediate or high-risk prostate cancer. RESULTS: From 20 institutions, 134 patients enrolled. The median follow-up was 5.16 years (range, 1.43-6.47 years). The number of patients with low, intermediate, and high-risk prostate cancer was 20, 80, and 34, respectively. The 5-year overall, biochemical failure-free, and clinical failure-free survival was 94.5%, 96.0%, and 99.2%, respectively. The 5-year biochemical failure-free survival for patients with low-, intermediate-, and high-risk disease was 94.1%, 97.4%, and 93.9%, respectively. The incidences of grade 2 gastrointestinal (GI) and genitourinary (GU) late toxicities at 5 years were 5.3% and 5.3%, respectively. There are no acute or late toxicities ≥ grade 3. Of 124 patients who were followed for up to 5 years, the grade 2 late GU or GI toxicities were 10.5% (90% confidence intervals, 6.3-16.2%, p = 0.0958). CONCLUSION: The safety and efficacy of moderately hypofractionated IMRT with prostate-based image-guidance was confirmed among Japanese patients with prostate cancer.

    DOI: 10.1007/s10147-024-02517-z

    PubMed

    researchmap

  • Notch signaling genes and CD8+ T-cell dynamics: Their contribution to immune-checkpoint inhibitor therapy in oral squamous cell carcinoma: A retrospective study. International journal

    Kazuhiro Ogi, Takahiro Iwamoto, Takashi Sasaya, Koyo Nishiyama, Takaaki Tokura, Takanori Sasaki, Hironari Dehari, Yohei Arihara, Kazuyuki Murase, Masato Saito, Masanori Someya, Kohichi Takada, Akihiro Miyazaki

    Cancer medicine   13 ( 5 )   e6985   2024.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Aberrant Notch signaling pathway has been related with the tumorigenesis in head and neck region, involving oral cavity. Here, we report the correlation between mutations in the Notch signaling pathway and CD8+ T-cell infiltration via PD-L1, which lead to enhanced antitumor immunity and may target for immune-checkpoint inhibitors (ICIs) therapy. METHODS: This retrospective study analyzed the results of immunohistochemical staining for PD-L1 and CD8+ T-cell infiltration in 10 patients and whole-exome sequencing (WES) was conducted on five of these patients to identify frequently mutated genes. RESULTS: Four of 10 patients were positive for PD-L1 and CD8+ T. By analyzing WES in three of these four patients, we notably identified the mutations of NOTCH1, FBXW7, and noncoding RNA intronic mutation in NOTCH2NLR in two of these three patients. This study may enable better selection of ICI therapy with CD8+ T-cell infiltration via PD-L1 expression for oral squamous cell carcinoma patients with mutations in Notch signaling pathway.

    DOI: 10.1002/cam4.6985

    PubMed

    researchmap

  • Identification and Quantification of Radiotherapy-related Protein Expression in Cancer Tissues Using the Qupath Software and Prediction of Treatment Response. International journal

    Tomokazu Hasegawa, Masanori Someya, Takaaki Tsuchiya, Mio Kitagawa, Yuki Fukushima, Toshio Gocho, Shoh Mafune, Ryuu Okuda, Juno Kaguchi, Atsuya Ohguro, Ryo Kamiyama, Ayato Ashina, Yuka Toshima, Yoshihiko Hirohashi, Toshihiko Torigoe, Koh-Ichi Sakata

    In vivo (Athens, Greece)   38 ( 3 )   1470 - 1476   2024

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: Automated measurement of immunostained samples can enable more convenient and objective prediction of treatment outcome from radiotherapy. We aimed to validate the performance of the QuPath image analysis software in immune cell markers detection by comparing QuPath cell counting results with those of physician manual cell counting. PATIENTS AND METHODS: CD8- and FoxP3-stained cervical, CD8-stained oropharyngeal, and Ku70-stained prostate cancer tumor sections were analyzed in 104 cervical, 92 oropharyngeal, and 58 prostate cancer patients undergoing radiotherapy at our Institution. RESULTS: QuPath and manual counts were highly correlated. When divided into two groups using ROC curves, the agreement between QuPath and manual counts was 89.4% for CD8 and 88.5% for FoxP3 in cervical cancer, 87.0% for CD8 in oropharyngeal cancer and 80.7% for Ku70 in prostate cancer. In cervical cancer, the high CD8 group based on QuPath counts had a better prognosis and the low CD8 group had a significantly worse prognosis [p=0.0003; 5-year overall survival (OS), 65.9% vs. 34.7%]. QuPath counts were more predictive than manual counts. Similar results were observed for FoxP3 in cervical cancer (p=0.002; 5-year OS, 62.1% vs. 33.6%) and CD8 in oropharyngeal cancer (p=0.013; 5-year OS, 80.2% vs. 47.2%). In prostate cancer, high Ku70 group had worse and low group significantly better outcome [p=0.007; 10-year progression-free survival (PFS), 56.0% vs. 93.8%]. CONCLUSION: QuPath showed a strong correlation with manual counting, confirming its utility and accuracy and potential applicability in clinical practice.

    DOI: 10.21873/invivo.13593

    PubMed

    researchmap

  • [RPT Doi Award: Virtual clinical trial based on outcome modeling with iteratively redistributed extrapolation data].

    Kohei Oguma, Taiki Magome, Masanori Someya, Tomokazu Hasegawa, Koh-Ichi Sakata

    Igaku butsuri : Nihon Igaku Butsuri Gakkai kikanshi = Japanese journal of medical physics : an official journal of Japan Society of Medical Physics   44 ( 3 )   52 - 52   2024

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.11323/jjmp.44.3_52

    PubMed

    researchmap

  • Prediction of Treatment Response Based on Nutritional Status and Tumor Immunity in Oropharyngeal Cancer Patients Treated With Chemoradiotherapy. International journal

    Mio Kitagawa, Juno Kaguchi, Masanori Someya, Yuki Fukushima, Tomokazu Hasegawa, Takaaki Tsuchiya, Toshio Gocho, Shoh Mafune, Yutaro Ikeuchi, Ryu Okuda, Atsuya Ohguro, Ryo Kamiyama, Ayato Ashina, Yuka Toshima, Yoshihiko Hirohashi, Toshihiko Torigoe, Koh-Ichi Sakata

    Cancer diagnosis & prognosis   4 ( 6 )   789 - 796   2024

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: Radiotherapy (RT) for advanced oropharyngeal cancer (OPC) is effective, especially when combined with chemotherapy (CRT). However, its success can vary depending on factors, such as tumor stage, HPV infection (p16 status), and the patient's nutritional and immune status. This study examined the controlling nutritional status (CONUT) score and tumor immunity as predictive factors for treatment outcomes in OPC, aiming to develop a personalized risk score. PATIENTS AND METHODS: A retrospective analysis was conducted on 84 patients with OPC treated with definitive RT or CRT, and survival outcomes were compared based on various factors, including BMI, CONUT score, CD8 expression, and HLA class II expression. RESULTS: We observed better overall survival (OS) rates in CD8-positive patients and those with higher HLA class II expression. The univariate analysis identified stage, p16 status, BMI, CONUT score, and CD8 expression as significantly associated with OS. In multivariate analysis, stage, BMI, and CONUT score remained significant predictors of OS. A risk scoring system was developed based on stage, p16 status, BMI, CONUT score, and CD8 expression. Patients were categorized into low-risk and high-risk groups, with significantly better survival in the low-risk group. CONCLUSION: A combined risk score incorporating clinical, nutritional, and immune factors can improve the prediction of treatment outcomes for OPC patients. This risk stratification may enable personalized treatment plans and improve ΟS rates.

    DOI: 10.21873/cdp.10397

    PubMed

    researchmap

  • Prediction of late adverse events in pelvic cancer patients receiving definitive radiotherapy using radiation-induced gamma-H2AX foci assay. International journal

    Masanori Someya, Tomokazu Hasegawa, Asako J Nakamura, Takaaki Tsuchiya, Mio Kitagawa, Toshio Gocho, Sho Mafune, Yutaro Ikeuchi, Hiroshi Tauchi, Koh-Ichi Sakata

    Journal of radiation research   64 ( 6 )   948 - 953   2023.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Radiation can induce DNA double-stranded breaks, which are typically detected by the fluorescence of phosphorylated histone H2AX. In this study, we examined the usefulness of the dynamics of radiation-induced gamma-H2AX foci of peripheral blood lymphocytes (PBLs), as a marker of DNA repair ability, in predicting late adverse events from radiotherapy. A total of 46 patients with cervical, vaginal and anal canal cancers treated with radical radiotherapy between 2014 and 2019 were included in this analysis. Concurrent chemotherapy was administered in 36 cases (78.3%). Peripheral blood was obtained before treatment, and then irradiated ex vivo with 1 Gy X-ray. The ratio of radiation-induced gamma-H2AX foci in PBLs measured at 30 min and at 4 h was defined as the foci decay ratio (FDR). With a median follow-up of 54 months, 9 patients (19.6%) were observed to have late genitourinary or gastrointestinal (GU/GI) toxicity. The FDR ranged from 0.51 to 0.74 (median 0.59), with a significantly higher incidence of Grade 1 or higher late adverse events in the FDR ≥ 0.59 group. In multivariate analysis, FDR ≥ 0.59 and hypertension also emerged as significant factors associated with the development of late toxicities. Overall, our results suggest that measurement of radiation-induced gamma-H2AX foci in PBLs may predict the risk of late GU/GI toxicities from chemoradiotherapy, which can enable tailoring the radiation dose to minimize adverse effects.

    DOI: 10.1093/jrr/rrad079

    PubMed

    researchmap

  • Analysis of treatment response with proteins related to tumor immunity in postoperative irradiated cervical cancer patients International journal

    Shoh Mafune, Masanori Someya, Tomokazu Hasegawa, Takaaki Tsuchiya, Mio Kitagawa, Toshio Gocho, Ryu Okuda, Masahiro Iwasaki, Motoki Matsuura, Terufumi Kubo, Yoshihiko Hirohashi, Toshihiko Torigoe, Tsuyoshi Saito, Koh-ichi Sakata

    Anticancer research   44 ( 7 )   3077 - 3086   2023.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: This study evaluated the association between programmed cell death-ligand 1 (PD-L1) and prognosis in patients with cervical cancer treated with postoperative radiation and the impact of neoadjuvant chemotherapy (NAC) on this association. PATIENTS AND METHODS: Immunohistochemical analysis was performed on biopsy specimens from 42 patients who did not receive NAC and from paired samples before (biopsies) and after (resected tissues) chemotherapy from 46 patients who received NAC to determine the association of PD-L1 with radiotherapy outcomes. RESULTS: In the non-NAC group, patients with ≥10% PD-L1-expressing tumor cells prior to treatment had better recurrence-free survival (RFS) than those with <10% PD-L1-expressing tumor cells (p=0.001). In the NAC group, RFS was significantly lower (p=0.005) in the group with a ≥5% reduction of PD-L1 expression in tumor cells after chemotherapy than in those with <5% reduction. In multivariate analysis, only PD-L1 expression (non-NAC group) and the change in PD-L1 expression (NAC group) were associated with RFS. CONCLUSION: Low PD-L1 expression in a cervical tumor prior to treatment was identified as a risk factor for a poor outcome after postoperative radiotherapy. Furthermore, NAC induces an immunological shift that reduces PD-L1 levels in tumor cells, thereby negatively impacting treatment outcomes.

    DOI: 10.21203/rs.3.rs-3574884/v1

    PubMed

    researchmap

  • 放射線感受性の個人差に基づく次世代の放射線治療と放射線防護 腫瘍および正常組織の放射線感受性予測に基づいた個別化放射線治療の実践(Personalized radiotherapy based on the prediction of radiosensitivity of tumors and normal tissues)

    Someya Masanori, Hasegawa Tomokazu, Tsuchiya Takaaki, Kitagawa Mio, Gocho Toshio, Mafune Shoh, Sakata Koh-ichi

    日本放射線影響学会大会講演要旨集   66回   12 - 12   2023.11

     More details

    Language:English   Publisher:(一社)日本放射線影響学会  

    Ichushi

    researchmap

  • Immunohistological evaluation of patients treated with intra-arterial chemoradiotherapy and surgery for oral cancer.

    Yutaro Ikeuchi, Masanori Someya, Tomokazu Hasegawa, Masato Saito, Shoh Mafune, Takaaki Tsuchiya, Mio Kitagawa, Toshio Gocho, Hironari Dehari, Kazuhiro Ogi, Takanori Sasaki, Yoshihiko Hirohashi, Toshihiko Torigoe, Naoki Hirokawa, Akihiro Miyazaki, Koh-Ichi Sakata

    Medical molecular morphology   56 ( 4 )   288 - 296   2023.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Preoperative intra-arterial chemoradiotherapy (IACRT) can improve the outcome and reduce the extent of surgery in patients with advanced oral cancer. However, the response to this regimen varies among patients, which may be related to the immune status of the tumor. We investigated the effects of proteins involved in tumor immunity on the outcomes of combined IACRT and surgery for oral cancer. We examined CD8 + and FoxP3 + tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression on immune cells and tumor cells in pretreatment biopsy samples from 69 patients diagnosed with oral cancer treated with IACRT at our institution during 2000-2020. Patients with abundant CD8 + TILs had significantly better 5-year disease-specific survival (DSS) compared to that of patients with less infiltration of these cells (P = 0.016). Patients with higher FoxP3 + T-cells invasion had significantly better DSS compared to that of less FoxP3 (P = 0.005). Patients with high PD-L1 expression in tumor cells and immune cells had significantly better DSS than that of patients with low PD-L1 expression in these cells (P = 0.009 and P = 0.025, respectively). Collectively, these results suggest that the tumor immune microenvironment could affect outcomes of IACRT treatment in oral cancer.

    DOI: 10.1007/s00795-023-00367-8

    PubMed

    researchmap

  • 【膵癌診療ガイドライン2022改訂のポイント】放射線療法

    伊藤 芳紀, 中村 聡明, 大栗 隆行, 染谷 正則, 篠藤 誠

    膵臓   38 ( 2 )   121 - 126   2023.4

  • Virtual clinical trial based on outcome modeling with iteratively redistributed extrapolation data.

    Kohei Oguma, Taiki Magome, Masanori Someya, Tomokazu Hasegawa, Koh-Ichi Sakata

    Radiological physics and technology   16 ( 2 )   262 - 271   2023.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Virtual clinical trials (VCTs) can potentially simulate clinical trials on a computer, but their application with a limited number of past clinical cases is challenging due to the biased estimation of the statistical population. In this study, we developed ExMixup, a novel training technique based on machine learning, using iteratively redistributed extrapolated data. Information obtained from 100 patients with prostate cancer and 385 patients with oropharyngeal cancer was used to predict the recurrence after radiotherapy. Model performance was evaluated by developing outcome prediction models based on three types of training methods: training with original data (baseline), interpolation data (Mixup), and interpolation + extrapolation data (ExMixup). Two types of VCTs were conducted to predict the treatment response of patients with distinct characteristics compared to the training data obtained from patient cohorts categorized under risk classification or cancer stage. The prediction models developed with ExMixup yielded concordance indices (95% confidence intervals) of 0.751 (0.719-0.818) and 0.752 (0.734-0.785) for VCTs on the prostate and oropharyngeal cancer datasets, respectively, which significantly outperformed the baseline and Mixup models (P < 0.01). The proposed approach could enhance the ability of VCTs to predict treatment results in patients excluded from past clinical trials.

    DOI: 10.1007/s12194-023-00715-4

    PubMed

    researchmap

  • 末梢血リンパ球TCRレパトア解析を用いたNSCLCの治療効果予測(Prediction of Treatment Response in NSCLC using Peripheral Blood Lymphocyte TCR Repertoire Analysis)

    Someya Masanori, Hasegawa Tomokazu, Kitagawa Mio, Tsuchiya Takaaki, Fukushima Yuki, Gocho Toshio, Mafune Shou, Kanaseki Takayuki, Tokita Serina, Sakata Koh-ichi

    日本医学放射線学会学術集会抄録集   82回   S173 - S173   2023.3

     More details

    Language:English   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • Combined chemoradiotherapy and programmed cell death-ligand 1 blockade leads to changes in the circulating T-cell receptor repertoire of patients with non-small-cell lung cancer. International journal

    Masanori Someya, Serina Tokita, Takayuki Kanaseki, Mio Kitagawa, Tomokazu Hasegawa, Takaaki Tsuchiya, Yuki Fukushima, Toshio Gocho, Yoh Kozuka, Shoh Mafune, Yutaro Ikeuchi, Mamoru Takahashi, Keigo Moniwa, Kazuhiko Matsuo, Tadashi Hasegawa, Toshihiko Torigoe, Koh-Ichi Sakata

    Cancer science   113 ( 12 )   4394 - 4400   2022.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Combined chemoradiotherapy (CRT) and programmed cell death-ligand 1 (PD-L1) blockade is a new care standard for unresectable stage III non-small-cell lung cancer (NSCLC). Although this consolidation therapy has improved the overall survival of patients with NSCLC, the synergistic action mechanisms of CRT and immunotherapy on T cells remain unclear. In addition, there is a paucity of reliable biomarkers to predict clinical responses to therapy. In this study, we analyzed T-cell receptor (TCR) sequences in the peripheral blood of five patients with NSCLC. T-cell receptor analysis was undertaken before treatment, after CRT, and after PD-L1 blockade. Notably, we observed the expansion and alteration of the dominant T-cell clonotypes in all cases with a complete response. In contrast, neither expansion nor alteration of the TCR repertoire was observed in cases with progressive disease. T cell expansion was initiated after CRT and was further enhanced after PD-L1 blockade. Our findings suggest the systemic effect of CRT on circulating T cells in addition to the curative effect on limited tumor sites. Dynamic changes in circulating T-cell clonotypes could have a prognostic significance for combined CRT and PD-L1 blockade.

    DOI: 10.1111/cas.15566

    PubMed

    researchmap

  • Predictive value of an exosomal microRNA-based signature for tumor immunity in cervical cancer patients treated with chemoradiotherapy.

    Masanori Someya, Tomokazu Hasegawa, Takaaki Tsuchiya, Mio Kitagawa, Yuki Fukushima, Toshio Gocho, Shoh Mafune, Yutaro Ikeuchi, Yoh Kozuka, Masashi Idogawa, Yoshihiko Hirohashi, Toshihiko Torigoe, Masahiro Iwasaki, Motoki Matsuura, Tsuyoshi Saito, Koh-Ichi Sakata

    Medical molecular morphology   56 ( 1 )   38 - 45   2022.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Resistance of cervical cancer to radiotherapy with concurrent chemotherapy (CCRT) results in a poor prognosis. To identify new biomarkers for predicting the treatment response and prognosis, we explored exosomal microRNA (miRNA) expression signatures associated with the outcome of cervical cancer patients treated with CCRT. Exosomes were isolated from the plasma of 45 patients prior to CCRT during 2014-2020, and miRNA analysis was performed by next-generation sequencing. At a median follow-up of 38 months, 26 patients were recurrence free, 15 patients had died of the disease, and 4 patients received salvage chemotherapy due to distant metastasis. Of the 2522 miRNAs detected, 9 (miR-148a-5p, 1915-3p, 3960, 183-5p, 196b-5p, 200c-3p, 182-5p, 374a-5p, and 431-5p) showed differential expression between the recurrence-free and recurrence groups. Patients were divided into high- and low-risk groups according to the cutoff of the miRNAs-based risk score calculated from respective expression levels. The high-risk group had significantly worse disease-specific survival than the low-risk group (p < 0.001). In addition, miR-374a-5p and miR-431-5p expression showed a weak inverse correlation with tumor-infiltrating CD8+ and FOXP3+ T cells, suggesting a potential inhibitory effect on CCRT by suppressing tumor immunity. This miRNA signature could improve non-invasive monitoring and personalized treatment for cervical cancer.

    DOI: 10.1007/s00795-022-00338-5

    PubMed

    researchmap

  • Clinical and histopathologic effects of neoadjuvant intra-arterial chemoradiotherapy with cisplatin in combination with oral S-1 on stage III and IV oral cancer. International journal

    Kazushige Koike, Nobuhide Ohashi, Koyo Nishiyama, Junya Okamoto, Takanori Sasaki, Kazuhiro Ogi, Hironari Dehari, Naoki Hirokawa, Masanori Someya, Masato Saito, Hiroki Okuda, Akemi Otani, Tomoko Sonoda, Taro Sugawara, Tadashi Hasegawa, Hiroyoshi Hiratsuka, Koh-Ichi Sakata, Akihiro Miyazaki

    Oral surgery, oral medicine, oral pathology and oral radiology   134 ( 3 )   347 - 353   2022.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: The aim of this study was to examine the clinical and histopathologic effects of neoadjuvant intra-arterial chemoradiotherapy (IACRT) using cisplatin in combination with oral S-1 (tegafur/gimeracil/oteracil potassium) on stage III and IV oral squamous cell carcinoma. STUDY DESIGN: Thirty patients received infusions of superselective intra-arterial cisplatin 60 mg/m2 by the Seldinger method and conventional external beam radiotherapy (total 40 Gy) combined with oral S-1 on the day of irradiation. Curative surgery and neck dissection were performed 4 to 6 weeks after IACRT. The clinical response of the primary lesion was evaluated approximately 4 weeks after IACRT. The surgically resected specimens were examined for histologic features according to the grading system for histologic evaluation and for residual tumor grade (RGrades). RESULTS: Histopathologic evaluation of the therapeutic effect was grade 2 in 10 patients and grade 3 in 16 patients. According to the distribution of RGrades, the remaining tumor cells were mostly in the central area of the primary lesion, as seen in 24 patients. CONCLUSIONS: These findings indicate that neoadjuvant IACRT with cisplatin and oral S-1 was an effective treatment, suggesting the possibility of reducing the extent of curative surgery based on RGrades.

    DOI: 10.1016/j.oooo.2022.04.042

    PubMed

    researchmap

  • Delayed-onset abscopal effect after palliative radiotherapy for acral melanoma treated with anti-PD-1 therapy. International journal

    Hiroshi Sasaki, Junji Kato, Kohei Horimoto, Sayuri Sato, Yuna Hosokawa, Toshiya Handa, Eri Kobayashi, Kazuki Furudate, Haruka Sigyo, Takaaki Tsuchiya, Masanori Someya, Hisashi Uhara

    The Journal of dermatology   49 ( 8 )   e255-e256   2022.3

     More details

  • Radiotherapy for HPV-related cancers: prediction of therapeutic effects based on the mechanism of tumor immunity and the application of immunoradiotherapy.

    Masanori Someya, Yuki Fukushima, Tomokazu Hasegawa, Takaaki Tsuchiya, Mio Kitagawa, Toshio Gocho, Shoh Mafune, Yutaro Ikeuchi, Yoh Kozuka, Yoshihiko Hirohashi, Toshihiko Torigoe, Masahiro Iwasaki, Motoki Matsuura, Tsuyoshi Saito, Koh-Ichi Sakata

    Japanese journal of radiology   40 ( 5 )   458 - 465   2022.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Human papillomavirus (HPV)-related cancer is one of the diseases entities for which the applications of radiotherapy have been increasing. Recently, the process of carcinogenesis from HPV infection and the mechanism of tumor immunity that develops during disease progression have been elucidated. In this review, we will describe the mechanism of tumor immunity and how chemoradiotherapy may overcome and improve the efficacy of tumor immunity. We will also discuss the usefulness of proteins involved with tumor immunity as a predictive marker of radiotherapy response, and present an overview of ongoing clinical trials of combinations of immune checkpoint inhibitors and radiotherapy to demonstrate the promising combination therapy that has been currently emerging.

    DOI: 10.1007/s11604-021-01231-4

    PubMed

    researchmap

  • Stiff coils enhance shape retention and pressure resistance in an aneurysm model even at low volume. International journal

    Hiroki Okuda, Naoki Hirokawa, Masato Saitoh, Akemi Otani, Masanori Someya, Yoko Usami, Koh-Ichi Sakata

    Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy   31 ( 5 )   1 - 10   2021.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: To elucidate the characteristics of 3 D frame coils and identify the optimal coil for visceral aneurysms. MATERIAL AND METHODS: Using a vascular model, we compared the postembolization coil distribution and repulsive force of three coils: Guglielmi detachable coil (GDC; stock wire diameter, 0.004 in; primary diameter, 0.015 in), Target XL (0.003, 0.014), and Target XXL (0.003, 0.017). Additionally, the coil area, roundness, and center of gravity were quantitatively compared. The coil repulsive force was measured by compressing the postembolization vessel model with a digital force gauge. RESULTS: There were no significant differences in the coil area and roundness among the three coil types. Compared with the Target coils, the GDC deployed evenly along the vessel wall, its center of gravity was less displaced, and although it had the lowest embolic density, its repulsive force was greater regardless of the number of coils used. CONCLUSIONS: GDC coils with a larger stock wire diameter and a smaller primary diameter unfolded evenly along the wall and had a greater repulsive force. Coil stiffness contributes to coil stability and shape retention, indicating the possibility of preventing recurrence by selecting a frame coil with a focus on coil stiffness.

    DOI: 10.1080/13645706.2021.1980051

    PubMed

    researchmap

  • Prediction of treatment response from the microenvironment of tumor immunity in cervical cancer patients treated with chemoradiotherapy.

    Masanori Someya, Takaaki Tsuchiya, Yuki Fukushima, Tomokazu Hasegawa, Masakazu Hori, Mio Kitagawa, Toshio Gocho, Shoh Mafune, Yutaro Ikeuchi, Yoshihiko Hirohashi, Toshihiko Torigoe, Masahiro Iwasaki, Motoki Matsuura, Tsuyoshi Saito, Yoshihisa Matsumoto, Koh-Ichi Sakata

    Medical molecular morphology   54 ( 3 )   245 - 252   2021.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    To supplement clinical decision-making in the management of cervical cancer, various prognostic factors, including tumor immune microenvironments, were examined in patients with cervical cancer treated with definitive chemoradiotherapy. We retrospectively analyzed the expression of CD8, FoxP3, HLA-1, PD-L1, and XRCC4 in 100 cases of cervical cancer. The observed tumor immune microenvironments were also classified into three types: inflamed, excluded, and cold type. Less FoxP3+ T cells and cold-type tumor were found to be poor prognostic factors in addition to non-SCC, large pre-treatment tumor volume, and three or less cycles of concurrent chemotherapy based on multivariate analysis. Cold-type tumors had significantly worse prognoses than the other two types, whereas inflamed- and excluded-type tumors showed similar 5-year disease-specific survival (P < 0.001; 0% vs. 60.3% vs. 72.3%). Radiotherapy could overcome the inhibitory immune microenvironment that occurs in excluded type. Individualized combination therapy adapted to pre-treatment tumor immunity may be necessary to improve radiotherapy outcomes in cervical cancer.

    DOI: 10.1007/s00795-021-00290-w

    PubMed

    researchmap

  • 肛門管癌に対するS-1+MMCを用いた化学放射線療法

    池内 佑太郎, 福島 悠希, 眞船 翔, 小塚 陽介, 土屋 高旭, 長谷川 智一, 堀 正和, 染谷 正則, 坂田 耕一

    北海道放射線医学雑誌   1   22 - 26   2021.3

     More details

    Language:Japanese   Publisher:(NPO)メディカルイメージラボ  

    Ichushi

    researchmap

  • Association between radiotherapy-induced alteration of programmed death ligand 1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy. Reviewed International journal

    Takaaki Tsuchiya, Masanori Someya, Yu Takada, Tomokazu Hasegawa, Mio Kitagawa, Yuki Fukushima, Toshio Gocho, Masakazu Hori, Kensei Nakata, Yoshihiko Hirohashi, Toshihiko Torigoe, Tsuyoshi Saito, Koh-Ichi Sakata

    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]   196 ( 8 )   725 - 735   2020.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: To evaluate radiotherapy-induced changes in the expression of programmed death ligand 1 (PD-L1), programmed death 1 (PD-1), and human leukocyte antigen class I (HLA-1) in patients with uterine cervical cancer, as well as infiltration of CD8+ and Forkhead box P3+ (FoxP3+) T lymphocytes into tumor tissue and the prognostic value of these parameters. MATERIALS AND METHODS: We performed immunohistochemical analysis of pre-radiotherapy biopsies and corresponding post-radiotherapy resected tissues in 104 uterine cervical cancer patients undergoing preoperative chemoradiotherapy or radiotherapy alone. We scored the expression of various proteins to distinguish positive from negative samples. RESULTS: PD-L1-expressing tumor cells (PD-L1 TC) increased significantly after chemoradiotherapy (p = 0.043). CD8+ T cell infiltration (p = 0.002) and FoxP3+ T cell infiltration (p = 0.003) decreased significantly after chemoradiotherapy. Expression of PD‑1, PD-L1-expressing immune cells (PD-L1 IC), and HLA‑1 did not change after chemoradiotherapy. In biopsy specimens obtained before chemoradiotherapy or radiotherapy, greater infiltration of CD8+ T cells (p = 0.001) and FoxP3+ T cells (p = 0.003) were significant predictors of better overall survival (OS). In surgical specimens obtained after chemoradiotherapy or radiotherapy, greater infiltration of PD-L1 TC was the only significant predictor of better OS (p < 0.001) and was related to a significantly lower probability of out-of-field recurrence (p = 0.005). CONCLUSION: Chemoradiotherapy induced an immunologic shift that increased PD-L1 TC. Chemoradiotherapy has immunological effects that can influence the results of treatment for uterine cervical cancer.

    DOI: 10.1007/s00066-019-01571-1

    PubMed

    researchmap

  • Prediction of Results of Radiotherapy With Ku70 Expression and an Artificial Neural Network Reviewed International journal

    TOMOKAZU HASEGAWA, MASANORI SOMEYA, MASAKAZU HORI, TAKAAKI TSUCHIYA, YUUKI FUKUSHIMA, YOSHIHISA MATSUMOTO, KOH-ICHI SAKATA

    In Vivo   34 ( 5 )   2865 - 2872   2020.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.21873/invivo.12114

    PubMed

    Web of Science

    researchmap

  • Evaluation of the urethral alpha/beta ratio and tissue repair half-time for iodine-125 prostate brachytherapy with or without supplemental external beam radiotherapy International journal

    Toshio Gocho, Masakazu Hori, Yuuki Fukushima, Masanori Someya, Mio Kitagawa, Tomokazu Hasegawa, Takaaki Tsuchiya, Masato Hareyama, Masaru Takagi, Kohei Hashimoto, Naoya Masumori, Koh-ichi Sakata

    BRACHYTHERAPY   19 ( 3 )   290 - 297   2020.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.brachy.2020.02.007

    PubMed

    Web of Science

    researchmap

  • Chemotherapy after progression on nivolumab is essential for responders with genetic alterations of driver gene: Review of two recurrent/metastatic oral squamous cell carcinoma patients. Reviewed International journal

    Kazuhiro Ogi, Junichi Kobayashi, Takafumi Nakagaki, Junya Okamoto, Kazushige Koike, Naoki Hirokawa, Masanori Someya, Hiroki Sakamoto, Kohichi Takada, Takashi Tokino, Yasushi Sasaki, Hiroyoshi Hiratsuka, Akihiro Miyazaki

    Oral oncology   102   104509 - 104509   2020.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Elsevier {BV}  

    DOI: 10.1016/j.oraloncology.2019.104509

    PubMed

    researchmap

  • 放射線治療を施行した進行子宮頸癌患者における腫瘍免疫と生存の関連性(Association between tumor Immunity and survival in patients with advanced uterine cervical cancer treated with raiotherapy)

    Someya Masanori, Hasegawa Tomokazu, Tsuchiya Takaaki, Fukushima Yuuki, Kitagawa Mio, Hori Masakazu, Sakata Koh-ichi, Takada Yu, Nakata Kensei, Miura Katsutoshi

    日本医学放射線学会学術集会抄録集   79回   S176 - S176   2020.2

     More details

    Language:English   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • Phase 2 Study of Neoadjuvant Treatment of Sequential S-1-Based Concurrent Chemoradiation Therapy Followed by Systemic Chemotherapy with Gemcitabine for Borderline Resectable Pancreatic Adenocarcinoma (HOPS-BR 01). Reviewed International journal

    Tsuyoshi Hayashi, Toru Nakamura, Yasutoshi Kimura, Makoto Yoshida, Masanori Someya, Hiroshi Kawakami, Yusuke Sakuhara, Norio Katoh, Kuniyuki Takahashi, Yoshiyasu Ambo, Katsutoshi Miura, Masayo Motoya, Eiichi Tanaka, Katsuhiko Murakawa, Takumi Yamabuki, Hajime Yamazaki, Akio Katanuma, Satoshi Hirano

    International journal of radiation oncology, biology, physics   105 ( 3 )   606 - 617   2019.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Elsevier {BV}  

    PURPOSE: Preoperative treatment is recommended for borderline resectable pancreatic ductal adenocarcinoma. However, the standard treatment has not yet been determined. We conducted a multicenter phase 2 study to investigate the efficacy of neoadjuvant treatment of sequential chemoradiation followed by chemotherapy. METHODS AND MATERIALS: All enrolled patients were treated by preoperative chemoradiation (a total dose of 50.4 Gy in 28 fractions and orally administered S-1 at 80 mg/m2 on the day of irradiation) followed by chemotherapy (administration of gemcitabine at 1000 mg/m2/dose on days 1, 8, and 15 in 3 cycles of 4 weeks) and attempted curative resection. The primary outcome was an R0 resection rate among patients who completed preoperative treatment and pancreatectomy. The threshold of the R0 resection rate was defined as 74% based on a previous study of up-front surgery. RESULTS: Forty-five patients were included. Twenty-one patients could not undergo pancreatectomy because of progressive diseases (n = 14), adverse events (n = 5), or consent withdrawal (n = 2), and 4 patients underwent additional resection after dropping out. The resection rates were 53.3% and 62.2% in the per-protocol set (PPS) and full analysis set (FAS) populations, respectively. The R0 resection rates were 95.8% (95% confidence interval, 78.9%-99.9%) and 96.4% (81.7%-99.9%) in the PPS and FAS populations, respectively. The median overall survival and progression-free survival of all the included patients were 17.3 and 10.5 months, respectively. The median survival time of the patients with pancreatectomy was significantly longer than that of the patients without pancreatectomy in the PPS (27.9 vs 12.3 months; P = .001) and FAS populations (32.2 vs 11.8 months; P < .001). CONCLUSIONS: This study revealed that a long duration of preoperative treatment of sequential chemoradiation followed by systemic chemotherapy provides a high rate of R0 resection and sufficient survival time in patients undergoing pancreatectomy.

    DOI: 10.1016/j.ijrobp.2019.07.004

    PubMed

    researchmap

  • Influence of XRCC4 expression by breast cancer cells on ipsilateral recurrence after breast-conserving therapy. Reviewed International journal

    Mio Kitagawa, Masanori Someya, Tomokazu Hasegawa, Toshihiko Mikami, Kazuaki Asaishi, Tadashi Hasegawa, Yoshihisa Matsumoto, Goro Kutomi, Ichiro Takemasa, Koh-Ichi Sakata

    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]   195 ( 7 )   648 - 658   2019.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: We examined the expression of nonhomologous end-joining (NHEJ) proteins by breast cancer cells in patients with or without ipsilateral breast tumor recurrence (IBTR) after breast-conserving therapy. We also investigated whether there was a difference of NHEJ-related protein expression by tumor cells between two types of IBTR, i.e., true recurrence (TR) with regrowth from the tumor bed or development of a new primary tumor (NP). PATIENTS AND METHODS: The original cohort comprised 560 breast cancer patients who received breast-conserving therapy between February 1995 and March 2006, including 520 patients without IBTR and 40 patients with IBTR. Propensity score matching was employed to select 40 trios (120 patients) consisting of 1 patient with IBTR and 2 patients without IBTR. Immunohistochemical examination of proteins related to NHEJ was performed in surgical specimens. RESULTS: The 40 patients with IBTR included 22 patients who developed TR and 18 who had NP. The 15-year overall survival rate was 85.9% for patients with NP and 95.5% for those with TR, while it was 96.5% for patients without IBTR. Patients with high XRCC4 expression in tumor cells had significantly higher IBTR rates than those with low XRCC4 expression (P < 0.001). The frequency of TR was significantly higher in patients with high expression of XRCC4 than in those with low XRCC4 expression (p < 0.001). XRCC4 expression by tumor cells was not significantly related to development of NP. CONCLUSION: IBTR due to TR may be related to low radiosensitivity of tumor cells, possibly related to high XRCC4 expression.

    DOI: 10.1007/s00066-019-01468-z

    PubMed

    researchmap

  • Histopathological differences of experimental aneurysms treated with bare platinum, fibered, and bioactive coils. Reviewed International journal

    Yoko Usami, Naoki Hirokawa, Masato Saitoh, Hiroki Okuda, Masanori Someya, Tadashi Hasegawa, Yasunari Takakuwa, Koh-Ichi Sakata

    Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy   28 ( 3 )   172 - 177   2019.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: To evaluate the histopathological features of experimental aneurysms embolized with bare platinum, fibered, and bioactive coils. MATERIAL AND METHODS: Twelve experimental aneurysms were constructed in three swine. The aneurysms were divided into four groups and were embolized using a bare platinum coil alone (P group, n = 2), a bioactive coil alone (B group, n = 2), a combination of fibered and bare platinum coils (F/P group, n = 4) and a combination of fibered and bioactive coils (F/B group, n = 4). Histopathological data for all aneurysms recorded at 63 days were analyzed in terms of neointima formation, fibrosis, foreign-body giant-cell infiltration, and organization. RESULTS: Fibrosis was significantly greater in group B compared with that in group F/P (p = .02). Inflammation with foreign-body giant-cell infiltration was significantly greater in groups F/P and F/B compared with that in groups P and B (p = .007). CONCLUSION: The present study revealed that the embolic effect of fibered coils was not a thrombus but instead was a foreign-body response in the chronic phase.

    DOI: 10.1080/13645706.2018.1499532

    PubMed

    researchmap

  • Efficacy of combined radiotherapy and anti-programmed death 1 therapy in acral and mucosal melanoma. Reviewed International journal

    Junji Kato, Tokimasa Hida, Masanori Someya, Sayuri Sato, Masahide Sawada, Kohei Horimoto, Mao Fujioka, Tomoyuki Minowa, Yoshiyuki Matsui, Takaaki Tsuchiya, Mio Kitagawa, Kensei Nakata, Koh-Ichi Sakata, Toshihiko Torigoe, Hisashi Uhara

    The Journal of dermatology   46 ( 4 )   328 - 333   2019.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/1346-8138.14805

    PubMed

    Web of Science

    researchmap

  • Successful rechallenge with nivolumab therapy after radiotherapy in mucosal melanoma. Reviewed International journal

    Junji Kato, Tokimasa Hida, Kohei Horimoto, Sayuri Sato, Keiju Kobayashi, Masahide Sawada, Mao Fujioka, Takaaki Tsuchiya, Masanori Someya, Hisashi Uhara

    The Journal of dermatology   46 ( 2 )   e72-e73 - e73   2019.2

     More details

  • 当院で腔内照射を施行した子宮頸癌の線量解析(DVH Analysis of Intracavitary Brachytherapy for Uterine Cervical Cancer)

    Someya Masanori, Hasegawa Tomokazu, Tsuchiya Takaaki, Kitagawa Mio, Gocho Toshio, Fukushima Yuuki, Takada Yu, Miura Katsutoshi, Hori Masakazu, Sakata Koh-ichi

    日本医学放射線学会学術集会抄録集   78回   S264 - S264   2019.2

     More details

    Language:English   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • Influence of PD-L1 expression in immune cells on the response to radiation therapy in patients with oropharyngeal squamous cell carcinoma. Reviewed International journal

    Yuki Fukushima, Masanori Someya, Kensei Nakata, Masakazu Hori, Mio Kitagawa, Tomokazu Hasegawa, Takaaki Tsuchiya, Toshio Gocho, Hikaru Ikeda, Yoshihiko Hirohashi, Toshihiko Torigoe, Shintaro Sugita, Tadashi Hasegawa, Tetsuo Himi, Koh-Ichi Sakata

    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology   129 ( 2 )   409 - 414   2018.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND AND PURPOSE: To investigate influences of proteins involved with tumor immunity on outcomes of radiotherapy for oropharyngeal squamous cell carcinoma (OPSCC). MATERIAL AND METHODS: We performed immunohistochemical staining to examine expressions of p16 and proteins involved with tumor immunity in 92 OPSCC patients treated with radiotherapy. RESULTS: Patients with abundant infiltrating CD8-positive cells had the significantly better overall survival (OS) rate than patients with fewer CD8-positive cells (p = 0.026). Patients with higher PD-L1 expression in tumor cells (TC 1-3) had a better outcome than those with low PD-L1 expression in tumor cells (TC 0) for both OS (p = 0.019) and progression-free survival (PFS) rate (p = 0.032). Patients with high PD-L1 expression in infiltrating immune cells (IC 3) showed significantly better OS (p = 0.009) and PFS (p = 0.011) than those with low PD-L1 expression (IC 0-2). Patients with p16-negative and IC 3 showed similar OS to patients with p16-positive and IC 0-2. P16-positive tumors had a significantly higher CD8-positive cell infiltration and PD-L1 expression in tumor cells than p16-negative tumors. CONCLUSIONS: In addition to tumor p16 expression, PD-L1 expression in TC and IC can be useful for predicting the response of OPSCC to radiotherapy.

    DOI: 10.1016/j.radonc.2018.08.023

    PubMed

    researchmap

  • Differential diagnosis between intraductal papillary mucinous neoplasm with an associated invasive carcinoma and pancreatic ductal adenocarcinoma on ultrasonography: the utility of echo intensity and contrast enhancement. Reviewed International journal

    Masato Saito, Naoki Hirokawa, Yoko Usami, Masanori Someya, Koh-Ichi Sakata

    Ultrasonography (Seoul, Korea)   36 ( 3 )   260 - 269   2017.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Korean Society of Ultrasound in Medicine  

    PURPOSE: The aim of this study was to investigate the utility of echo intensity and contrast enhancement in the differential diagnosis between intraductal papillary mucinous neoplasm with an associated invasive carcinoma (IPMN-IC) and pancreatic ductal adenocarcinoma (PDAC) on ultrasonography. METHODS: This study included eight and 37 patients who had pathologically confirmed IPMN-IC and PDAC, respectively, and were enrolled for a comparative analysis of the sonographic features of the tumors. In the quantitative echo intensity evaluation, the two groups were compared with respect to the difference between the tumor intensity and the pancreatic intensity (TI-PI) and between the tumor intensity and the vascular intensity (TI-VI). In the quantitative contrast enhancement evaluation, the increase in echo intensity (ΔTI) and increase in echo intensity per unit of time (slope) were compared between the groups. The echo intensity and contrast enhancement were also compared between the two groups in patients with T3-T4 disease. In addition, the correlations of the histological type, tumor size, stromal type, and T factor with echogenicity and contrast enhancement were analyzed. RESULTS: IPMN-IC had significantly greater echo intensity and contrast enhancement than PDAC (TI-PI, P=0.004; TI-VI, P=0.001; ΔTI, P=0.012; slope, P=0.002). In T3-T4 disease, IPMN-IC also showed greater echo intensity and faster enhancement than PDAC. Echo intensity and contrast enhancement were correlated with histological type (TI-PI, P=0.003; TI-VI, P<0.001; ΔTI, P=0.007; slope, P<0.001). CONCLUSION: IPMN-IC and PDAC can be differentiated by the quantitative evaluation of echo intensity and contrast enhancement.

    DOI: 10.14366/usg.16039

    PubMed

    researchmap

  • Influence of XRCC4 expression in esophageal cancer cells on the response to radiotherapy. Reviewed

    Masakazu Hori, Masanori Someya, Yoshihisa Matsumoto, Kensei Nakata, Mio Kitagawa, Tomokazu Hasegawa, Takaaki Tsuchiya, Yuki Fukushima, Toshio Gocho, Yasushi Sato, Hiroyuki Ohnuma, Junji Kato, Shintaro Sugita, Tadashi Hasegawa, Koh-Ichi Sakata

    Medical molecular morphology   50 ( 1 )   25 - 33   2017.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DNA double-strand break (DSB) is one of the most serious forms of damage induced by ionizing irradiation and is mainly repaired by the non-homologous end joining (NHEJ) repair. Immunohistochemical analysis of proteins involved in NHEJ, such as XRCC4 (X-ray repair cross-complementing protein 4), Ku86 and DNA-PKcs (DNA-dependent protein kinase, catalytic subunits), may be useful for predicting tumor radiosensitivity. We examined 92 patients with esophageal squamous cell carcinoma (ECSS) who were treated by radiotherapy between 1999 and 2008. Immunohistochemical examination of tumor tissue for Ki-67 and DSB-related proteins, including XRCC4, Ku86, and DNA-PKcs, was performed using pretreatment biopsy specimens. Low expression of XRCC4 was detected in 31 of 92 examined samples (33.7 %). The 5-year overall survival (OS) rate was 67.7 % in the low expression group and 31.0 % in the high expression group (P = 0.00). Multivariate analysis confirmed that advanced T-stage (HR 3.24, P = 0.01), radiation dose less than 66 Gy (HR 2.23, P = 0.02), absence of systemic chemotherapy (HR 2.59, P = 0.05), and high expression of XRCC4 (HR 12.0, P = 0.02) were independent prognostic factors for predicting poor OS. Other DSB-related proteins and Ki-67 were not predictive factors. XRCC4 expression might have an influence on results of radiotherapy for patients with ESCC.

    DOI: 10.1007/s00795-016-0144-5

    PubMed

    researchmap

  • Expression of Ku70 predicts results of radiotherapy in prostate cancer. Reviewed International journal

    Tomokazu Hasegawa, Masanori Someya, Masakazu Hori, Yoshihisa Matsumoto, Kensei Nakata, Masanori Nojima, Mio Kitagawa, Takaaki Tsuchiya, Naoya Masumori, Tadashi Hasegawa, Koh-Ichi Sakata

    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]   193 ( 1 )   29 - 37   2017.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND AND PURPOSE: Therapeutic strategy for prostate cancer is decided according to T stage, Gleason score, and prostate-specific antigen (PSA) level. These clinical factors are not accurate enough to predict individual risk of local failure of prostate cancer after radiotherapy. Parameters involved with radiosensitivity are required to improve the predictive capability for local relapse. PATIENTS AND METHODS: We analyzed 58 patients with localized adenocarcinoma of the prostate between August 2007 and October 2010 treated with 76 Gy of intensity-modulated radiotherapy (IMRT) as a discovery cohort and 42 patients between March 2001 and May 2007 treated with three-dimensional conformal radiotherapy (3D-CRT) as a validation cohort. Immunohistochemical examination for proteins involved in nonhomologous end-joining was performed using biopsy specimens. RESULTS: Ku70 expression was not correlated with various clinical parameters, such as the Gleason score and D'amico risk classification, indicating that Ku70 expression was an independent prognostic factor. The predictive value for PSA relapse was markedly improved after the combination of Gleason score and Ku70 expression, as compared with Gleason score alone. In patients treated with radiotherapy and androgen deprivation therapy (ADT), no relapses were observed in patients with Gleason score ≤7 or low Ku70 expression. In contrast, patients with Gleason score ≥8 and high Ku70 expression had high PSA relapse rates. In the validation cohort, similar results were obtained. CONCLUSION: Treatment with 76 Gy and ADT can be effective for patients with Gleason score ≤7 or low Ku70 expression, but is not enough for patients with Gleason score ≥8 and high Ku70 expression and, thus, require other treatment approaches.

    DOI: 10.1007/s00066-016-1023-7

    PubMed

    researchmap

  • Influence of Ku86 and XRCC4 expression in uterine cervical cancer on the response to preoperative radiotherapy. Reviewed

    Yu Takada, Masanori Someya, Yoshihisa Matsumoto, Masaaki Satoh, Kensei Nakata, Masakazu Hori, Masato Saito, Naoki Hirokawa, Kunihiko Tateoka, Mizue Teramoto, Tsuyoshi Saito, Tadashi Hasegawa, Koh-Ichi Sakata

    Medical molecular morphology   49 ( 4 )   210 - 216   2016.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00795-016-0136-5

    PubMed

    Web of Science

    researchmap

  • A Phase 1/2 Study of Definitive Chemoradiation Therapy Using Docetaxel, Nedaplatin, and 5-Fluorouracil (DNF-R) for Esophageal Cancer. Reviewed International journal

    Hiroyuki Ohnuma, Yasushi Sato, Masahiro Hirakawa, Yutaka Okagawa, Takahiro Osuga, Tsuyoshi Hayashi, Tsutomu Sato, Koji Miyanishi, Masayoshi Kobune, Rishu Takimoto, Tamotsu Sagawa, Masakazu Hori, Masanori Someya, Kensei Nakata, Koh-Ichi Sakata, Tetsuji Takayama, Junji Kato

    International journal of radiation oncology, biology, physics   93 ( 2 )   382 - 90   2015.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: Patient survival in esophageal cancer (EC) remains poor. The purpose of this study was to investigate a regimen of definitive chemoradiation therapy (CRT) that exerts good local control of EC. We performed a phase 1/2 study to assess the safety and efficacy of CRT with docetaxel, nedaplatin, and 5-fluorouracil (DNF-R). METHODS AND MATERIALS: Eligible patients presented with stage IB to IV EC. Patients received 2 cycles of docetaxel (20, 30, or 40 mg/m(2)) and nedaplatin (50 mg/m(2)) on days 1 and 8 and a continuous infusion of 5-fluorouracil (400 mg/m(2)/day) on days 1 to 5 and 8 to 12, every 5 weeks, with concurrent radiation therapy (59.4 Gy/33 fractions). The recommended dose (RD) was determined using a 3 + 3 design. RESULTS: In the phase 1 study, the dose-limiting toxicities were neutropenia and thrombocytopenia. The RD of docetaxel was determined to be 20 mg/m(2). In the phase 2 study, grade 3 to 4 acute toxicities included neutropenia (42.8%), febrile neutropenia (7.14%), thrombocytopenia (17.9%), and esophagitis (21.4%). Grade 3 to 4 late radiation toxicity included esophagostenosis (10.7%). The complete response rate was 82.1% (95% confidence interval: 67.9-96.3%). Both the median progression-free survival and overall survival were 41.2 months. CONCLUSIONS: DNF-R showed good tolerability and strong antitumor activity, suggesting that it is a potentially effective therapeutic regimen for EC.

    DOI: 10.1016/j.ijrobp.2015.05.041

    PubMed

    researchmap

  • Analysis of Prostate Deformation during a Course of Radiation Therapy for Prostate Cancer. Reviewed International journal

    Takuya Nakazawa, Kunihiko Tateoka, Yuichi Saito, Tadanori Abe, Masaki Yano, Yuji Yaegashi, Hirokazu Narimatsu, Kazunori Fujimoto, Akihiro Nakata, Kensei Nakata, Masanori Someya, Masakazu Hori, Masato Hareyama, Koichi Sakata

    PloS one   10 ( 6 )   e0131822   2015

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: Accurate analysis of the correlation between deformation of the prostate and displacement of its center of gravity (CoG) is important for efficient radiation therapy for prostate cancer. In this study, we addressed this problem by introducing a new analysis approach. METHOD: A planning computed tomography (CT) scan and 7 repeat cone-beam CT scans during the course of treatment were obtained for 19 prostate cancer patients who underwent three-dimensional conformal radiation therapy. A single observer contoured the prostate gland only. To evaluate the local deformation of the prostate, it was divided into 12 manually defined segments. Prostate deformation was calculated using in-house developed software. The correlation between the displacement of the CoG and the local deformation of the prostate was evaluated using multiple regression analysis. RESULTS: The mean value and standard deviation (SD) of the prostate deformation were 0.6 mm and 1.7 mm, respectively. For the majority of the patients, the local SD of the deformation was slightly lager in the superior and inferior segments. Multiple regression analysis revealed that the anterior-posterior displacement of the CoG of the prostate had a highly significant correlation with the deformations in the middle-anterior (p < 0.01) and middle-posterior (p < 0.01) segments of the prostate surface (R2 = 0.84). However, there was no significant correlation between the displacement of the CoG and the deformation of the prostate surface in other segments. CONCLUSION: Anterior-posterior displacement of the CoG of the prostate is highly correlated with deformation in its middle-anterior and posterior segments. In the radiation therapy for prostate cancer, it is necessary to optimize the internal margin for every position of the prostate measured using image-guided radiation therapy.

    DOI: 10.1371/journal.pone.0131822

    PubMed

    researchmap

  • Phase I study of oral S-1 and concurrent radiotherapy in patients with head and neck cancer. Reviewed International journal

    Kensei Nakata, Koh-Ichi Sakata, Masanori Someya, Katsutoshi Miura, Junichi Hayashi, Masakazu Hori, Masaru Takagi, Tetsuo Himi, Atsushi Kondo, Masato Hareyama

    Journal of radiation research   54 ( 4 )   679 - 83   2013.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    This study investigated the maximum tolerated dose (MTD) of S-1 with concurrent radiotherapy in patients with head and neck cancer, based on the frequency of dose-limiting toxicities (DLT). S-1 was administered orally at escalating doses from 40 mg/m(2) b.i.d. on the days of delivering radiotherapy, which was given at a total dose of 64-70 Gy in 32-35 fractions over 6-7 weeks. A total of 12 patients (3 patients at 40 mg/m(2), 6 patients at 60 mg/m(2), and 3 patients at 80 mg/m(2)) were enrolled in this trial. At the dose of 80 mg/m(2), two of the three patients developed DLT (Grade 3 anorexia and rhabdomyolysis) due to S-1, so the MTD was determined to be 80 mg/m(2). Among the 12 enrolled patients, 9 (75%) showed a complete response and 3 (25%) showed a partial response. The overall response rate was 100%. The recommended dose of S-1 with concurrent radiotherapy is 60 mg/m(2).

    DOI: 10.1093/jrr/rrs133

    PubMed

    researchmap

  • Analysis and results of Ku and XRCC4 expression in hypopharyngeal cancer tissues treated with chemoradiotherapy. Reviewed International journal

    Jyunichi Hayashi, Koh-Ichi Sakata, Masanori Someya, Yoshihisa Matsumoto, Masaaki Satoh, Kensei Nakata, Masakazu Hori, Masaru Takagi, Atsushi Kondoh, Tetsuo Himi, Masato Hareyama

    Oncology letters   4 ( 1 )   151 - 155   2012.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DNA double-strand break (DSB) is one of the most serious forms of damage induced by ionizing irradiation. Non-homologous end-joining (NHEJ) is a key mechanism of DNA DSB repair. The immunohistochemical analysis of proteins involved in NHEJ may have potential as a predictive assay for tumor radiosensitivity. We examined the correlation between the expression of proteins involved in DNA DSB in biopsy specimens and the results of chemoradiotherapy in hypopharyngeal cancers. Fifty-seven patients with previously untreated squamous cell carcinoma of the hypopharynx were treated between March 2002 and December 2009. Most patients (75%) had stage III or IV disease. The chemotherapy consisted of cisplatin plus 5FU or S-1. A tumor dose of 50 Gy was usually administered to the primary tumor and regional lymph nodes. Doses of 10-20 Gy were usually added to the primary tumor with reduced fields after 50 Gy. The 5-year disease-free survival rate was 100% for patients in stage I, 90% in stage II, 64% in stage III and 50% in stage IV. In stages I-III, patients with a lower expression of Ku70 or XRCC4 tended to have better locoregional control. These results indicated that a lower expression of Ku70 or XRCC4 may be correlated with higher radiosensitivity. Two patients had distant metastasis alone, of which one had 0% expression of Ku70 and the other had 0% expression of Ku86. The absence of Ku70 or Ku86 expression indicates low DNA-PK activity. Low DNA-PK activity due to a low expression of Ku may result in the genetic alteration of cancer cells, leading to a higher tendency of distant metastasis. This finding suggests that proteins involved in NHEJ may have an impact on the treatment results of chemoradiotherapy in hypopharyngeal cancer.

    PubMed

    researchmap

  • The combination of olaparib and camptothecin for effective radiosensitization. Reviewed International journal

    Katsutoshi Miura, Koh-ichi Sakata, Masanori Someya, Yoshihisa Matsumoto, Hideki Matsumoto, Akihisa Takahashi, Masato Hareyama

    Radiation oncology (London, England)   7   62 - 62   2012.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Poly (ADP-ribose) polymerase-1 (PARP-1) is a key enzyme involved in the repair of radiation-induced single-strand DNA breaks. PARP inhibitors such as olaparib (KU-0059436, AZD-2281) enhance tumor sensitivity to radiation and to topoisomerase I inhibitors like camptothecin (CPT). Olaparib is an orally bioavailable inhibitor of PARP-1 and PARP-2 that has been tested in multiple clinical trials. The purpose of this study was to investigate the characteristics of the sensitizing effect of olaparib for radiation and CPT in order to support clinical application of this agent. METHODS: DLD-1 cells (a human colorectal cancer cell line) and H1299 cells (a non-small cell lung cancer cell line) with differences of p53 gene status were used. The survival of these cells was determined by clonogenic assay after treatment with drugs and X-ray irradiation. The γH2AX focus formation assay was performed to examine the influence of olaparib on induction and repair of double-stranded DNA breaks after exposure to radiation or CPT. RESULTS: A radiosensitizing effect of olaparib was seen even at 0.01 μM. Its radiosensitizing effect after exposure for 2 h was similar to that after 24 h. H1299 cells with depletion or mutation of p53 were more radioresistant than H1299 cells with wild-type p53. However, similar enhancement of radiosensitization by olaparib was observed with all of the tested cell lines regardless of the p53 status. Olaparib also sensitized cells to CPT. This sensitizing effect was seen at low concentrations of olaparib such as 0.01 μM, and its sensitizing effect was the same at both 0.01 μM and 1 μM. The combination of olaparib and CPT had a stronger radiosensitizing effect. The results of the γH2AX focus assay corresponded with the clonogenic assay findings. CONCLUSION: Olaparib enhanced sensitivity to radiation and CPT at low concentrations and after relatively short exposure times such as 2 h. The radiosensitizing effect of olaprib was not dependent on the p53 status of tumor cells. These characteristics could be advantageous for clinical radiotherapy since tumor cells may be exposed to low concentrations of olaparib and/or may have different levels of p53 mutation. The combination of olaparib and CPT had a stronger radiosensitizing effect, indicating that combining a PARP inihibitor with a topoiomerase I inhibitor could be promising for clinical radiosensitization.

    DOI: 10.1186/1748-717X-7-62

    PubMed

    researchmap

  • The combination of hyperthermia or chemotherapy with gimeracil for effective radiosensitization Reviewed

    M. Takagi, K. Sakata, M. Someya, Y. Matsumoto, H. Tauchi, M. Hareyama, M. Fukushima

    STRAHLENTHERAPIE UND ONKOLOGIE   188 ( 3 )   255 - 261   2012.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s00066-011-0043-6

    PubMed

    Web of Science

    researchmap

  • A clinical survey of hospitalization with radical radiotherapy for early stage glottic laryngeal cancer:

    Kensei Nakata, Koichi Sakata, Masaru Takagi, Masanori Someya, Atsushi Kondo, Tetsuo Himi, Masato Hareyama

    Japanese Journal of Head and Neck Cancer   38 ( 3 )   315 - 317   2012

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    DOI: 10.5981/jjhnc.38.315

    researchmap

  • Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase, inhibits the early step in homologous recombination. Reviewed International journal

    Koh-Ichi Sakata, Masanori Someya, Yoshihisa Matsumoto, Hiroshi Tauchi, Masahiro Kai, Minoru Toyota, Masaru Takagi, Masato Hareyama, Masakazu Fukushima

    Cancer science   102 ( 9 )   1712 - 6   2011.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Gimeracil (5-chloro-2, 4-dihydroxypyridine) is an inhibitor of dihydropyrimidine dehydrogenase (DPYD), which degrades pyrimidine including 5-fluorouracil in the blood. Gimeracil was originally added to an oral fluoropyrimidine derivative S-1 to yield prolonged 5-fluorouracil concentrations in serum and tumor tissues. We have already reported that gimeracil had radiosensitizing effects by partially inhibiting homologous recombination (HR) in the repair of DNA double strand breaks. We investigated the mechanisms of gimeracil radiosensitization. Comet assay and radiation-induced focus formation of various kinds of proteins involved in HR was carried out. siRNA for DPYD were transfected to HeLa cells to investigate the target protein for radiosensitization with gimeracil. SCneo assay was carried out to examine whether DPYD depletion by siRNA inhibited HR repair of DNA double strand breaks. Tail moments in neutral comet assay increased in gimeracil-treated cells. Gimeracil restrained the formation of foci of Rad51 and replication protein A (RPA), whereas it increased the number of foci of Nbs1, Mre11, Rad50, and FancD2. When HeLa cells were transfected with the DPYD siRNA before irradiation, the cells became more radiosensitive. The degree of radiosensitization by transfection of DPYD siRNA was similar to that of gimeracil. Gimeracil did not sensitize DPYD-depleted cells. Depletion of DPYD by siRNA significantly reduced the frequency of neopositive clones in SCneo assay. Gimeracil partially inhibits the early step in HR. It was found that DPYD is the target protein for radiosensitization by gimeracil. The inhibitors of DPYD, such as gimeracil, could enhance the efficacy of radiotherapy through partial suppression of HR-mediated DNA repair.

    DOI: 10.1111/j.1349-7006.2011.02004.x

    PubMed

    researchmap

  • Gene expression associated with DNA-dependent protein kinase activity under normoxia, hypoxia, and reoxygenation. Reviewed International journal

    Tadashi Tsuchimoto, Koh-ichi Sakata, Masanori Someya, Hiroyuki Yamamoto, Ryoichi Hirayama, Yoshihisa Matsumoto, Yoshiya Furusawa, Masato Hareyama

    Journal of radiation research   52 ( 4 )   464 - 71   2011

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1269/jrr.10137

    PubMed

    researchmap

  • The association of DNA-dependent protein kinase activity of peripheral blood lymphocytes with prognosis of cancer Reviewed

    Someya, M., Sakata, K-I, Matsumoto, Y., Kamdar, R. P., Kai, M., Toyota, M., Hareyama, M.

    British Journal of Cancer   104 ( 11 )   1724 - 1729   2011

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1038/bjc.2011.158

    PubMed

    Web of Science

    researchmap

  • Gimeracil sensitizes cells to radiation via inhibition of homologous recombination. Reviewed International journal

    Masaru Takagi, Koh-ichi Sakata, Masanori Someya, Hiroshi Tauchi, Kenta Iijima, Yoshihisa Matsumoto, Toshihiko Torigoe, Akari Takahashi, Masato Hareyama, Masakazu Fukushima

    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology   96 ( 2 )   259 - 66   2010.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND AND PURPOSE: 5-Chloro-2,4-dihydroxypyridine (Gimeracil) is a component of an oral fluoropyrimidine derivative S-1. Gimeracil is originally added to S-1 to yield prolonged 5-FU concentrations in tumor tissues by inhibiting dihydropyrimidine dehydrogenase, which degrades 5-FU. We found that Gimeracil by itself had the radiosensitizing effect. METHODS AND MATERIALS: We used various cell lines deficient in non-homologous end-joining (NHEJ) or homologous recombination (HR) as well as DLD-1 and HeLa in clonogenic assay. gamma-H2AX focus formation and SCneo assay was performed to examine the effects of Gimeracil on DNA double strand break (DSB) repair mechanisms. RESULTS: Results of gamma-H2AX focus assay indicated that Gimeracil inhibited DNA DSB repair. It did not sensitize cells deficient in HR but sensitized those deficient in NHEJ. In SCneo assay, Gimeracil reduced the frequency of neo-positive clones. Additionally, it sensitized the cells in S-phase more than in G0/G1. CONCLUSIONS: Gimeracil inhibits HR. Because HR plays key roles in the repair of DSBH caused by radiotherapy, Gimeracil may enhance the efficacy of radiotherapy through the suppression of HR-mediated DNA repair pathways.

    DOI: 10.1016/j.radonc.2010.05.020

    PubMed

    researchmap

  • Phase I Study of Oral S-1 and Concurrent Radiotherapy in Patients with Head and Neck Cancer Reviewed

    K. Nakata, M. Someya, M. Takagi, J. Hayashi, K. Miura, K. Sakata, M. Hareyama

    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS   78 ( 3 )   S450 - S451   2010

     More details

    Language:English  

    Web of Science

    researchmap

  • The treatment outcome of patients undergoing breast-conserving therapy: the clinical role of postoperative radiotherapy. Reviewed

    Atsushi Oouchi, Koh-Ichi Sakata, Hideji Masuoka, Mitsuharu Tamakawa, Hisayasu Nagakura, Masanori Someya, Kensei Nakata, Kazuaki Asaishi, Minoru Okazaki, Yutaka Okazaki, Tousei Ohmura, Masato Hareyama, Masakazu Hori, Izuru Shimokawara, Akira Okazaki, Yoshiki Watanabe, Tsuyoshi Yamada, Tomokazu Yuyama, Taishi Satoh, Koichi Hirata

    Breast cancer (Tokyo, Japan)   16 ( 1 )   49 - 57   2009

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Treatment outcome was evaluated in patients who underwent breast-conserving therapy and tangential irradiation. After verifying background factors including systemic therapy, the clinical efficacy of postoperative irradiation was investigated. METHOD: There were 708 study subjects, all of whom had early breast cancer treated between 1992 and 2002. The median follow-up period was 83 months. After breast-conserving surgery, in patients with negative surgical margins, only tangential irradiation at 48 Gy/24 fr was performed. In contrast, in those with positive surgical margins, 10 Gy of radiation boost to the tumor bed with electrons was administered after tangential irradiation with 50 Gy/25 fr. Treatment outcome was analyzed using the Kaplan-Meier method and Cox's proportional hazards regression model. RESULTS: The disease-free survival and no-recurrence rates within the ipsilateral breast after 5 years were 93.4 and 97.2%, respectively. Risk factors for recurrence within the ipsilateral breast included younger age of patient, the number of positive lymph nodes, and no endocrine therapy. However, the surgical margin was not a risk factor. Risk factors for relapse outwith the ipsilateral breast included younger age, the number of positive lymph nodes, and recurrence within the ipsilateral breast. CONCLUSIONS: From our analysis of 708 Japanese women who received breast-conserving therapy, which can be regarded as a standard method in Japan, the treatment outcome was compatible with previous reports from other countries.

    DOI: 10.1007/s12282-008-0079-3

    PubMed

    researchmap

  • [Clinical application of altered fractionation theory]. Reviewed

    Koh-ichi Sakata, Masanori Someya, Kensei Nakata, Masaru Takagi, Masato Hareyama

    Gan to kagaku ryoho. Cancer & chemotherapy   35 ( 11 )   1823 - 6   2008.11

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    Altered fractionation schedules are based on two different concepts of radiobiology. One concept is that the radiation repair capability of cells in late responding tissues is higher than that of cells in acute responding tissues which include tumor tissues. Hyperfractionation utilizes this concept. The other concept is that accelerated repopulation of tumor cells occurs in a later period of radiation therapy. In order to overcome repopulation of tumor cells, accelerated hyperfractionation is proposed. These two concepts are independent and some fractionation methods include both concepts. Clinical results of altered fractionation schedules of radiation therapy could be predicted with a biological model (the linear quadratic model theory)for fractionated radiation. When this biological model is applied to tumors in which the tumor cell repopulation during radiotherapy period is negligible, the correction for tumor proliferation is required. Since the calculation of the biological effect dose with this model uses several assumptions, we should consider the biological effect dose as a crude approximation. Especially, in case of concomitant chemotherapy and altered fractionation, it is difficult to predict its results with a simple radiobiology model. The randomized trial is required to examine the significance of chemoradiotherapy using altered fractionation.

    PubMed

    researchmap

  • Hyperfractionated accelerated radiotherapy for T1,2 glottic carcinoma. Consideration of time-dose factors. Reviewed International journal

    Koh-ichi Sakata, Masanori Someya, Masakazu Hori, Kensei Nakata, Masaru Takagi, Masato Hareyama

    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]   184 ( 7 )   364 - 9   2008.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND AND PURPOSE: Hyperfractionated accelerated radiotherapy without a split (AF) has been performed to improve the local control probability of early glottic carcinomas since 1990 in the authors' institution. Here, they report their experience treating early glottic cancer patients with AF in a single institution who have a long follow-up period. PATIENTS AND METHODS: 131 T1 N0 M0 glottic cancers and 65 T2 N0 M0 glottic cancers were treated with conventional fractionation (CF) from 1984 to 1989 and with AF since 1990. CF consisted of five daily fractions of 2 Gy per week, to a total dose of 64 Gy. AF consisted of 1.72 Gy per fraction, two fractions per day, 5 days a week, to a total dose of 55 or 58.5 Gy. RESULTS: The 5-year local control probability for T1 tumors was 94% with 58.5 Gy and 87% with 55 Gy of AF, whereas it amounted to 80% with CF. For T2 tumors, it was 56% with 58.5 Gy and 68% with 55 Gy of AF, whereas it amounted to 64% with CF. The data of T2 should be evaluated with caution due to the small number of patients. Patients with AF had more severe mucosal reactions but no severe late reactions. CONCLUSION: AF significantly improved the local control rates for T1 glottic cancer.

    DOI: 10.1007/s00066-008-1819-1

    PubMed

    researchmap

  • Brachytherapy for oral tongue cancer: an analysis of treatment results with various biological markers. Reviewed International journal

    Koh-ichi Sakata, Masanori Someya, Hisayasu Nagakura, Kensei Nakata, Atushi Oouchi, Masaru Takagi, Masato Hareyama

    Japanese journal of clinical oncology   38 ( 6 )   402 - 7   2008.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: Low-dose-rate (LDR) brachytherapy is an effective treatment for tongue cancer. However, little is known about the biological mechanism underlying this therapy, characterized by delivery of continuous exposures of LDR irradiation. It is reported that lower microvessel density (MVD), lower Ki-67 index or higher expression of endogenous hypoxic markers such as carbonic CA IX and Glut-1 are related to the poor control of tumors treated with external irradiation. To elucidate the biological characteristics of LDR brachytherapy, we analyzed our results in cases of tongue cancer treated with LDR brachytherapy by using immunohistochemical stainings with antibodies against Ki-67 and MVD, Glut-1 and CA IX. METHODS: The prognostic value of Ki-67 index, MVD and the expression of CA IX and Glut-1 was assessed in 68 tongue cancers treated with LDR brachytherapy. The specimens were taken from tongue cancers before radiation therapy and immunohistochemical staining was performed. RESULTS: The local recurrence-free survival rates were significantly different between T1+T2 and T3 (P = 0.00067), but not between low and high Ki-67 indexes (P = 0.54), between low and high MVD (P = 0.071), low and high CA IX indexes (P = 0.062) or low and high Glut-1 indexes (P = 0.107). T stage, the size of the tumor was the only significant factor for local control in multivariate analyses (P = 0.0377). CONCLUSION: LDR could overcome the radioresistence of non-cycling and hypoxic cells; however, we cannot draw firm conclusions due to the limited number of patients.

    DOI: 10.1093/jjco/hyn050

    PubMed

    researchmap

  • Tissue oxygenation in a murine SCC VII tumor after X-ray irradiation as determined by EPR spectroscopy. Reviewed International journal

    Hirotada Fujii, Koh-Ichi Sakata, Yoshihiro Katsumata, Rikiya Sato, Makoto Kinouchi, Masanori Someya, Shin-Ichiro Masunaga, Masato Hareyama, Harold M Swartz, Hiroshi Hirata

    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology   86 ( 3 )   354 - 60   2008.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: The goal of this study was to clarify the dynamics of oxygenation (partial pressure of oxygen, pO(2)) in SCC VII murine tumors in mice after X-ray irradiation. MATERIALS AND METHODS: Changes in pO(2) in tumors were measured by 1.2-GHz electron paramagnetic resonance (EPR) spectroscopy after they were exposed to various doses of irradiation. The pO(2) in tumors was followed for up to six days after irradiation at doses of 0, 5, 10, 15, and 20 Gy. Paramagnetic crystals were used as an oximetry probe and implanted into normal or tumor tissues in mice for prolonged periods. RESULTS: The pattern of tumor oxygen after a single dose of radiation with the 5-Gy dose was different from those with other doses (10, 15, and 20 Gy). After 5 Gy, pO(2) increased rapidly (P<0.01, Student's t test) and then returned to the level observed before irradiation by 12h (P<0.01). In contrast, after 10, 15, or 20 Gy, pO(2) increased rapidly by 6h after irradiation, continued to increase until at least 24h (P<0.01), and then gradually decreased. CONCLUSIONS: In tumors that received 5 Gy, post-irradiation increases in pO(2) at 4h after irradiation were detected by EPR oximetry (P<0.01) noninvasively.

    PubMed

    researchmap

  • The enhanced expression of the matrix metalloproteinase 9 in nasal NK/T-cell lymphoma. Reviewed International journal

    Koh-ichi Sakata, Masanori Someya, Mutsuko Omatsu, Hiroko Asanuma, Tadashi Hasegawa, Shingo Ichimiya, Masato Hareyama, Tetsuo Himi

    BMC cancer   7   229 - 229   2007.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Nasal NK/T cell lymphoma is an aggressive disease and has a poor prognosis. Nasal NK/T cell lymphoma is refractory to conventional chemotherapy and has strong tendency of widespread relapse or dissemination into distant sites. METHODS: We immunohistochemically studied nasal NK/T-cell lymphoma to elucidate the unique characteristics of nasal NK/T-cell lymphoma, such as its higher metastatic tendency and its vast necrosis which leads to destruction of the involved tissues. The expression of P-glycoprotein and MMP-9 was evaluated in the 20 patients with nasal NK/T-cell lymphoma and 25 with nasal non-NK/T-cell lymphoma and the relationship between expression of these proteins and clinical results were analyzed in this report. RESULTS: Overall 5-year survival rates for patients with nasal NK/T cell lymphoma, and nasal non-NK/T cell lymphoma were 51%, and 84%. Distant involvement free 5-year survival rates for patients with nasal NK/T cell lymphoma, and nasal non-NK/T cell lymphoma were 53%, and 79%. Overall positivity for P-glycoprotein was observed in 10 of 19 patients with NTL and in 13 of 23 patients with non-NTL. When the overall survival rate was compared between patients with P-glycoprotein positive and negative, there was no difference between them. Sixteen of the 19 patients with nasal NK/T cell lymphoma expressed MMP-9. In contrast, only 8 of the 22 patients with nasal non-NK/T cell lymphoma expressed MMP-9. Distant involvement free 5-year survival rates for patients with MMP-9 negative, and MMP-9 positive were 92%, and 61%, respectively. The difference was statistically significant (p = 0.027). CONCLUSION: Positive immunoreactivity for P-glycoprotein was not an independent prognostic factor in nasal NK/T-cell lymphomas, which stresses the importance of exploring other mechanisms of drug resistance. The strong expression of MMP-9 is uniquely characteristic of nasal NK/T cell lymphoma and may contribute to its strong tendency to disseminatate and the extensive necrosis which is always seen. However, our results are based on univariate comparisons, and as such, should be viewed with some caution.

    PubMed

    researchmap

  • Ability to repair DNA double-strand breaks related to cancer susceptibility and radiosensitivity. Reviewed

    Koh-Ichi Sakata, Masanori Someya, Yoshihisa Matsumoto, Masato Hareyama

    Radiation medicine   25 ( 9 )   433 - 8   2007.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Traditional radiobiology has aimed at elucidating the mechanism of radiosensitivity of cancer cells and normal cells. Because the mechanism of DNA double-strand break (DSB) repair, which is inherently important to radiosensitivity, was unknown, it has been difficult to obtain results applicable to clinical radiotherapy from traditional radiobiology research. Today, however, the molecular mechanism of DNA DSB repair has been elucidated because of the rapid advances in molecular biology. In DNA DSB repair, at least two major repair mechanisms, homologous recombination and nonhomologous end joining (NHEJ) have been reported. In the NHEJ pathway, DSBs are directly, or after processing of the DNA ends, rejoined at an appropriate chromosomal end. DNA-dependent protein kinase (DNA-PK) plays an important role in DNA DSB repair by NHEJ. We have investigated how the ability of repair of DNA DSB influences cancer susceptibility and the radiosensitivity of tumors and normal tissues by focusing on the activity of DNA-PK. In the near future, research on DNA DSB repair mechanism will be able to be applied to research on carcinogenesis, prediction of radiosensitivity of tumors and normal cells, and sensitization of tumor cells.

    PubMed

    researchmap

  • The efficacy and usefulness of problem based learning in undergraduate medical school education of radiation oncology

    Minako Uchino, Tomoko Itazawa, Masanori Someya, Satoaki Nakamura

    Journal of JASTRO   19 ( 3 )   139 - 145   2007.9

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    researchmap

  • cDNA analysis of gene expression associated with DNA-dependent protein kinase activity. Reviewed International journal

    Koh-ichi Sakata, Hiroyuki Yamamoto, Yoshihisa Matsumoto, Masanori Someya, Masato Hareyama

    International journal of oncology   30 ( 2 )   413 - 20   2007.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DNA-dependent protein kinase (DNA-PK) is thought to play a pivotal role in DNA double-strand break repair. We recently demonstrated the association of DNA-PK activity in peripheral blood lymphocytes (PBL) with the incidence of chromosomal aberrations and the risk of cancer. In this study, we applied cDNA array technology to find the expression of genes which are associated with DNA-PK activity in PBLs with various levels of DNA-PK activity. Most genes correlated with DNA-PK activity involved cell cycle regulation. Moreover, the transcription factor E2F1, which plays an important role in cell cycle progression, exhibited strong correlation with the DNA-PK activity and Rbp130, which is considered a negative regulator of E2F, showed inverse correlation with DNA-PK activity. In silico promoter analyses showed the presence of at least one E2F binding site in the promoter regions of Ku70, Ku86, DNA-PKcs and genes associated with DNA-PK activity. In order to examine the relationship among the E2F1 expression, the expression of genes related with DNA-PK activity, and DNA-PK activity, we activated PMLs by PHA to progress the cell cycle. After PHA activation of PML, the expression of E2F1 and DNA-PK activity increased. The expression of most genes in PHA-stimulated PBLs had a similar relationship with DNA-PK activity to that without PHA stimulation. These results indicate that the E2F transcription factor may regulate the concerted expression of genes related with DNA-PK activity.

    PubMed

    researchmap

  • The application of theory of altered fractionation on clinics

    Koh-ichi Sakata, Masanori Someya, Kensei Nakata, Masaru Takagi, Kazuo Kojima, Masato Hareyama

    Toukeibu Gan   33 ( 3 )   280 - 282   2007

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.5981/jjhnc.33.280

    researchmap

  • A clinical study of hypoxia using endogenous hypoxic markers and polarographic oxygen electrodes. Reviewed International journal

    Koh-ichi Sakata, Masanori Someya, Hisayasu Nagakura, Kensei Nakata, Atushi Oouchi, Masato Hareyama, Masaaki Satoh

    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]   182 ( 9 )   511 - 7   2006.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: To examine various kinds of endogenous hypoxia markers' expression in the tissues of uterine cervix cancer and to elucidate the characteristics and pitfalls when they are used as a hypoxia marker, by comparing these expressions with tumor oxygen partial pressure (pO2) values. PATIENTS AND METHODS: Assessment of pO2 using polarographic oxygen electrodes was performed in 69 patients with cervix carcinomas. Biopsies were taken from the region of electrode measurements. Expression of endogenous hypoxic markers in biopsy specimens such as vascular endothelial growth factor, glucose transporter-1 (GLUT-1), involucrin, and osteopontin was detected by immunohistochemistry. A double immunolabeling technique with GLUT-1 and MIB-1 as a marker of proliferation was also performed. RESULTS: There was no significant correlation between expression of endogenous hypoxic markers and pO2. The only significant association seen was between the fraction of necrosis and pO2. A significant but weak correlation was found among expression of endogenous hypoxic markers. The levels of necrosis were related negatively with levels of expression of endogenous hypoxic markers. The double immunolabeling technique with GLUT-1 and MIB-1 indicated that there were about 20% MIB-1-positive tumor cells without GLUT-1 expression in tissues adjacent to areas of necrosis. CONCLUSION: The existence of necrosis affected the expression of endogenous hypoxic markers. Some hypoxic tumor cells without expressions of hypoxia markers can maintain clonogenicity and influence the treatment results. The combined use of hypoxic markers is recommended because their expression is influenced by factors other than hypoxia.

    PubMed

    researchmap

  • The association of DNA-dependent protein kinase activity with chromosomal instability and risk of cancer. Reviewed International journal

    Masanori Someya, Koh-ichi Sakata, Yoshihisa Matsumoto, Hiroyuki Yamamoto, Manami Monobe, Hideyuki Ikeda, Koichi Ando, Yoshio Hosoi, Norio Suzuki, Masato Hareyama

    Carcinogenesis   27 ( 1 )   117 - 22   2006.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The DNA double-strand breaks (DSBs) repair pathway has been implicated in maintaining genomic integrity via suppression of chromosomal rearrangements. DNA-dependent protein kinase (DNA-PK) has an important role with DNA DSBs repair. In this study, 93 of untreated cancer patients and 41 of cancer-free healthy volunteers were enrolled. Peripheral blood was collected, separated and centrifuged; DNA-PK activity was measured by DNA-pull-down assay. The expressions of DNA-PKcs, Ku70 and Ku86 were examined by RT-PCR assay and western blotting. Chromosomal aberrations were examined by cytogenetic methods. DNA-PK activities of peripheral blood lymphocytes (PBL) in patients with uterine cervix or breast cancer were significantly lower than those in normal volunteers. Age and smoking had no association with DNA-PK activity, whereas DNA-PK activity and the expression of Ku70, Ku86 and DNA-PKcs in RT-PCR were interrelated. A similar tendency was seen in western blot assay but less clear than in RT-PCR. Therefore, the association between DNA-PK activity and expression of DNA-PK in protein level could not be concluded. The frequency of chromosome aberration, such as dicentric chromosomes and excess fragment increased as the DNA-PK activity decreased. In conclusion, DNA-PK activity is associated with chromosomal instability. DNA-PK activity in PBL is associated with risk of breast and uterine cervix cancer. DNA-PK activity in PBL can be used to select individuals for whom an examination should be performed because of their increased susceptibility to breast and uterine cervix cancer.

    PubMed

    researchmap

  • Three cases of diffuse large B-cell lymphoma of the mandible treated with radiotherapy and chemotherapy. Reviewed

    Masanori Someya, Koh-Ichi Sakata, Hisayasu Nagakura, Katsuya Itou, Kensei Nakata, Atsushi Oouchi, Masaaki Satoh, Masato Hareyama

    Radiation medicine   23 ( 4 )   296 - 302   2005.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    CASE REPORT: We report three cases of diffuse large B-cell lymphoma of the mandible and a review of the literature. All 3 of our patients had stage I AE disease and had complete remission for more than 2 years after 42-46 Gy of irradiation to the primary tumor with regional lymph nodes and 3 courses of chemotherapy consisting of cyclophosphamide, adriamycin, vincristine, and predonisolone (CHOP). Literature analysis, although biased toward published data, indicated that the 3-year disease-specific survival rates for non-Hodgkin's lymphoma (NHL) of the mandible were 90.5% and 47.6% for stages I and II, respectively. The treatment results for NHL of the mandible may be similar to general primary bone NHL and to other extranodal NHL's. CONCLUSION: Radiotherapy alone is not sufficient for tumor control for stage I+II, disease, and combination chemotherapy may be needed.

    PubMed

    researchmap

  • Analysis of local control in patients with non-Hodgkin's lymphoma according to the WHO classification. Reviewed International journal

    Koh-Ichi Sakata, Masaaki Satoh, Masanori Someya, Hisayasu Nagakura, Atushi Oouchi, Kensei Nakata, Katsuhisa Kogawa, Kazumitsu Koito, Masato Hareyama, Tetsuo Himi

    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]   181 ( 6 )   385 - 91   2005.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: To analyze the influence of radiotherapy doses, chemotherapy doses, and clinical parameters on in-field disease control to assess the optimal radiation doses for treatment of non-Hodgkin's lymphoma according to the newly proposed WHO classification. PATIENTS AND METHODS: Subjects consisted of 35 extranodal marginal-zone B-cell lymphomas of mucosa-associated lymphoid tissue (MALT) type, 75 diffuse large B-cell lymphomas (DLBCL), 14 follicular lymphomas, 17 extranodal natural killer (NK)/T-cell lymphomas, nasal type, eight unclassified peripheral T-cell lymphomas, four anaplastic large-cell lymphomas, T/null cell type, and five others. 59 patients received radiotherapy alone. 98 patients received CHOP, modified CHOP, or more intensive chemotherapy, and six patients were treated with other combination. RESULTS: No patients with MALT lymphoma had in-field local recurrence. There were no recurrences in DLBCL patients who received chemotherapy in which the doses of adriamycin were > 200 mg/m(2), nor in DLBCL patients who were treated with > 45 Gy. Only nine of 15 patients with T-cell lymphoma treated with < or = 50 Gy and three of five patients treated with > 50 Gy had local control. The dose of adriamycin had no influence on local control of T-cell lymphoma. CONCLUSION: T/NK-cell lymphomas were more radioresistant than B-cell lymphomas. The prognosis for peripheral T/NK-cell lymphomas is poor even when treated by irradiation combined with chemotherapy.

    PubMed

    researchmap

  • Preliminary clinical results of conformal radiation therapy for prostate cancer

    Atsushi Oouchi, T. Nakata, K. Aratani, M. Hori, T. Tsuchimoto, M. Someya, H. Nagakura, K. Sakata, M. Hareyama, N. Masumori, Y. Tsukamoto

    Japanese Journal of Clinical Radiology   50 ( 5 )   633 - 637   2005

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    researchmap

  • Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma. Reviewed International journal

    Koh-ichi Sakata, Masaaki Satoh, Masanori Someya, Hiroko Asanuma, Hisayasu Nagakura, Atushi Oouchi, Kensei Nakata, Katsuhisa Kogawa, Kazumitsu Koito, Masato Hareyama, Tetsuo Himi

    Cancer   100 ( 2 )   356 - 65   2004.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Non-Hodgkin lymphoma (NHL) represents a heterogeneous group of tumors that vary with regard to their biologic aggressiveness and clinical course. In in vitro studies, matrix metalloproteinase 9 (MMP9) was reportedly expressed by human NHL cells and elevated levels of MMP9 have been observed in a subset of patients with high-grade NHL. METHODS: The expression of MMP2 and MMP9 was evaluated in 158 patients with NHL and the relation between the expression of these proteins and clinicopathologic factors was analyzed. All but 1 patient had received radiation therapy and 92 patients also were treated with intensive combination chemotherapy. RESULTS: Nearly all the patients with extranodal natural killer NK/T-cell lymphoma nasal type and anaplastic large cell lymphoma, T-cell/null cell type expressed MMP9. In contrast, only a small fraction of the patients with mucosa-associated lymphoid tissue (MALT) lymphomas and follicular lymphomas expressed MMP9. Approximately 50% of the diffuse large B-cell lymphoma (DLBCL) cases expressed MMP9. The expression of MMP2 was noted in some of the patients with DLBCL and nasal NK/T-cell lymphoma. The overall survival rates of patients who expressed MMP9 were significantly lower than that of those who did not. Such a correlation was not demonstrated in MMP2 expression. When MMP9 expression was analyzed in DLBLC patients, the overall survival rates of patients who expressed MMP9 were significantly lower than those who did not express MMP9. Chemotherapy was associated with better overall survival in DLBCL patients who expressed MMP9. Overall survival rates of T-cell/NK-cell lymphoma patients who expressed MMP9 appeared to be lower than that in those who did not express MMP9. However, chemotherapy was not found to improve overall survival in patients who expressed MMP9. CONCLUSIONS: MMP9 expression was observed in patients with aggressive NHL and was characterized by poor overall survival.

    PubMed

    researchmap

  • Treatment strategy for oropharyngeal carcinoma (from the standpoint of radiotherapy)

    Koh-ichi Sakata, Masato Hareyama, Masanori Someya, Hisayasu Nagakura, Atsushi Oouchi, Katsushi Asano, Shinji Ooguro

    Toukeibu Gan   30 ( 3 )   419 - 422   2004

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.5981/jjhnc.30.419

    researchmap

  • THE CAREER PATHS OF THE PARTICIPANTS IN A RADIATION ONCOLOGY SEMINAR FOR MEDICAL DOCTOR CANDIDATES IN 1997

    IMAGUMBAI Toshiyuki, UCHINO Minako, ITAZAWA Tomoko, SOMEYA Masanori, BITO Seiji

    J Jpn Soc Ther Radiol Oncol   16 ( 4 )   225 - 229   2004

     More details

    Language:Japanese   Publisher:Japanese Society for Therapeutic Radiology and Oncology  

    Since 1995, the Japanese Society for Therapeutic Radiology and Oncology (JASTRO) has held a teaching seminar for medical doctor candidates. In 1997, thirty-three students participated in the seminar. After graduation, eighteen (18/33) of the participants became radiologists and twelve of them (12/18) majored in radiation oncology. These results imply that the seminar might have an impact on their career paths. Hence, we propose that the seminar can have an influence upon the career decision of medical students, and it could yield a breakthrough to overcome in the shortage of radiation oncologists in Japan.

    DOI: 10.11182/jastro1989.16.225

    J-GLOBAL

    researchmap

  • High-dose-rate intracavitary brachytherapy: results of analyses of late rectal complications. Reviewed International journal

    Koh-ichi Sakata, Hisayasu Nagakura, Atushi Oouchi, Masanori Someya, Kensei Nakata, Mitsuo Shido, Kazumitsu Koito, Satoru Sagae, Ryuichi Kudo, Masato Hareyama

    International journal of radiation oncology, biology, physics   54 ( 5 )   1369 - 76   2002.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: To examine the incidence of radiation-induced late rectal complications by analyzing the data of measured rectal doses in patients with cancer of the uterine cervix treated with high-dose-rate intracavitary brachytherapy. METHODS AND MATERIALS: We measured doses to the rectum in 105 patients with cancer of the cervix during high-dose-rate intracavitary brachytherapy with a semiconductor dosimeter that can measure five points in the rectum simultaneously. On the basis of these measurements, equivalent doses, to which the biologically equivalent doses were converted as if given as fractionated irradiation at 2 Gy/fraction, were calculated as components of the cumulative dose at five rectal points in intracavitary brachytherapy combined with the external whole pelvic dose. RESULTS: The calculated values of equivalent doses for late effects at the rectum ranged from 15 to 100 Gy (median 60 Gy for patients who did not develop complications and 76 Gy for patients who subsequently developed Grade II or III complications). When converted to a graph of absolute rectal complication probability, the data could be fitted to a sigmoid curve. The data showed a very definite dose-response relationship, with a threshold for complications at approximately 50 Gy and the curve starting to rise more steeply at approximately 60 Gy. The steepest part of the curve had a slope equivalent to approximately 4% incidence/1 Gy increase in equivalent doses. CONCLUSION: The radiation tolerance dose, 5% and 50% complication probability, was about 64 and 79 Gy, respectively. Our data almost agree with the prescribed dose for the rectum for the radiation tolerance doses on the basis of the recorded human and animal data. The probability of rectal complications increased drastically after the maximal rectal dose was >60 Gy.

    PubMed

    researchmap

  • High-dose-rate versus low-dose-rate intracavitary therapy for carcinoma of the uterine cervix: a randomized trial. Reviewed International journal

    Masato Hareyama, Koh-ichi Sakata, Atushi Oouchi, Hisayasu Nagakura, Mitsuo Shido, Masanori Someya, Kazumitsu Koito

    Cancer   94 ( 1 )   117 - 24   2002.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: This was a prospective randomized clinical trial undertaken at our institution to compare low-dose-rate (LDR) intracavitary radiation therapy versus high-dose-rate (HDR) intracavitary radiation therapy for the treatment of cervical carcinoma. METHODS: From January 1984 to December 1997, a total of 132 patients with Stage II or IIIB of invasive carcinoma of the uterine cervix were entered into this randomized study. Treatment arm by HDR or LDR was allocated according to the month of each patient's birth. External irradiation consisted of whole pelvis irradiation and pelvic irradiation. Doses of external irradiation for both groups were identical. The authors used 0.588 as the conversion factor of total intracavitary dose from LDR to HDR. RESULTS: The 5-year disease specific survival rates of Stage II and III patients treated with HDR were 69% and 51% whereas those with LDR were 87% and 60%, respectively. The 5-year pelvic recurrence free survival rates of Stage II and III patients treated with HDR were 89% and 73% whereas those with LDR were 100% and 70%, respectively. There was no significant difference in disease specific survival or pelvic recurrence free survival rates between HDR and LDR. The actuarial complication rate (Radiation Therapy Oncology Group Grade 3, 4, or 5) at 5 years was 10% in the HDR group and 13% in the LDR group, and the difference between the HDR and LDR groups was not statistically significant. CONCLUSIONS: The pelvic control or actuarial complication rates were comparable between HDR and LDR treatment. The difference between the disease specific survival rates for HDR and LDR was not statistically significant for Stage II or III, although in Stage II, patients treated with LDR appeared to have a better survival rate than those treated with HDR.

    PubMed

    researchmap

  • A case of hepatocellular carcinoma: The feasibility of intravenous contrast enhanced ultrasonography in evaluating percutaneous microwave coagulation therapy

    Naoki Hirokawa, Kazumitsu Koito, Sjsum, Kensei Nakata, Takeshi Ichimura, Masanori Someya, Takaharu Shounai, Naoya Yama, Hideki Hyoudou

    Journal of Medical Ultrasonics   29 ( 1 )   J17 - J21   2002

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    researchmap

  • Four Cases of Meningeal Hemangiopericytoma Treated with Surgery and Radiotherapy Reviewed

    M. Someya

    Japanese Journal of Clinical Oncology   31 ( 11 )   548 - 552   2001.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Oxford University Press (OUP)  

    DOI: 10.1093/jjco/hye116

    researchmap

▼display all

Books

  • 患者・市民のための膵がん診療ガイド

    日本膵臓学会, 日本膵臓学会膵癌診療ガイドライン改訂委員会( Role: Contributor放射線治療)

    金原出版  2023.5  ( ISBN:9784307204606

     More details

    Total pages:xi, 250p   Language:Japanese  

    CiNii Books

    researchmap

  • 密封小線源治療診療・物理QAマニュアル : 小線源治療部会ガイドラインに基づく

    日本放射線腫瘍学会小線源治療部会( Role: Contributor放射線生物学)

    金原出版  2022.5  ( ISBN:9784307071253

     More details

    Total pages:343p   Language:Japanese  

    CiNii Books

    researchmap

  • 患者さんと家族のための放射線治療Q&A 2020年版

    日本放射線腫瘍学会( Role: Contributor)

    金原出版  2020.9  ( ISBN:9784307071154

     More details

    Total pages:226p   Language:Japanese  

    CiNii Books

    researchmap

  • 患者・市民・医療者をつなぐ膵がん診療ガイドライン2019の解説

    日本膵臓学会, 日本膵臓学会膵癌診療ガイドライン改訂委員会( Role: Contributor放射線治療)

    金原出版  2020.7  ( ISBN:9784307204163

     More details

    Total pages:190p   Language:Japanese  

    CiNii Books

    researchmap

  • 患者さんと家族のための放射線治療Q&A 2015年版

    日本放射線腫瘍学会( Role: Contributor)

    金原出版  2015.11  ( ISBN:9784307071017

     More details

    Total pages:180p   Language:Japanese  

    CiNii Books

    researchmap

MISC

  • 子宮頸癌の放射線治療成績と末梢血リンパ球のDNA-PK活性の関係

    染谷 正則, 松本 健一, 福島 悠希, 後町 俊夫, 土屋 高旭, 長谷川 智一, 北川 未央, 堀 正和, 中田 健生, 坂田 耕一

    Japanese Journal of Radiology   36 ( Suppl. )   11 - 11   2018.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 前立腺癌放射線治療患者のリンパ球を用いた消化管および尿路の急性期有害事象予測

    染谷 正則, 堀 正和, 長谷川 智一, 中田 健生, 土屋 高旭, 北川 未央, 後町 俊夫, 福島 悠希, 舛森 直哉, 坂田 耕一

    日本癌治療学会学術集会抄録集   55回   O7 - 1   2017.10

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    Ichushi

    researchmap

  • 前立腺癌根治照射後の直腸障害とDVH解析

    染谷 正則, 中田 健生, 三浦 勝利, 堀 正和, 坂田 耕一

    Japanese Journal of Radiology   33 ( Suppl. )   5 - 5   2015.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • PARP阻害剤オラパリブの放射線増感効果のメカニズム

    染谷 正則, 三浦 勝利, 坂田 耕一, 中田 健生, 堀 正和, 畠中 正光

    Japanese Journal of Radiology   32 ( Suppl. )   5 - 5   2014.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • DNA修復の阻害による放射線増感効果の検討

    染谷 正則, 三浦 勝利, 高木 克, 坂田 耕一, 晴山 雅人

    Japanese Journal of Radiology   31 ( Suppl.I )   12 - 12   2013.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 放射線影響科学の基軸「線量」体系の未来を見据えた統合的研究 リンパ球を用いた個人のDNA修復特性と癌罹患性の解析

    染谷 正則, 坂田 耕一

    日本放射線影響学会大会講演要旨集   55回   61 - 61   2012.9

     More details

    Language:Japanese   Publisher:(一社)日本放射線影響学会  

    Ichushi

    researchmap

  • コメットアッセイ法を用いたギメラシルの放射線増感効果の検討

    染谷 正則, 三浦 勝利, 坂田 耕一, 晴山 雅人

    Japanese Journal of Radiology   30 ( Suppl.I )   6 - 6   2012.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • ギメラシルの放射線増感作用の放射線誘発γH2AXフォーカスによる解析

    染谷 正則, 高木 克, 小島 一男, 中田 健生, 坂田 耕一, 晴山 雅人, 田内 広, 松本 義久, 福島 正和

    日本医学放射線学会学術集会抄録集   67回   S254 - S254   2008.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 当科における食道癌の化学放射線治療成績

    染谷 正則, 中田 健生, 高木 亮, 坂田 耕一, 晴山 雅人

    日本癌治療学会誌   42 ( 2 )   585 - 585   2007.9

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    Ichushi

    researchmap

  • 乳癌患者におけるリンパ球DNA-PK活性、放射線誘発NBS1フォーカスと臨床的悪性度の関係

    染谷 正則, 坂田 耕一, 松本 義久, 晴山 雅人

    日本医学放射線学会学術集会抄録集   66回   S351 - S351   2007.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 当院におけるT1/2の声門癌に対する治療成績

    染谷 正則, 坂田 耕一, 晴山 雅人, 平 篤史, 坪田 大, 氷見 徹夫

    頭頸部癌   32 ( 2 )   153 - 153   2006.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    Ichushi

    researchmap

  • ヒトリンパ球のDNA-PK活性とNBS1フォーカス,染色体不安定性の関係について

    染谷 正則, 永倉 久泰, 大内 敦, 坂田 耕一, 晴山 雅人

    日本放射線腫瘍学会誌   17 ( Suppl.1 )   161 - 161   2005.10

     More details

    Language:Japanese   Publisher:(公社)日本放射線腫瘍学会  

    Ichushi

    researchmap

  • 下顎骨原発の悪性リンパ腫 症例報告と文献的考察

    染谷 正則, 中田 健生, 永倉 久泰, 大内 敦, 坂田 耕一, 晴山 雅人, 伊藤 克哉

    日本医学放射線学会雑誌   64 ( 8 )   575 - 575   2004.11

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • ヒト末梢血リンパ球のDNA-PK活性と染色体不安定性および発癌との関係について

    染谷 正則, 坂田 耕一, 安藤 興一, 細井 義夫, 鈴木 紀夫, 晴山 雅人

    日本放射線腫瘍学会誌   16 ( Suppl.1 )   156 - 156   2004.10

     More details

    Language:Japanese   Publisher:(公社)日本放射線腫瘍学会  

    Ichushi

    researchmap

  • 当院での小児腫瘍に対するTBI(Total Body Irradiation)の方法について

    染谷 正則, 中田 健生, 廣川 直樹, 市村 健, 永倉 久泰, 大内 敦, 坂田 耕一, 晴山 雅人, 鈴木 信寛, 工藤 亨

    小児がん   40 ( 4 )   635 - 635   2003.12

     More details

    Language:Japanese   Publisher:(NPO)日本小児がん学会  

    Ichushi

    researchmap

  • 頭頸部腫瘍患者における頸部照射後長期間での唾液量の検討

    染谷 正則, 中田 健生, 永倉 久泰, 大内 敦, 坂田 耕一, 晴山 雅人

    日本医学放射線学会雑誌   63 ( 9 )   605 - 605   2003.11

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 頭部放射線治療を行った小児血液腫瘍患者の遅発性有害反応の検討

    染谷 正則, 中田 健生, 永倉 久泰, 大内 敦, 坂田 耕一, 晴山 雅人

    日本放射線腫瘍学会誌   15 ( 1 )   43 - 49   2003.3

  • 頭頸部腫瘍患者における頸部照射後の唾液量の検討

    染谷 正則, 中田 健生, 永倉 久泰, 大内 敦, 坂田 耕一, 晴山 雅人

    日本医学放射線学会雑誌   63 ( 2 )   S290 - S290   2003.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 当院における舌癌組織内照射の治療成績

    染谷 正則, 永倉 久泰, 坂田 耕一, 晴山 雅人, 坪田 大, 氷見 徹夫

    頭頸部腫瘍   28 ( 2 )   463 - 463   2002.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    Ichushi

    researchmap

  • 小児脳腫瘍における放射線治療成績の検討

    染谷 正則, 伊藤 克哉, 中田 健生, 永倉 久泰, 大内 敦, 坂田 耕一, 晴山 雅人

    日本医学放射線学会雑誌   62 ( 1 )   45 - 45   2002.1

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 頭部放射線治療を行った小児患者の晩発性障害の検討

    染谷 正則, 中田 健生, 永倉 久泰, 大内 敦, 坂田 耕一, 晴山 雅人

    日本放射線腫瘍学会誌   13 ( Suppl.1 )   88 - 88   2001.10

     More details

    Language:Japanese   Publisher:(公社)日本放射線腫瘍学会  

    Ichushi

    researchmap

  • 小児ALL患者における予防的全脳照射の検討

    染谷 正則, 永倉 久泰, 大内 敦, 坂田 耕一, 晴山 雅人

    日本医学放射線学会雑誌   61 ( 6 )   319 - 319   2001.5

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 下顎骨原発悪性リンパ腫の3例

    染谷 正則, 永倉 久泰, 坂田 耕一, 晴山 雅人, 野口 誠, 小浜 源郁

    頭頸部腫瘍   27 ( 2 )   562 - 562   2001.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    Ichushi

    researchmap

  • 膵癌はナゼ治りにくいのか?膵癌治療の最前線 放射線治療

    染谷正則

    月刊臨床と研究   102 ( 4 )   2025

  • The early experience of PRRT treatment with Lu-177 for the treatment of neuroendocrine tumor

    奥田竜, 長谷川智一, 後町俊夫, 北川未央, 上山凌央, 賀口寿乃, 眞船翔, 土屋高旭, 染谷正則, 我妻康平, 坂田耕一

    北海道放射線医学雑誌   5   2025

  • 当院において根治的放射線治療を行った食道癌症例の検討

    大黒敦矢, 眞船翔, 戸島有香, 芦名彩斗, 上山凌央, 後町俊夫, 土屋高旭, 北川未央, 長谷川智一, 染谷正則

    北海道医学雑誌   99 ( 2 )   2024

  • Stage IVa食道癌に対するdocetaxel,nedaplatin,5-fluorouracil,放射線併用療法(DNF-R)の長期予後解析と至適治療の検討

    佐藤昌則, 大沼啓之, 中村元, 渋谷稜, 村瀬和幸, 高田弘一, 染谷正則, 坂田耕一, 宮西浩嗣

    日本消化器病学会雑誌(Web)   121   2024

  • 動注化学放射線療法と外科手術を行った口腔癌の免疫組織学的評価

    染谷正則, 池内佑太郎, 眞船翔, 長谷川智一, 土屋高旭, 北川未央, 後町俊夫, 坂田耕一

    日本免疫治療学会学術集会プログラム・抄録集   21st   2024

  • 頭頚部がん症状評価尺度MD Anderson Symptom Inventory Head and Neck module:MDASI-HN日本語版の信頼性・妥当性の検証

    澤口宙人, 川村三希子, 團塚恵子, 染谷正則, 中田健生, 宮下光令, 高田優

    日本がん看護学会学術集会(Web)   38th   2024

  • Stage IVa進行食道癌におけるDocetaxel/CDGP/5-FU・放射線同時併用療法(DNF-R)の予後解析

    佐藤 昌則, 大沼 啓之, 早坂 尚貴, 濱口 孝太, 村瀬 和幸, 高田 弘一, 宮西 浩嗣, 加藤 淳二, 染谷 正則, 坂田 耕一

    北海道医学雑誌   98 ( 2 )   139 - 139   2023.11

     More details

    Language:Japanese   Publisher:北海道医学会  

    Ichushi

    researchmap

  • 化学放射線+免疫療法を行った3期NSCLCにおける、末梢血リンパ細胞のTCRレパトア解析

    染谷 正則, 長谷川 智一, 北川 未央, 土屋 高旭, 後町 俊夫, 眞船 翔, 金関 貴幸, 蒔田 芹奈, 鳥越 俊彦, 坂田 耕一

    日本癌治療学会学術集会抄録集   61回   O46 - 3   2023.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    Ichushi

    J-GLOBAL

    researchmap

  • 【膵癌診療ガイドライン2022改訂のポイント】化学療法

    水野 伸匡, 井岡 達也, 上野 誠, 尾阪 将人, 染谷 正則, 奥坂 拓志

    膵臓   38 ( 2 )   127 - 132   2023.4

  • 【膵癌診療ガイドライン2022改訂のポイント】放射線療法

    伊藤 芳紀, 中村 聡明, 大栗 隆行, 染谷 正則, 篠藤 誠

    膵臓   38 ( 2 )   121 - 126   2023.4

  • Issues in the 2022 revision of the Clinical Practice Guidelines for Pancreatic Cancer -Radiotherapy-

    伊藤芳紀, 中村聡明, 大栗隆行, 染谷正則, 篠藤誠

    膵臓(Web)   38 ( 2 )   2023

  • 化学放射線療法+免疫療法を行った3期切除不能非小細胞肺癌における,末梢血リンパ細胞のTCRレパトア解析

    染谷正則, 長谷川智一, 北川未央, 土屋高旭, 眞船翔, 後町俊夫, 池内佑太郎, 金関貴幸, 鳥越俊彦, 坂田耕一

    日本免疫治療学会学術集会プログラム・抄録集   20th   2023

  • 動脈化学放射線療法と外科手術を行った口腔癌の免疫組織学的評価

    染谷正則

    日本バイオセラピィ学会学術集会総会プログラム・抄録集   36th   2023

  • 放射線照射7ヵ月後に非照射部の転移が縮小した悪性黒色腫の1例

    佐々木 洋, 加藤 潤史, 執行 遥香, 小林 英理, 古舘 和樹, 半田 稔也, 細川 夕菜, 佐藤 さゆり, 堀本 浩平, 宇原 久, 土屋 高旭, 染谷 正則

    日本皮膚科学会雑誌   132 ( 12 )   2697 - 2697   2022.11

     More details

    Language:Japanese   Publisher:(公社)日本皮膚科学会  

    Ichushi

    researchmap

  • 血中エクソソーム由来miRNAを用いた子宮頸癌の治療効果予測

    染谷 正則, 土屋 高旭, 福島 悠希, 長谷川 智一, 井戸川 雅史, 松浦 基樹, 岩崎 雅宏, 廣橋 良彦, 鳥越 俊彦, 齋藤 豪, 坂田 耕一

    日本癌治療学会学術集会抄録集   60回   P102 - 2   2022.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    Ichushi

    researchmap

  • 表在型食道癌ESD後のMM-SM癌における追加化学放射線療法の長期成績

    伊藤 亮, 大沼 啓之, 早坂 尚貴, 佐藤 昌則, 村瀬 和幸, 高田 弘一, 福島 悠希, 長谷川 智一, 土屋 高旭, 染谷 正則, 宮西 浩嗣, 坂田 耕一, 加藤 淳二

    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集   131回・125回   56 - 56   2022.9

     More details

    Language:Japanese   Publisher:日本消化器病学会-北海道支部  

    Ichushi

    researchmap

  • 表在型食道癌ESD後のMM-SM癌における追加化学放射線療法の長期成績

    伊藤 亮, 大沼 啓之, 早坂 尚貴, 佐藤 昌則, 村瀬 和幸, 高田 弘一, 福島 悠希, 長谷川 智一, 土屋 高旭, 染谷 正則, 宮西 浩嗣, 坂田 耕一, 加藤 淳二

    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集   131回・125回   56 - 56   2022.9

     More details

    Language:Japanese   Publisher:日本消化器病学会-北海道支部  

    Ichushi

    researchmap

  • 食道癌化学放射線療法症例における放射線胃炎のリスク因子の検討

    佐藤 昌則, 大沼 啓之, 早坂 尚貴, 伊藤 亮, 村瀬 和幸, 高田 弘一, 福島 悠希, 長谷川 智一, 土屋 高旭, 染谷 正則, 宮西 浩嗣, 坂田 耕一, 加藤 淳二

    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集   131回・125回   55 - 55   2022.9

     More details

    Language:Japanese   Publisher:日本消化器病学会-北海道支部  

    Ichushi

    researchmap

  • 化学放射線療法+免疫療法を行った3期切除不能非小細胞肺癌における,末梢血リンパ細胞のTCRレパトア解析

    染谷正則, 鳥越俊彦

    日本バイオセラピィ学会学術集会総会プログラム・抄録集   35th   2022

  • 血中エクソソーム由来miRNAを用いた子宮頸癌の治療効果予測

    染谷正則, 土屋高旭, 福島悠希, 長谷川智一, 井戸川雅史, 松浦基樹, 岩崎雅宏, 廣橋良彦, 鳥越俊彦, 齋藤豪, 坂田耕一

    日本癌治療学会学術集会(Web)   60th   2022

  • 血中エクソソームmiRNAを用いた子宮頸癌の治療効果予測

    染谷正則, 土屋高旭, 福島悠希, 池内佑太郎, 眞船翔, 小塚陽, 北川未央, 後町俊夫, 坂田耕一

    日本免疫治療学会学術集会プログラム・抄録集   19th   2022

  • 子宮頸癌根治照射症例におけるCD8の浸潤形式と予後との関連

    染谷 正則, 土屋 高旭, 福島 悠希, 長谷川 智一, 北川 未央, 後町 俊夫, 岩崎 雅宏, 松浦 基樹, 齋藤 豪, 坂田 耕一

    日本癌治療学会学術集会抄録集   59回   O37 - 7   2021.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    Ichushi

    J-GLOBAL

    researchmap

  • 進行食道癌に対するdocetaxel、nedaplatin、5-fluorouracil、放射線併用療法(DNF-R)による根治的化学放射線療法の第I/II相試験-アップデート解析

    佐藤 昌則, 大沼 啓之, 早坂 尚貴, 濱口 孝太, 村瀬 和幸, 高田 弘一, 福島 悠希, 長谷川 智一, 土屋 高旭, 染谷 正則, 宮西 浩嗣, 坂田 耕一, 加藤 淳二

    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集   129回・123回   26 - 26   2021.9

     More details

    Language:Japanese   Publisher:日本消化器病学会-北海道支部  

    Ichushi

    researchmap

  • 膵癌診療ガイドライン2022の改訂作業の概況(放射線療法)

    伊藤 芳紀, 中村 聡明, 大栗 隆行, 染谷 正則, 篠藤 誠, 梅澤 玲, 稲葉 浩二, 土屋 高旭, 小野 幸果

    膵臓   36 ( 3 )   A94 - A94   2021.8

     More details

    Language:Japanese   Publisher:(一社)日本膵臓学会  

    Ichushi

    researchmap

  • 腹腔動脈浸潤による切除不能膵頭体部癌 膵全摘・胃亜全摘回避のリカバリーショット

    木村 康利, 今村 将史, 永山 稔, 村上 武志, 伊東 竜哉, 吉田 真誠, 廣川 直樹, 染谷 正則, 竹政 伊知朗

    膵臓   36 ( 3 )   A380 - A380   2021.8

     More details

    Language:Japanese   Publisher:(一社)日本膵臓学会  

    Ichushi

    researchmap

  • 根治的放射線治療を行った中咽頭癌症例における腫瘍免疫と予後との関連

    福島 悠希, 染谷 正則, 坂田 耕一

    頭頸部癌   47 ( 2 )   225 - 225   2021.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    Ichushi

    researchmap

  • 根治的放射線治療を行った中咽頭癌症例における腫瘍免疫と予後との関連

    福島 悠希, 染谷 正則, 坂田 耕一

    頭頸部癌   47 ( 2 )   225 - 225   2021.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    Ichushi

    researchmap

  • 食道癌 診断と治療のup to date 食道腺癌を含めて 切除可能進行食道癌に対する三剤併用療法ベースの化学放射線療法は手術療法を代替できるか?:傾向スコアマッチング分析

    大沼 啓之, 小野山 直輝, 濱口 孝太, 早坂 尚貴, 佐藤 昌則, 村瀬 和幸, 高田 弘一, 宮西 浩嗣, 村上 武志, 伊東 竜哉, 信岡 隆幸, 竹政 伊知朗, 土屋 高旭, 長谷川 智一, 堀 正和, 染谷 正則, 坂田 耕一, 加藤 淳二

    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集   128回・122回   35 - 35   2021.3

     More details

    Language:Japanese   Publisher:日本消化器病学会-北海道支部  

    Ichushi

    researchmap

  • 食道癌 診断と治療のup to date 食道腺癌を含めて 切除可能進行食道癌に対する三剤併用療法ベースの化学放射線療法は手術療法を代替できるか?:傾向スコアマッチング分析

    大沼 啓之, 小野山 直輝, 濱口 孝太, 早坂 尚貴, 佐藤 昌則, 村瀬 和幸, 高田 弘一, 宮西 浩嗣, 村上 武志, 伊東 竜哉, 信岡 隆幸, 竹政 伊知朗, 土屋 高旭, 長谷川 智一, 堀 正和, 染谷 正則, 坂田 耕一, 加藤 淳二

    日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集   128回・122回   35 - 35   2021.3

     More details

    Language:Japanese   Publisher:日本消化器病学会-北海道支部  

    Ichushi

    researchmap

  • 根治的放射線治療を受けた子宮頸癌患者におけるCD8細胞浸潤の様態と予後との関連(Relationship between the Type of CD8 Invasion and Prognosis in Patients with Cervical Cancer Treated with Definitive Radiotherapy)

    Someya Masanori, Fukushima Yuuki, Tsuchiya Takaaki, Hasegawa Tomokazu, Hori Masakazu, Gocho Toshio, Kozuka Yohsuke, Ikeuchi Yutaro, Mafune Shoh, Sakata Koh-ichi

    日本医学放射線学会学術集会抄録集   80回   S194 - S194   2021.3

     More details

    Language:English   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 膵癌診療ガイドライン2022の改訂作業の概況(放射線療法)

    伊藤芳紀, 中村聡明, 大栗隆行, 染谷正則, 篠藤誠, 梅澤玲, 稲葉浩二, 土屋高旭, 小野幸果

    膵臓(Web)   36 ( 3 )   2021

  • 免疫放射線療法 HPV関連癌における癌免疫と放射線療法効果の関係性(Relationship between tumor immunity and radiotherapy effects in HPV associated cancer)

    染谷 正則, 土屋 高旭, 福島 悠希, 廣橋 良彦, 鳥越 俊彦, 坂田 耕一

    日本医学放射線学会秋季臨床大会抄録集   56回   S34 - S34   2020.10

     More details

    Language:English   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 根治放射線療を行った進行期子宮頸癌症例における腫瘍免疫と予後の関連

    染谷 正則, 土屋 高旭, 福島 悠希, 長谷川 智一, 高田 優, 中田 健生, 堀 正和, 三浦 勝利, 北川 未央, 後町 俊夫, 岩崎 雅宏, 松浦 基樹, 齋藤 豪, 坂田 耕一

    日本癌治療学会学術集会抄録集   58回   O16 - 4   2020.10

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    Ichushi

    researchmap

  • 再発または遠隔転移を有する口腔癌に対しニボルマブ投与は遺伝子変異が指標となるか

    荻 和弘, 小林 淳一, 西山 廣陽, 小池 和茂, 高田 弘一, 染谷 正則, 宮崎 晃亘

    日本癌治療学会学術集会抄録集   58回   P - 8   2020.10

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    Ichushi

    researchmap

  • がん免疫と放射線治療(基礎と臨床) HPV関連癌における腫瘍免疫と放射線治療効果との関係(An anti-tumor immunity and radiation: basic and clinicalresearch Relationship between tumor immunity and radiotherapy effects in HPV associated cancer)

    染谷 正則, 土屋 高旭, 福島 悠希, 廣橋 良彦, 鳥越 俊彦, 坂田 耕一

    日本放射線影響学会大会講演要旨集   63回   15 - 15   2020.10

     More details

    Language:English   Publisher:(一社)日本放射線影響学会  

    Ichushi

    researchmap

  • 切除可能進行食道癌に対する三剤併用療法ベースの化学放射線療法は手術療法を代替できるか? 傾向スコアマッチング分析

    大沼 啓之, 小野山 直輝, 濱口 孝太, 早坂 尚貴, 佐藤 昌則, 村瀬 和幸, 高田 弘一, 宮西 浩嗣, 伊東 竜哉, 信岡 隆幸, 竹政 伊知朗, 長谷川 智一, 堀 正和, 染谷 正則, 坂田 耕一, 加藤 淳二

    日本消化器病学会北海道支部例会プログラム・抄録集   126回   50 - 50   2020.3

     More details

    Language:Japanese   Publisher:日本消化器病学会-北海道支部  

    Ichushi

    researchmap

  • 【膵癌診療ガイドライン2019改訂のポイント】放射線療法

    伊藤 芳紀, 澁谷 景子, 中村 聡明, 大栗 隆行, 染谷 正則

    膵臓   35 ( 1 )   63 - 68   2020.2

  • 局所進行食道癌に対するDocetaxel/Nedaplatin/5-FU・放射線同時併用療法(DNF-R)の第II相試験 アップデート解析

    佐藤 昌則, 大沼 啓之, 早坂 尚貴, 村瀬 和幸, 高田 弘一, 宮西 浩嗣, 加藤 淳二, 平川 昌宏, 佐川 保, 堀 正和, 染谷 正則, 坂田 耕一

    北海道医学雑誌   94 ( 2 )   121 - 121   2019.11

     More details

    Language:Japanese   Publisher:北海道医学会  

    Ichushi

    researchmap

  • 放射線療法の進歩と明日への提言

    伊藤 芳紀, 澁谷 景子, 中村 聡明, 大栗 隆行, 染谷 正則, 堀 正和, 高橋 昌太郎, 篠藤 誠, 梅澤 玲

    膵臓   34 ( 3 )   A16 - A16   2019.6

     More details

    Language:Japanese   Publisher:日本膵臓学会  

    Ichushi

    researchmap

  • 粘液線維肉腫における不十分な切除縁症例に対する術後放射線治療成績

    江森 誠人, 清水 淳也, 水島 衣美, 村橋 靖崇, 山下 敏彦, 染谷 正則

    北海道整形災害外科学会雑誌   61 ( 136th suppl )   3 - 3   2019

     More details

    Language:Japanese   Publisher:北海道整形災害外科学会  

    Ichushi

    researchmap

  • 放射線療法分野の問題点と今後の課題

    伊藤 芳紀, 澁谷 景子, 中村 聡明, 大栗 隆行, 染谷 正則, 堀 正和, 高橋 昌太郎, 篠藤 誠, 梅澤 玲

    膵臓   33 ( 3 )   311 - 311   2018.5

     More details

    Language:Japanese   Publisher:日本膵臓学会  

    Ichushi

    researchmap

  • 放射線療法分野の問題点と今後の課題

    伊藤 芳紀, 澁谷 景子, 中村 聡明, 大栗 隆行, 染谷 正則, 堀 正和, 高橋 昌太郎, 篠藤 誠, 梅澤 玲

    膵臓   33 ( 3 )   311 - 311   2018.5

     More details

    Language:Japanese   Publisher:日本膵臓学会  

    Ichushi

    researchmap

  • 当院での子宮頸癌の根治的放射線治療成績 192-Ir HDR RALS導入後6年での解析

    松本 健一, 福島 悠希, 後町 俊夫, 土屋 高旭, 北川 未央, 堀 正和, 中田 健生, 染谷 正則, 坂田 耕一, 高田 優, 池田 光, 三浦 勝利

    Japanese Journal of Radiology   36 ( Suppl. )   6 - 6   2018.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 当院における肺癌に対する体幹部定位放射線治療の治療成績

    征矢野 崇, 松本 健一, 後町 俊夫, 福島 悠希, 土屋 高旭, 北川 未央, 堀 正和, 中田 健生, 染谷 正則, 坂田 耕一

    Japanese Journal of Radiology   36 ( Suppl. )   8 - 8   2018.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 中咽頭癌の治療成績ならびにHPV感染と免疫染色の関連性

    福島 悠希, 染谷 正則, 中田 健生, 堀 正和, 北川 未央, 土屋 高旭, 長谷川 智一, 後町 俊夫, 松本 健一, 坂田 耕一

    Japanese Journal of Radiology   36 ( Suppl. )   10 - 10   2018.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • メラノーマにおける抗PD-1抗体と放射線治療

    加藤潤史, 肥田時征, 堀本浩平, 佐藤さゆり, 澤田匡秀, 土屋高旭, 北川未央, 中田健生, 染谷正則, 宇原久

    日本臨床腫瘍学会学術集会(CD-ROM)   16th   2018

  • 食道癌生検標本における抗PD-L1抗体の発現

    堀 正和, 染谷 正則, 中田 健生, 北川 未央, 土屋 高旭, 長谷川 智一, 福島 悠希, 後町 俊夫, 松本 健一, 坂田 耕一

    北海道医学雑誌   92 ( 2 )   115 - 115   2017.11

     More details

    Language:Japanese   Publisher:北海道医学会  

    Ichushi

    researchmap

  • 当院における緩和的放射線治療の効果 PCUを有するがん専門病院と大学病院における緩和的放射線治療の比較を含めて

    日下部 俊朗, 照井 健, 石谷 邦彦, 小根 克之, 小館 篤, 中田 健生, 土屋 高旭, 北川 未央, 堀 正和, 染谷 正則, 坂田 耕一

    Palliative Care Research   12 ( Suppl. )   S508 - S508   2017.6

     More details

    Language:Japanese   Publisher:(NPO)日本緩和医療学会  

    Ichushi

    researchmap

  • Stage III、IV口腔癌に対するCDDP動注放射線同時併用療法の組織効果と治療経過

    宮崎 晃亘, 小林 淳一, 荻 和弘, 清水 翔太, 金子 剛, 五十嵐 友彦, 廣川 直樹, 染谷 正則, 坂田 耕一, 平塚 博義

    頭頸部癌   43 ( 2 )   236 - 236   2017.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    Ichushi

    researchmap

  • 抗PD-1抗体と放射線療法を併用した悪性黒色腫のin-transit転移症例

    佐藤 さゆり, 加藤 潤史, 澤田 匡秀, 高橋 仁美, 堀本 浩平, 染谷 正則, 宇原 久

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集   33回   154 - 154   2017.5

     More details

    Language:Japanese   Publisher:(一社)日本皮膚悪性腫瘍学会  

    Ichushi

    researchmap

  • 当院における塩化ラジウム-223の治療経験

    堀 正和, 染谷 正則, 中田 健生, 坂田 耕一

    核医学   54 ( 1 )   652 - 652   2017.2

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

    Ichushi

    researchmap

  • 口腔癌に対するCDDPを用いた放射線併用選択的動注化学療法を施行し5年以上経過した症例の検討

    小林 淳一, 宮崎 晃亘, 岡本 準也, 宮本 昇, 荻 和弘, 出張 裕也, 廣川 直樹, 染谷 正則, 坂田 耕一, 平塚 博義

    頭頸部癌   42 ( 2 )   253 - 253   2016.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    Ichushi

    researchmap

  • CRT後出血死に至った頸部食道癌の1例

    福島 悠希, 堀 正和, 中田 健生, 染谷 正則, 高田 優, 北川 未央, 長谷川 智一, 後町 俊夫, 松本 健一, 坂田 耕一

    Japanese Journal of Radiology   34 ( Suppl. )   11 - 11   2016.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 進行食道癌に対するdocetaxel、nedaplatin、5-FU、放射線同時併用療法(DNF-R)の第I/II相試験

    大沼 啓之, 佐藤 康史, 大須賀 崇裕, 林 毅, 佐藤 勉, 宮西 浩嗣, 小船 雅義, 瀧本 理修, 加藤 淳二, 佐川 保, 堀 正和, 染谷 正則, 中田 健生, 坂田 耕一

    北海道医学雑誌   90 ( 2 )   152 - 153   2015.11

     More details

    Language:Japanese   Publisher:北海道医学会  

    Ichushi

    researchmap

  • 頸部食道癌に対するIMRTの治療経験

    福島 悠希, 堀 正和, 染谷 正則, 中田 健生, 高田 優, 北川 未央, 長谷川 智一, 後町 俊夫, 坂田 耕一, 大沼 啓之, 佐藤 康史, 加藤 淳二

    北海道医学雑誌   90 ( 2 )   154 - 155   2015.11

     More details

    Language:Japanese   Publisher:北海道医学会  

    Ichushi

    researchmap

  • 当科における胆道癌に対するS-1併用放射線化学療法の成績

    小野 道洋, 石渡 裕俊, 植村 尚貴, 石川 和真, 佐藤 勉, 宮西 浩嗣, 佐藤 康史, 瀧本 理修, 小船 雅義, 今村 将史, 木村 康利, 染谷 正則, 坂田 耕一, 加藤 淳二

    日本消化器病学会雑誌   112 ( 臨増大会 )   A880 - A880   2015.9

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

    Ichushi

    researchmap

  • センチネルリンパ節手技を用いて術後放射線照射領域を決定したメルケル細胞癌6例

    加藤 潤史, 澄川 靖之, 高田 優, 中田 健生, 染谷 正則, 山下 利春

    日本癌治療学会誌   50 ( 3 )   863 - 863   2015.9

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    Ichushi

    researchmap

  • 食道 食道がんに対する集学的治療 進行食道癌に対するdocetaxel/nedaplatin/5-FU/放射線併用(DNF-R)療法の第I/II相試験

    佐藤 康史, 大沼 啓之, 平川 昌弘, 岡川 泰, 大須賀 崇裕, 佐藤 勉, 瀧本 理修, 小船 雅義, 佐川 保, 堀 正和, 染谷 正則, 中田 健生, 坂田 耕一, 高山 哲治, 加藤 淳二

    日本癌治療学会誌   50 ( 3 )   1085 - 1085   2015.9

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

    Ichushi

    researchmap

  • 前立腺癌に対するIMRTを用いた全骨盤照射の安全性

    堀 正和, 中田 健生, 染谷 正則, 北村 寛, 高橋 聡, 舛森 直哉, 坂田 耕一

    泌尿器外科   28 ( 8 )   1391 - 1393   2015.8

     More details

    Language:Japanese   Publisher:医学図書出版(株)  

    Ichushi

    researchmap

  • A phase I/II study of definitive chemoradiotherapy with docetaxel, nedaplatin, and 5-fluorouracil (DNF-R) for advanced esophageal cancer

    Yasushi Sato, Hiroyuki Ohnuma, Masahiro Hirakawa, Yutaka Okagawa, Takahiro Osuga, Kazuyuki Murase, Kohichi Takada, Yutaka Kawano, Satoshi Iyama, Tsuyoshi Hayashi, Tsutomu Sato, Koji Miyanishi, Rishu Takimoto, Masayoshi Kobune, Tamotsu Sagawa, Masakazu Hori, Masanori Someya, Koh-ichi Sakata, Tetsuji Takayama, Junji Kato

    JOURNAL OF CLINICAL ONCOLOGY   33 ( 3 )   2015.1

     More details

    Language:English   Publishing type:Research paper, summary (international conference)  

    Web of Science

    researchmap

  • 食道癌におけるドセタキセル併用化学放射線治療

    堀 正和, 染谷 正則, 中田 健生, 北川 未央, 土屋 高旭, 長谷川 智一, 小野寺 耕一, 坂田 耕一, 佐藤 康史, 大沼 啓之, 加藤 淳二

    北海道外科雑誌   59 ( 2 )   205 - 205   2014.12

     More details

    Language:Japanese   Publisher:北海道外科学会  

    Ichushi

    researchmap

  • 食道T1a-MM・SM癌におけるESD後追加治療の治療成績

    大沼 啓之, 佐藤 康史, 大須賀 崇裕, 定免 渉, 岡川 泰, 林 毅, 佐藤 勉, 宮西 浩嗣, 小船 雅義, 瀧本 理修, 加藤 淳二, 堀 正和, 中田 健生, 染谷 正則, 坂田 耕一

    北海道外科雑誌   59 ( 2 )   204 - 204   2014.12

     More details

    Language:Japanese   Publisher:北海道外科学会  

    Ichushi

    researchmap

  • 子宮全摘術後の腟断端残存/再発腫瘍に対する腔内照射の治療成績

    中田 健生, 染谷 正則, 堀 正和, 高田 優, 北川 未央, 長谷川 智一, 後町 俊夫, 坂田 耕一

    臨床放射線   59 ( 10 )   1372 - 1378   2014.10

     More details

    Language:Japanese   Publisher:金原出版(株)  

    Ichushi

    researchmap

  • 外照射併用シード療法におけるIMRTと四門照射の比較

    堀 正和, 中田 健生, 染谷 正則, 坂田 耕一, 北村 寛, 高橋 聡, 舛森 直哉

    泌尿器外科   27 ( 8 )   1359 - 1360   2014.8

     More details

    Language:Japanese   Publisher:医学図書出版(株)  

    Ichushi

    researchmap

  • 当院における中下咽頭癌IMRTの治療成績

    中田 健生, 北川 未央, 堀 正和, 長谷川 智一, 三浦 勝利, 染谷 正則, 舘岡 邦彦, 坂田 耕一, 畠中 正光

    Japanese Journal of Radiology   32 ( Suppl. )   5 - 5   2014.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 当科の食道がんに対する放射線治療成績

    堀 正和, 中田 健生, 染谷 正則, 高木 克, 三浦 勝利, 北川 未央, 長谷川 智一, 坂田 耕一, 畠中 正光

    Japanese Journal of Radiology   32 ( Suppl. )   5 - 5   2014.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 上咽頭癌に対する強度変調放射線治療 当院での治療成績

    北川 未央, 中田 健生, 坂田 耕一, 染谷 正則, 舘岡 邦彦, 堀 正和, 高木 克, 三浦 勝利, 畠中 正光

    Japanese Journal of Radiology   32 ( Suppl. )   5 - 5   2014.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 進行食道癌に対するDocetaxel/CDGP/5-FU・放射線同時併用療法(DNF-R)による第I/II相試験(中間報告)

    佐藤 康史, 大沼 啓之, 平川 昌宏, 林 毅, 佐藤 勉, 宮西 浩嗣, 瀧本 理修, 小船 雅義, 加藤 淳二, 佐川 保, 堀 正和, 中田 健生, 染谷 正則, 坂田 耕一

    北海道外科雑誌   58 ( 2 )   214 - 215   2013.12

     More details

    Language:Japanese   Publisher:北海道外科学会  

    Ichushi

    researchmap

  • 食道癌におけるXRCC4遺伝子発現と放射線治療成績

    堀 正和, 中田 健生, 染谷 正則, 三浦 勝利, 坂田 耕一

    北海道外科雑誌   58 ( 2 )   216 - 216   2013.12

     More details

    Language:Japanese   Publisher:北海道外科学会  

    Ichushi

    researchmap

  • メルケル細胞癌の術後放射線治療 ICGを用いた照射領域の検討

    加藤 潤史, 中田 健生, 染谷 正則, 菅 裕司, 澄川 靖之, 小野 一郎, 山下 利春

    日本皮膚悪性腫瘍学会学術大会プログラム・抄録集   29回   144 - 144   2013.8

     More details

    Language:Japanese   Publisher:(一社)日本皮膚悪性腫瘍学会  

    Ichushi

    researchmap

  • 食道癌におけるXRCC4、DNA-PKcs、Ku蛋白の発現と放射線治療成績の検討

    堀 正和, 中田 健生, 染谷 正則, 三浦 勝利, 坂田 耕一

    日本食道学会学術集会プログラム・抄録集   67回   205 - 205   2013.6

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    Ichushi

    researchmap

  • 蝶形骨洞癌に対する化学放射線治療を施行した3例

    土屋 高旭, 中田 健生, 堀 正和, 三浦 勝利, 林 潤一, 高木 克, 染谷 正則, 坂田 耕一, 晴山 雅人

    Japanese Journal of Radiology   31 ( Suppl.I )   12 - 12   2013.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 早期喉頭癌根治的放射線治療における分割照射法による入院期間の検討

    中田 健生, 坂田 耕一, 高木 克, 染谷 正則, 近藤 敦, 氷見 徹夫, 晴山 雅人

    頭頸部癌   38 ( 3 )   315 - 317   2012.10

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    Ichushi

    researchmap

  • 口腔癌に対するCDDPを用いた放射線併用選択的動注化学療法の検討

    小林 淳一, 宮崎 晃亘, 仲盛 健治, 荻 和弘, 出張 裕也, 廣川 直樹, 染谷 正則, 坂田 耕一, 平塚 博義

    日本癌治療学会誌   47 ( 3 )   1408 - 1408   2012.10

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    Ichushi

    researchmap

  • 食道癌に対するDocetaxel/CDGP/5-FU・放射線同時併用療法 第I/II相試験(中間報告)

    大沼 啓之, 佐藤 康史, 池田 裕貴, 神原 悠輔, 平川 昌宏, 佐川 保, 林 毅, 佐藤 勉, 宮西 浩嗣, 染谷 正則, 坂田 耕一, 晴山 雅人, 瀧本 理修, 小船 雅義, 加藤 淳二

    日本癌治療学会誌   47 ( 3 )   1174 - 1174   2012.10

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    Ichushi

    researchmap

  • 口腔癌に対するCDDPを用いた放射線併用選択的動注化学療法の検討

    小林 淳一, 宮崎 晃亘, 仲盛 健治, 荻 和弘, 出張 裕也, 曽我部 陽平, 五十嵐 友彦, 染谷 正則, 坂田 耕一, 晴山 雅人, 平塚 博義

    頭頸部癌   38 ( 2 )   245 - 245   2012.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    Ichushi

    researchmap

  • 当院における下咽頭癌の放射線治療成績の検討

    林 潤一, 三浦 勝利, 中田 健生, 染谷 正則, 堀 正和, 坂田 耕一, 晴山 雅人

    Japanese Journal of Radiology   30 ( Suppl.I )   5 - 5   2012.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 電子スピン共鳴装置を用いた照射後腫瘍内酸素濃度の測定

    坂田 耕一, 染谷 正則, 晴山 雅人, 藤井 博匡, 佐藤 力哉, 平田 拓

    日本医学放射線学会学術集会抄録集   71回   S290 - S290   2012.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 放射線による細胞死を考える(その2) 治療戦略に向けて DNA損傷修復機構の治療戦略への応用

    田内 広, 船生 悠美, 大原 麻希, 坂田 耕一, 染谷 正則, 関 良太, 飯島 健太, 小松 賢志, 晴山 雅人

    日本放射線影響学会大会講演要旨集   54回   55 - 55   2011.11

     More details

    Language:Japanese   Publisher:(一社)日本放射線影響学会  

    Ichushi

    researchmap

  • 高齢者舌がん、頸部転移に対して放射線併用動注化学療法を施行してCRが得られた1例

    小林 淳一, 宮崎 晃亘, 仲盛 健治, 出張 裕也, 染谷 正則, 廣川 直樹, 晴山 雅人, 平塚 博義

    日本癌治療学会誌   46 ( 2 )   788 - 788   2011.9

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    Ichushi

    researchmap

  • 当科における食道癌の治療成績 化学療法同時併用症例および腔内照射併用症例の検討

    堀 正和, 中田 健生, 染谷 正則, 坂田 耕一, 佐藤 康史, 佐竹 保, 加藤 淳二, 晴山 雅人

    日本食道学会学術集会プログラム・抄録集   65回   319 - 319   2011.9

     More details

    Language:Japanese   Publisher:(NPO)日本食道学会  

    Ichushi

    researchmap

  • 【基礎と臨床の対話】放射線増感剤の基礎と臨床 ギメラシルによる放射線増感作用

    坂田 耕一, 高木 克, 染谷 正則, 田内 広, 松本 義久, 晴山 雅人, 福島 正和

    癌の臨床   56 ( 6 )   441 - 443   2011.4

     More details

    Language:Japanese   Publisher:(株)篠原出版新社  

    Ichushi

    researchmap

  • 食道癌に対するDocetaxel/CDGP/5-FU・放射線同時併用療法(DNF-R)による第I相試験

    佐藤 康史, 平川 昌宏, 大沼 啓之, 佐川 保, 加藤 淳二, 染谷 正則, 坂田 耕一, 晴山 雅人

    北海道外科雑誌   55 ( 2 )   196 - 196   2010.12

     More details

    Language:Japanese   Publisher:北海道外科学会  

    Ichushi

    researchmap

  • 口腔癌に対する放射線併用選択的動注化学療法の検討

    小林 淳一, 宮崎 晃亘, 仲盛 健治, 安倍 聖人, 荻 和弘, 染谷 正則, 廣川 直樹, 晴山 雅人, 平塚 博義

    日本癌治療学会誌   45 ( 2 )   866 - 866   2010.9

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    Ichushi

    researchmap

  • Two cases of stage I and IIA rectal cancer treated by S-1 with concurrent radiotherapy

    浅井真友美, 中田健生, 高田優, 小島一男, 高木克, 染谷正則, 坂田耕一, 晴山雅人

    臨床放射線   55 ( 7 )   924 - 927   2010.7

     More details

  • 舌根部腺様嚢胞癌の1例

    高田 優, 高木 克, 林 潤一, 小島 一男, 中田 健生, 染谷 正則, 坂田 耕一, 晴山 雅人

    Japanese Journal of Radiology   28 ( Suppl.I )   15 - 15   2010.7

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 頭頸部癌に対するTS1併用化学放射線治療の第I相試験

    中田 健生, 染谷 正則, 高木 克, 坂田 耕一, 晴山 雅人

    頭頸部癌   36 ( 2 )   254 - 254   2010.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    Ichushi

    researchmap

  • 低酸素及び再酸素状態でのDNA-PK発現及びDNA-PK活性について

    坂田 耕一, 染谷 正則, 土本 正, 高木 克, 中田 健生, 小島 一男, 晴山 雅人

    日本医学放射線学会学術集会抄録集   69回   S297 - S297   2010.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 口腔癌に対する選択的動注化学放射線療法の検討

    小林 淳一, 宮崎 晃亘, 仲盛 健治, 出張 裕也, 安倍 聖人, 荻 和弘, 曽我部 陽平, 染谷 正則, 廣川 直樹, 晴山 雅人, 平塚 博義

    日本癌治療学会誌   44 ( 2 )   800 - 800   2009.9

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    Ichushi

    researchmap

  • ギメラシルの放射線増感効果の検討

    高木 克, 坂田 耕一, 染谷 正則, 林 潤一, 小島 一男, 中田 健生, 晴山 雅人, 松本 義久, 田内 広, 福島 正和

    頭頸部癌   35 ( 2 )   179 - 179   2009.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    Ichushi

    researchmap

  • 動注化学放射線療法を行った口腔扁平上皮癌症例の臨床的検討

    仲盛 健治, 宮崎 晃亘, 出張 裕也, 平塚 博義, 染谷 正則, 晴山 雅人

    頭頸部癌   35 ( 2 )   144 - 144   2009.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    Ichushi

    researchmap

  • 肺小細胞癌脳転移において長期生存をみた一例

    林 潤一, 小島 一男, 三浦 勝利, 高木 克, 中田 健生, 染谷 正則, 坂田 耕一, 晴山 雅人

    Japanese Journal of Radiology   27 ( Suppl. )   6 - 6   2009.4

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 頭頸部癌におけるTS1併用化学放射線療法の初期治療経験

    中田 健生, 小島 一男, 三浦 勝利, 林 潤一, 高木 克, 染谷 正則, 坂田 耕一, 晴山 雅人, 池田 光, 堀 正和

    Japanese Journal of Radiology   27 ( Suppl. )   5 - 5   2009.4

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 全身照射後に発生した二次癌の2例

    三浦 勝利, 高木 克, 中田 健生, 染谷 正則, 坂田 耕一, 晴山 雅人

    Japanese Journal of Radiology   27 ( Suppl. )   6 - 6   2009.4

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 急性リンパ性白血病(ALL)の精巣浸潤に対する放射線治療

    小島 一男, 三浦 勝利, 林 潤一, 高木 克, 中田 健生, 染谷 正則, 永倉 久泰, 大内 敦, 坂田 耕一, 晴山 雅人

    Japanese Journal of Radiology   27 ( Suppl. )   6 - 6   2009.4

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 【放射線治療の進歩 多分割照射の基礎と臨床】多分割照射の理論の臨床への応用

    坂田 耕一, 染谷 正則, 中田 健生, 高木 克, 晴山 雅人

    癌と化学療法   35 ( 11 )   1823 - 1826   2008.11

     More details

    Language:Japanese   Publisher:(株)癌と化学療法社  

    Ichushi

    researchmap

  • I-125前立腺組織内照射におけるSeed Migrationの検討

    高木 克, 林 潤一, 小島 一男, 中田 健生, 染谷 正則, 坂田 耕一, 館岡 邦彦, 浅沼 治, 佐藤 香織, 晴山 雅人

    日本放射線腫瘍学会誌   20 ( 2 )   86 - 86   2008.6

     More details

    Language:Japanese   Publisher:(公社)日本放射線腫瘍学会  

    Ichushi

    researchmap

  • 早期前立腺癌に対する低線量率組織内照射の初期経験

    高木 克, 小島 一男, 堀 正和, 土本 正, 染谷 正則, 大内 敦, 坂田 耕一, 晴山 雅人, 舘岡 邦彦, 浅沼 治, 佐藤 香織, 山品 将祥

    Radiation Medicine   26 ( Suppl.I )   6 - 6   2008.4

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 当院における乳房温存療法の動向(第2報)

    大内 敦, 小島 一男, 高木 克, 堀 正和, 染谷 正則, 坂田 耕一, 晴山 雅人, 山品 将祥, 荒谷 和紀, 永倉 久泰

    Radiation Medicine   26 ( Suppl.I )   5 - 5   2008.4

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 当科における食道癌の放射線治療成績 化学放射線療法・腔内照射の治療成績を中心に

    堀 正和, 染谷 正則, 高木 克, 小島 一男, 三浦 勝利, 土本 正, 大内 敦, 坂田 耕一, 晴山 雅人, 永倉 久泰

    Radiation Medicine   26 ( Suppl.I )   12 - 12   2008.4

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 前立腺癌に対する外照射および組織内照射後のPSA値の変動

    高木 克, 小島 一男, 堀 正和, 土本 正, 染谷 正則, 大内 敦, 坂田 耕一, 晴山 雅人

    Radiation Medicine   26 ( Suppl.I )   12 - 12   2008.4

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • ギメラシルの放射線増感効果の分子メカニズム

    坂田 耕一, 染谷 正則, 高木 克, 中田 健生, 小島 一男, 晴山 雅人, 田内 広, 松本 義久, 福島 正和

    日本医学放射線学会学術集会抄録集   67回   S254 - S255   2008.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 分割照射や抗癌剤併用におけるギメラシルの放射線増感作用の検討

    高木 克, 坂田 耕一, 染谷 正則, 林 潤一, 小島 一男, 中田 健生, 晴山 雅人, 松本 義久, 田内 広, 福島 正和

    日本医学放射線学会学術集会抄録集   67回   S254 - S254   2008.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 乳房温存療法の治療成績 dとly因子の検討

    大内 敦, 中田 健生, 小島 一男, 高木 克, 染谷 正則, 坂田 耕一, 晴山 雅人, 増岡 秀次, 下川原 出, 浅石 和昭, 岡崎 稔, 渡部 芳樹, 岡崎 亮, 岡崎 裕, 山田 毅, 湯山 友一, 大村 東生, 永倉 久泰, 堀 正和

    北海道外科雑誌   52 ( 2 )   231 - 231   2007.12

     More details

    Language:Japanese   Publisher:北海道外科学会  

    Ichushi

    researchmap

  • 当科における食道癌の化学放射線治療成績

    堀 正和, 染谷 正則, 大内 敦, 坂田 耕一, 晴山 雅人, 佐藤 康史, 高山 哲治, 新津 洋司郎, 永倉 久泰

    北海道外科雑誌   52 ( 2 )   218 - 218   2007.12

     More details

    Language:Japanese   Publisher:北海道外科学会  

    Ichushi

    researchmap

  • 多分割照射の基礎と臨床 多分割照射の理論の臨床への応用

    坂田 耕一, 染谷 正則, 中田 健生, 高木 克, 小島 一男, 晴山 雅人

    頭頸部癌   33 ( 3 )   280 - 282   2007.10

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    Ichushi

    researchmap

  • 【放射線生物学が描く、照射技術を超える放射線治療戦略とは】放射線による生物学的初期反応と修復 先行指標を求めて 発癌、放射線感受性とDNA2本鎖切断修復能

    坂田 耕一, 染谷 正則, 晴山 雅人

    癌の臨床   53 ( 6 )   361 - 364   2007.10

  • 放射線腫瘍学の卒前教育における問題解決型学習の有用性について

    内野 三菜子, 板澤 朋子, 染谷 正則, 中村 聡明

    日本放射線腫瘍学会誌   19 ( 3 )   139 - 146   2007.9

     More details

    Language:Japanese   Publisher:(公社)日本放射線腫瘍学会  

    Ichushi

    researchmap

  • Post-PlanningにおけるMRI fusion 11症例の検討

    高木 克, 三浦 勝利, 林 潤一, 小島 一男, 中田 健生, 染谷 正則, 坂田 耕一, 晴山 雅人, 館岡 邦彦, 浅沼 治, 佐藤 香織, 斉藤 航

    日本放射線腫瘍学会誌   19 ( 3 )   219 - 219   2007.9

     More details

    Language:Japanese   Publisher:(公社)日本放射線腫瘍学会  

    Ichushi

    researchmap

  • JASTRO平成16・17年度研究調査報告 卒前におけるセミナー形式専門的教育がキャリアパスに与える影響の検討 参加者の視点でみたJASTRO学生セミナー

    板澤 朋子, 内野 三菜子, 今葷倍 敏行, 染谷 正則, 尾藤 誠司

    日本放射線腫瘍学会誌   19 ( 2 )   127 - 133   2007.6

     More details

    Language:Japanese   Publisher:(公社)日本放射線腫瘍学会  

    Ichushi

    researchmap

  • 「医学生のための放射線治療セミナー」における問題解決型学習導入の試み

    内野 三菜子, 板澤 朋子, 染谷 正則, 中村 聡明

    医学教育   38 ( Suppl. )   86 - 86   2007.6

     More details

    Language:Japanese   Publisher:(一社)日本医学教育学会  

    Ichushi

    researchmap

  • 頬粘膜癌に対する低線量率組織内照射の治療成績

    高木 克, 堀 正和, 土本 正, 染谷 正則, 大内 敦, 坂田 耕一, 晴山 雅人, 永倉 久泰, 中田 健生, 齋藤 明夫

    頭頸部癌   33 ( 2 )   125 - 125   2007.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    Ichushi

    researchmap

  • 当科におけるT1,T2期声門癌の治療成績

    堀 正和, 坂田 耕一, 大内 敦, 永倉 久泰, 染谷 正則, 中田 健生, 土本 正, 荒谷 和紀, 晴山 雅人

    Radiation Medicine   25 ( Suppl.I )   6 - 6   2007.4

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • MFHは40Gyで治るか?

    永倉 久泰, 荒谷 和紀, 堀 正和, 土本 正, 染谷 正則, 玉川 光春, 大内 敦, 坂田 耕一, 晴山 雅人

    Radiation Medicine   25 ( Suppl.I )   16 - 16   2007.4

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 肺定位放射線治療におけるX線ビームの決定方法

    舘岡 邦彦, 大内 敦, 永倉 久泰, 染谷 正則, 荒谷 和則, 堀 正和, 坂田 耕一, 晴山 雅人

    Radiation Medicine   25 ( Suppl.I )   18 - 18   2007.4

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 進行膵管癌に対する化学放射線治療の成績

    廣川 直樹, 小井戸 一光, 永倉 久泰, 西田 睦, 佐藤 大志, 土本 正, 堀 正和, 河合 有里子, 染谷 正則, 大内 敦, 坂田 耕一, 晴山 雅人

    Radiation Medicine   25 ( Suppl.I )   7 - 7   2007.4

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 当科における乳房温存療法の動向

    荒谷 和紀, 大内 敦, 佐藤 大志, 堀 正和, 染谷 正則, 土本 正, 永倉 久泰, 坂田 耕一, 晴山 雅人, 中田 健生

    Radiation Medicine   25 ( Suppl.I )   16 - 16   2007.4

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 前立腺がんの原体照射治療成績

    大内 敦, 永倉 久泰, 染谷 正則, 堀 正和, 荒谷 和紀, 坂田 耕一, 晴山 雅人

    Radiation Medicine   25 ( Suppl.I )   18 - 18   2007.4

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 骨原発悪性リンパ腫の放射線治療成績

    山品 将祥, 染谷 正則, 土本 正, 小野寺 麻希, 笠原 理子, 林 潤一, 大内 敦, 坂田 耕一, 晴山 雅人

    Radiation Medicine   25 ( Suppl.I )   29 - 29   2007.4

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 様々な生物学的指標を用いた舌癌組織内照射の治療成績の分析

    坂田 耕一, 染谷 正則, 中田 健生, 高木 克, 大内 敦, 永倉 久泰, 晴山 雅人

    日本医学放射線学会学術集会抄録集   66回   S254 - S254   2007.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 乳房温存療法の治療成績 接線照射708例の検討

    大内 敦, 小島 一男, 高木 克, 堀 正和, 染谷 正則, 坂田 耕一, 晴山 雅人, 永倉 久泰, 大村 東生, 浅石 和昭, 下川原 出, 増岡 秀次, 岡崎 稔, 岡崎 亮, 渡部 芳樹, 岡崎 裕, 山田 毅, 湯山 友一, 中田 健生

    北海道外科雑誌   51 ( 2 )   81 - 81   2006.12

     More details

    Language:Japanese   Publisher:北海道外科学会  

    Ichushi

    researchmap

  • 2本鎖DNA切断修復研究と臨床応用

    坂田 耕一, 染谷 正則, 晴山 雅人

    札幌医学雑誌   75 ( 4-6 )   13 - 18   2006.12

  • がん専門医を目指す初期研修のあり方 放射線腫瘍学の場合

    内野 三菜子, 手島 昭樹, 染谷 正則, 錦織 宏, 土器屋 卓志

    日本癌治療学会誌   41 ( 2 )   576 - 576   2006.9

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

    Ichushi

    researchmap

  • 早期前立腺癌に対する低線量率組織内照射の初期経験

    高木 克, 小島 一男, 堀 正和, 土本 正, 染谷 正則, 大内 敦, 坂田 耕一, 晴山 雅人, 舘岡 邦彦, 浅沼 治, 佐藤 香織, 山品 将祥

    日本放射線腫瘍学会誌   18 ( 3 )   176 - 176   2006.9

     More details

    Language:Japanese   Publisher:(公社)日本放射線腫瘍学会  

    Ichushi

    researchmap

  • 第1回〜第8回「医学生のための放射線治療セミナー」参加者進路追跡調査

    内野 三菜子, 板澤 朋子, 染谷 正則, 今葷倍 敏行

    医学教育   37 ( Suppl. )   76 - 76   2006.7

     More details

    Language:Japanese   Publisher:(一社)日本医学教育学会  

    Ichushi

    researchmap

  • パクリタキセルを用いた進行膵管癌に対する化学放射線療法の治療成績

    堀 正和, 小井戸 一光, 廣川 直樹, 佐藤 大志, 西田 睦, 永倉 久泰, 染谷 正則, 大内 敦, 坂田 耕一, 晴山 雅人

    膵臓   21 ( 3 )   267 - 267   2006.6

     More details

    Language:Japanese   Publisher:日本膵臓学会  

    Ichushi

    researchmap

  • 超音波生体作用の治療への応用 現状と展望 家兎VX2皮下腫瘍に対するマイクロバブル併用下HIFU

    廣川 直樹, 小井戸 一光, 堀 正和, 佐藤 大志, 河合 有里子, 染谷 正則, 兵頭 秀樹, 晴山 雅人, 西田 睦

    超音波医学   33 ( Suppl. )   S238 - S238   2006.4

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    Ichushi

    researchmap

  • DNA arrayを用いたDNA-PK活性に影響する蛋白の解析

    坂田 耕一, 染谷 正則, 晴山 雅人

    日本医学放射線学会学術集会抄録集   65回   S172 - S172   2006.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • THE CAREER PATHS OF PARTICIPANTS IN A RADIATION ONCOLOGY SEMINAR FOR MEDICAL DOCTOR CANDIDATES FROM 1995 TO 2002

    ITAZAWA Tomoko, UCHINO Minako, IMAGUMBAI Toshiyuki, SOMEYA Masanori, BITO Seiji

    17 ( 4 )   215 - 219   2006.1

     More details

    Language:Japanese  

    researchmap

  • 「医学生・研修医のための放射線治療セミナー」参加者における放射線腫瘍学の知識と経験 小テストの試みとセミナーの今後のあり方

    内野 三菜子, 板澤 朋子, 染谷 正則, 今葷倍 敏行, 尾藤 誠司

    日本放射線腫瘍学会誌   17 ( 4 )   207 - 213   2006.1

  • 造影超音波による膵管癌血流の定量的評価

    西田 睦, 小井戸 一光, 廣川 直樹, 堀 正和, 佐藤 大志, 河井 有里子, 染谷 正則, 庄内 孝春, 兵頭 秀樹, 晴山 雅人, 中島 康博

    超音波医学   33 ( 1 )   92 - 92   2006.1

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    Ichushi

    researchmap

  • 「医学生のための放射線治療セミナー」参加者のキャリアパス

    板澤 朋子, 今葷倍 敏行, 内野 三菜子, 染谷 正則

    日本放射線腫瘍学会誌   17 ( Suppl.1 )   92 - 92   2005.10

     More details

    Language:Japanese   Publisher:(公社)日本放射線腫瘍学会  

    Ichushi

    J-GLOBAL

    researchmap

  • 経過観察中に膵管癌発見の契機となった超音波所見の検討

    西田 睦, 小井戸 一光, 廣川 直樹, 佐藤 大志, 河合 有里子, 染谷 正則, 庄内 孝春, 山 直也, 兵頭 秀樹, 晴山 雅人, 白石 祐子, 新山 智美, 木村 もと子, 今井 希一

    超音波医学   32 ( 5 )   479 - 479   2005.9

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    Ichushi

    researchmap

  • 「医学生のための放射線治療セミナー」参加者のキャリアパス

    内野 三菜子, 板澤 朋子, 今葷倍 敏行, 染谷 正則, 尾藤 誠司

    医学教育   36 ( Suppl. )   53 - 53   2005.7

     More details

    Language:Japanese   Publisher:(一社)日本医学教育学会  

    Ichushi

    J-GLOBAL

    researchmap

  • ヒト末梢血リンパ球のDNA-PK活性と染色体不安定性および癌罹患リスクとの関係について

    染谷 正則, 坂田 耕一, 永倉 久泰, 晴山 雅人

    頭頸部癌   31 ( 2 )   270 - 270   2005.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    Ichushi

    researchmap

  • 【前立腺癌に対する治療戦略 治療法による棲み分けは可能か?】原体照射法による初期治療成績

    大内 敦, 中田 健生, 荒谷 和紀, 堀 正和, 土本 正, 染谷 正則, 永倉 久泰, 坂田 耕一, 晴山 雅人, 舛森 直哉, 塚本 泰司

    臨床放射線   50 ( 5 )   633 - 637   2005.5

     More details

    Language:Japanese   Publisher:金原出版(株)  

    Ichushi

    researchmap

  • 造影超音波による化学放射線療法の治療効果判定に関する検討

    佐藤 大志, 小井戸 一光, 西田 睦, 廣川 直樹, 河合 有里子, 染谷 正則, 庄内 孝春, 山 直也, 兵頭 秀樹

    超音波医学   32 ( Suppl. )   S179 - S179   2005.4

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    Ichushi

    researchmap

  • 集束超音波によるラット肝癌の治療効果およびアポトーシスの検討

    廣川 直樹, 小井戸 一光, 西田 睦, 佐藤 大志, 河合 有里子, 染谷 正則, 庄内 孝春, 山 直也, 兵頭 秀樹, 工藤 信樹, 山本 克之, 晴山 雅人

    超音波医学   32 ( Suppl. )   S242 - S242   2005.4

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    Ichushi

    researchmap

  • DD-723を用いた造影超音波による肝腫瘍の存在診断能の検討

    西田 睦, 小井戸 一光, 廣川 直樹, 佐藤 大志, 河合 有里子, 染谷 正則, 庄内 孝春, 山 直也, 兵頭 秀樹, 晴山 雅人

    超音波医学   32 ( Suppl. )   S192 - S192   2005.4

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    Ichushi

    researchmap

  • APLIOにおける375ATと375BTプローブの造影能の比較

    廣川 直樹, 小井戸 一光, 佐藤 大志, 河合 有里子, 中田 健生, 染谷 正則, 兵頭 秀樹, 晴山 雅人, 西田 睦, 市村 健, 嶺 喜隆

    超音波医学   32 ( 2 )   201 - 201   2005.3

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    Ichushi

    researchmap

  • 造影エコーによるUAE治療効果判定

    佐藤 大志, 小井戸 一光, 廣川 直樹, 西田 睦, 山 直也, 染谷 正則, 兵頭 秀樹, 晴山 雅人

    超音波医学   32 ( 2 )   203 - 203   2005.3

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    Ichushi

    researchmap

  • 肝・胆・膵領域におけるdifferential Tissue Harmonic Imagingの有用性の検討

    西田 睦, 小井戸 一光, 廣川 直樹, 佐藤 大志, 河合 有里子, 染谷 正則, 庄内 孝春, 中田 健生, 山 直也, 兵頭 秀樹, 晴山 雅人, 市村 健, 川岸 哲也

    超音波医学   32 ( 2 )   201 - 201   2005.3

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    Ichushi

    researchmap

  • 微小電極を用いた子宮頸癌の酸素分圧測定と低酸素マーカーの発現

    坂田 耕一, 染谷 正則, 永倉 久泰, 大内 敦, 中田 健生, 晴山 雅人

    日本医学放射線学会学術集会抄録集   64回   S175 - S175   2005.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 「医学生のための放射線治療セミナー」参加者のキャリアパス

    板澤 朋子, 内野 三菜子, 今葷倍 敏行, 染谷 正則, 尾藤 誠司

    日本医学放射線学会学術集会抄録集   64回   S345 - S345   2005.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 造影超音波検査による進行膵管癌の治療効果判定 CD34抗体による免疫染色との対比検討

    西田 睦, 小井戸 一光, 市村 健, 廣川 直樹, 中田 健生, 染谷 正則, 庄内 孝春, 山 直也, 兵頭 秀樹, 晴山 雅人, 木村 幸子, 佐藤 昌昭, 大谷 静治

    超音波医学   32 ( 1 )   23 - 23   2005.1

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    Ichushi

    researchmap

  • 自己免疫性膵炎の治療効果と増悪の判定に造影超音波が有用であった一例

    小井戸 一光, 市村 健, 廣川 直樹, 西田 睦, 河合 有里子, 染谷 正則, 庄内 孝春, 中田 健生, 山 直也, 兵頭 秀樹

    超音波医学   32 ( 1 )   33 - 33   2005.1

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    Ichushi

    researchmap

  • 頸部リンパ節良悪性鑑別のための新しい造影エコー法Micro Flow Imaging

    小井戸 一光, 西田 睦, 市村 健, 廣川 直樹, 河合 有里子, 染谷 正則, 庄内 孝春, 中田 健生, 山 直也, 兵頭 秀樹

    超音波医学   32 ( 1 )   32 - 32   2005.1

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    Ichushi

    researchmap

  • 腔内照射を併用した化学放射線療法(第2報)

    永倉 久泰, 中田 健生, 染谷 正則, 大内 敦, 阪田 耕一, 晴山 雅人, 高山 哲治, 新津 洋司郎

    北海道外科雑誌   49 ( 2 )   216 - 216   2004.12

     More details

    Language:Japanese   Publisher:北海道外科学会  

    Ichushi

    researchmap

  • 子宮頸癌化学放射線療法の合併症

    永倉 久泰, 中田 健生, 染谷 正則, 大内 敦, 坂田 耕一, 晴山 雅人

    日本医学放射線学会雑誌   64 ( 8 )   576 - 576   2004.11

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 前立腺がんに対する治療戦略 治療法による棲み分けは可能か 原体照射法による初期治療成績

    大内 敦, 中田 健生, 荒谷 和紀, 染谷 正則, 永倉 久泰, 坂田 耕一, 晴山 雅人

    日本放射線腫瘍学会誌   16 ( Suppl.1 )   82 - 82   2004.10

     More details

    Language:Japanese   Publisher:(公社)日本放射線腫瘍学会  

    Ichushi

    researchmap

  • 「医学生のための放射線治療セミナー」参加者のキャリアパス

    板澤 朋子, 今葷倍 敏行, 内野 三菜子, 染谷 正則

    日本放射線腫瘍学会誌   16 ( Suppl.1 )   174 - 174   2004.10

     More details

    Language:Japanese   Publisher:(公社)日本放射線腫瘍学会  

    Ichushi

    researchmap

  • 中咽頭癌の治療戦略(放射線治療の立場から)

    坂田 耕一, 晴山 雅人, 染谷 正則, 永倉 久泰, 大内 敦, 浅野 勝士, 大黒 慎二

    頭頸部癌   30 ( 3 )   419 - 422   2004.10

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    Ichushi

    researchmap

  • 頸部リンパ節微細血管描出のための新しい造影US法

    西田 睦, 小井戸 一光, 市村 健, 廣川 直樹, 河合 有里子, 染谷 正則, 庄内 孝春, 中田 健生, 山 直也, 神山 直久

    超音波医学   31 ( 5 )   J347 - J353   2004.9

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    Ichushi

    researchmap

  • 当院でのケロイドの術後照射

    永倉 久泰, 中田 健生, 大内 敦, 染谷 正則, 坂田 耕一, 晴山 雅人, 藤田 龍哉

    日本医学放射線学会雑誌   64 ( 4 )   265 - 265   2004.5

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 頸部リンパ節微細血管構築描出のための新しい造影エコー法

    西田 睦, 小井戸 一光, 市村 健, 廣川 直樹, 河合 有里子, 染谷 正則, 庄内 孝春, 中田 健生, 山 直也, 兵頭 秀樹, 晴山 雅人, 中屋 重光, 神山 直久

    超音波医学   31 ( Suppl. )   S96 - S96   2004.4

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    Ichushi

    researchmap

  • 造影超音波による肝良性結節の診断

    河合 有里子, 西田 睦, 小井戸 一光, 市村 健, 廣川 直樹, 兵頭 秀樹, 庄内 孝春, 染谷 正則, 中田 健生

    超音波医学   31 ( Suppl. )   S257 - S257   2004.4

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    Ichushi

    researchmap

  • MMP9の発現は,非ホジキンリンパ腫の予後因子である

    坂田 耕一, 大内 敦, 永倉 久泰, 染谷 正則, 中田 健生, 伊藤 克哉, 志藤 光男, 晴山 雅人

    日本医学放射線学会雑誌   64 ( 2 )   S261 - S261   2004.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 食道癌化学放射線療法における腔内照射併用例と非併用例との比較

    永倉 久泰, 染谷 正則, 中田 健生, 大内 敦, 坂田 耕一, 晴山 雅人

    日本医学放射線学会雑誌   63 ( 9 )   604 - 604   2003.11

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 睾丸原発悪性リンパ腫の治療

    御供 麻希, 染谷 正則, 坂田 耕一, 大内 敦, 永倉 久泰, 中田 健生, 晴山 雅人

    日本医学放射線学会雑誌   63 ( 9 )   608 - 608   2003.11

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 胃亜全摘後に生じた胃空腸横行結腸瘻の1例

    高木 克, 中田 健生, 大内 敦, 玉川 光春, 永倉 久泰, 染谷 正則, 晴山 雅人

    日本医学放射線学会雑誌   63 ( 9 )   600 - 600   2003.11

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 舌根部腫瘍に対する低線量率組織内照射

    荒谷 和紀, 永倉 久泰, 中田 健生, 染谷 正則, 大内 敦, 坂田 耕一, 晴山 雅人, 池田 光, 小柴 隆蔵

    日本医学放射線学会雑誌   63 ( 9 )   607 - 607   2003.11

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 放射線化学療法により著明な腫瘍縮小効果を認めたStage IVb膵癌の1例

    小島 一男, 小井戸 一光, 廣川 直樹, 市村 健, 宇佐見 陽子, 中田 健生, 染谷 正則, 永倉 久泰, 大内 敦, 坂田 耕一, 晴山 雅人

    日本医学放射線学会雑誌   63 ( 9 )   600 - 600   2003.11

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • ケロイドの放射線治療

    中田 健生, 染谷 正則, 永倉 久泰, 大内 敦, 坂田 耕一, 晴山 雅人

    日本放射線腫瘍学会誌   15 ( Suppl.1 )   118 - 118   2003.10

     More details

    Language:Japanese   Publisher:(公社)日本放射線腫瘍学会  

    Ichushi

    researchmap

  • 鼻性T細胞リンパ腫におけるMMP9の発現

    坂田 耕一, 大内 敦, 永倉 久泰, 染谷 正則, 中田 健生, 伊藤 克哉, 志藤 光男, 晴山 雅人

    日本放射線腫瘍学会誌   15 ( Suppl.1 )   79 - 79   2003.10

     More details

    Language:Japanese   Publisher:(公社)日本放射線腫瘍学会  

    Ichushi

    researchmap

  • 低線量率腔内照射を併用した食道癌化学放射線療法

    永倉 久泰, 染谷 正則, 中田 健生, 大内 敦, 坂田 耕一, 晴山 雅人

    日本放射線腫瘍学会誌   15 ( Suppl.1 )   139 - 139   2003.10

     More details

    Language:Japanese   Publisher:(公社)日本放射線腫瘍学会  

    Ichushi

    researchmap

  • 子宮頸癌HDR-RALS治療における直腸線量実測による線量評価

    坂田 耕一, 大内 敦, 永倉 久泰, 染谷 正則, 中田 健生, 晴山 雅人

    日本放射線腫瘍学会誌   15 ( 3 )   233 - 233   2003.9

     More details

    Language:Japanese   Publisher:(公社)日本放射線腫瘍学会  

    Ichushi

    researchmap

  • ワークフロートコントロールシステムを用いた腹部造影超音波検査

    市村 健, 小井戸 一光, 廣川 直樹, 西田 睦, 中田 健生, 染谷 正則, 庄内 孝春, 山 直也, 兵頭 秀樹, 晴山 雅人, 佐野 明洋, 神山 直久, 小笠原 洋一

    超音波医学   30 ( 4 )   J566 - J567   2003.7

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    Ichushi

    researchmap

  • 退形成性膵管癌の1例

    小島 一男, 小井戸 一光, 市村 健, 廣川 直樹, 西田 睦, 中田 健生, 染谷 正則, 庄内 孝春, 山 直也, 兵頭 秀樹, 晴山 雅人, 木村 弘通, 山 光進

    超音波医学   30 ( 4 )   J571 - J571   2003.7

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    Ichushi

    researchmap

  • 造影超音波による進行性膵癌の治療効果判定

    西田 睦, 小井戸 一光, 市村 健, 廣川 直樹, 中田 健生, 染谷 正則, 庄内 孝春, 山 直也, 兵頭 秀樹, 大谷 静治, 木村 幸子, 佐藤 昌明

    膵臓   18 ( 3 )   436 - 436   2003.6

     More details

    Language:Japanese   Publisher:日本膵臓学会  

    Ichushi

    researchmap

  • Ki-67,MVDを用いた舌癌組織内照射の治療成績の分析

    坂田 耕一, 伊藤 克哉, 永倉 久泰, 大内 敦, 染谷 正則, 中田 健生, 晴山 雅人, 氷見 徹夫

    頭頸部腫瘍   29 ( 2 )   315 - 315   2003.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    Ichushi

    researchmap

  • 造影超音波による原発性肝癌門脈腫瘍栓の治療効果判定

    西田 睦, 小井戸 一光, 市村 健, 廣川 直樹, 中田 健生, 染谷 正則, 庄内 孝春, 山 直也, 兵頭 秀樹

    超音波医学   30 ( Suppl. )   S361 - S361   2003.4

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    Ichushi

    researchmap

  • 造影超音波による進行膵癌の化学放射線療法前後の治療効果判定

    市村 健, 小井戸 一光, 廣川 直樹, 西田 睦, 中田 健生, 染谷 正則, 庄内 孝春, 山 直也, 兵頭 秀樹

    超音波医学   30 ( Suppl. )   S296 - S296   2003.4

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    Ichushi

    researchmap

  • 3D造影超音波検査(3D-EU)を用いた肝腫瘍の非手術的治療効果判定

    市村 健, 小井戸 一光, 廣川 直樹, 中田 健生, 染谷 正則, 庄内 孝春, 山 直也, 兵頭 秀樹, 西田 睦

    超音波医学   30 ( 2 )   J236 - J237   2003.3

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    Ichushi

    researchmap

  • 造影超音波検査による進行膵管癌の化学放射線療法の治療効果判定

    西田 睦, 小井戸 一光, 市村 健, 廣川 直樹, 中田 健生, 染谷 正則, 庄内 孝春, 山 直也, 兵頭 秀樹, 晴山 雅人

    超音波医学   30 ( 2 )   J238 - J238   2003.3

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    Ichushi

    researchmap

  • 【癌の骨転移】治療 骨転移に対する放射線治療

    晴山 雅人, 中田 健生, 坂田 耕一, 大内 敦, 伊藤 克也, 永倉 久泰, 染谷 正則, 市村 健, 廣川 直樹, 佐藤 大志

    THE BONE   17 ( 2 )   189 - 194   2003.3

  • Ki-67,MVDを用いた舌癌組織内照射の治療成績の分析

    坂田 耕一, 伊藤 克哉, 大内 敦, 永倉 久泰, 染谷 正則, 中田 健生, 志藤 光男, 晴山 雅人

    日本医学放射線学会雑誌   63 ( 2 )   S120 - S121   2003.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 腔内照射を併用した化学放射線療法

    永倉 久泰, 中田 健夫, 染谷 正則, 大内 敦, 坂田 耕一, 晴山 雅人, 高山 哲治, 遠藤 高夫

    北海道外科雑誌   47 ( 2 )   99 - 99   2002.12

     More details

    Language:Japanese   Publisher:北海道外科学会  

    Ichushi

    researchmap

  • N2梨状陥凹癌に対する治療戦略 下咽頭癌治療法の検討-N2梨状陥凹癌の治療戦略

    晴山 雅人, 中田 健生, 大内 敦, 坂田 耕一, 永倉 久泰, 染谷 正則, 氷見 徹夫, 西尾 正道, 明神 美弥子, 朝倉 光司

    頭頸部腫瘍   28 ( 3 )   547 - 551   2002.11

  • 腔内照射を併用した食道癌化学放射線療法

    永倉 久泰, 中田 健生, 染谷 正則, 大内 敦, 坂田 耕一, 晴山 雅人

    日本医学放射線学会雑誌   62 ( 12 )   715 - 715   2002.10

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 3-D超音波が癌の進展度診断に有用であった,胆嚢管癌と膵癌の2例

    土本 正, 小井戸 一光, 市村 健, 廣川 直樹, 染谷 正則, 庄内 孝春, 山 直也, 兵頭 秀樹, 河合 有里子, 晴山 雅人

    超音波医学   29 ( 4 )   J401 - J401   2002.7

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    Ichushi

    researchmap

  • 造影超音波検査による肝腫瘍の鑑別診断 CT,CTAとの対比

    小井戸 一光, 市村 健, 廣川 直樹, 土本 正, 染谷 正則, 庄内 孝春, 山 直也, 兵頭 秀樹, 河合 有里子, 晴山 雅人

    超音波医学   29 ( 4 )   J400 - J400   2002.7

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    Ichushi

    researchmap

  • 当院における前立腺癌放射線治療の検討

    中田 健生, 染谷 正則, 永倉 久泰, 大内 敦, 坂田 耕一, 晴山 雅人

    日本医学放射線学会雑誌   62 ( 6 )   302 - 302   2002.5

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • N2梨状陥凹癌に対する治療戦略 下咽頭癌治療法の検討

    晴山 雅人, 中田 健生, 大内 敦, 坂田 耕一, 永倉 久泰, 染谷 正則, 氷見 徹夫, 朝倉 光司

    頭頸部腫瘍   28 ( 2 )   354 - 354   2002.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    Ichushi

    researchmap

  • Dynamic flowを用いた肝腫瘍に対する非手術的治療の効果判定

    市村 健, 小井戸 一光, 廣川 直樹, 河合 有里子, 中田 健生, 庄内 孝春, 染谷 正則, 山 直也, 兵頭 秀樹, 佐藤 武史

    超音波医学   29 ( Suppl. )   S375 - S375   2002.5

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    Ichushi

    researchmap

  • 腟壁浸潤を伴う子宮頸癌に対する腔内照射

    永倉 久泰, 中田 健生, 染谷 正則, 大内 敦, 坂田 耕一, 晴山 雅人

    日本医学放射線学会雑誌   62 ( 6 )   302 - 302   2002.5

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 当院におけるIMRTの問題点

    大内 敦, 舘岡 邦彦, 中田 健生, 染谷 正則, 永倉 久泰, 坂田 耕一, 晴山 雅人

    日本医学放射線学会雑誌   62 ( 3 )   S257 - S257   2002.3

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 子宮頸癌HDR-RALS治療における直腸線量実測による線量評価

    坂田 耕一, 大内 敦, 永倉 久泰, 染谷 正則, 中田 健生, 晴山 雅人

    日本医学放射線学会雑誌   62 ( 3 )   S181 - S181   2002.3

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 経静脈性造影超音波が肝癌の経皮的マイクロウェーブ凝固療法の治療効果判定に有用であった1例

    廣川 直樹, 小井戸 一光, 中田 健生, 市村 健, 染谷 正則, 庄内 孝春, 山 直也, 兵頭 秀樹

    超音波医学   29 ( 1 )   J17 - J21   2002.1

     More details

    Language:Japanese   Publisher:(公社)日本超音波医学会  

    Ichushi

    researchmap

  • 食道腔内照射におけるチューブ式アプリケーターと食道粘膜との密着度

    永倉 久泰, 染谷 正則, 伊藤 克哉, 中田 健生, 大内 敦, 坂田 耕一, 晴山 雅人

    日本医学放射線学会雑誌   62 ( 1 )   44 - 45   2002.1

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

    Ichushi

    researchmap

  • 頭頸部癌の機能温存療法の現状と将来 喉頭癌の機能温存療法の現状と将来 放射線治療の立場から

    坂田 耕一, 晴山 雅人, 染谷 正則, 永倉 久泰, 大内 敦, 氷見 徹夫

    頭頸部腫瘍   27 ( 3 )   635 - 638   2001.11

  • IMRTに関するの出力補正の検討

    舘岡 邦彦, 大内 敦, 中田 健生, 染谷 正則, 永倉 久泰, 坂田 耕一, 晴山 雅人

    日本放射線腫瘍学会誌   13 ( Suppl.1 )   114 - 114   2001.10

     More details

    Language:Japanese   Publisher:(公社)日本放射線腫瘍学会  

    Ichushi

    researchmap

  • IMRTのQAにおける問題点

    大内 敦, 舘岡 邦彦, 中田 健生, 染谷 正則, 永倉 久泰, 坂田 耕一, 晴山 雅人

    日本放射線腫瘍学会誌   13 ( Suppl.1 )   114 - 114   2001.10

     More details

    Language:Japanese   Publisher:(公社)日本放射線腫瘍学会  

    Ichushi

    researchmap

  • DNA2重鎖切断修復に関わる遺伝子の放射線感受性の異なる腫瘍における発現

    坂田 耕一, 染谷 正則, 永倉 久泰, 大内 敦, 晴山 雅人, 鈴木 紀夫

    日本放射線腫瘍学会誌   13 ( Suppl.1 )   86 - 86   2001.10

     More details

    Language:Japanese   Publisher:(公社)日本放射線腫瘍学会  

    Ichushi

    researchmap

  • 経静脈性造影超音波検査による膵管癌と腫瘤形成性膵炎の鑑別

    廣川 直樹, 小井戸 一光, 中田 健生, 庄内 孝春, 染谷 正則, 晴山 雅人, 市村 健

    膵臓   16 ( 3 )   317 - 317   2001.6

     More details

    Language:Japanese   Publisher:日本膵臓学会  

    Ichushi

    researchmap

  • Pancreas: imaging diagnosis with color/power Doppler ultrasonography, endoscopic ultrasonography, and intraductal ultrasonography

    K Koito, T Namieno, T Nagakawa, N Hirokawa, T Ichimura, T Syonai, N Yama, M Someya, K Nakata, K Sakata, M Hareyama

    EUROPEAN JOURNAL OF RADIOLOGY   38 ( 2 )   94 - 104   2001.5

     More details

  • 頭頸部腫瘍領域における静止画及び動画の安価な電子保存システムの構築

    永倉 久泰, 染谷 正則, 大内 敦, 坂田 耕一, 晴山 雅人, 平尾 元康, 氷見 徹夫

    頭頸部腫瘍   27 ( 2 )   365 - 365   2001.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    Ichushi

    researchmap

  • 頭頸部癌の機能温存療法の現状と将来 喉頭癌の機能温存療法の現状と将来(放射線治療の立場から)

    坂田 耕一, 大内 敦, 永倉 久泰, 染谷 正則, 晴山 雅人, 氷見 徹夫

    頭頸部腫瘍   27 ( 2 )   306 - 306   2001.5

     More details

    Language:Japanese   Publisher:(一社)日本頭頸部癌学会  

    Ichushi

    researchmap

  • 頭頸部癌の標準的治療:何を求めて,どの科が治療する 頭頸部癌の放射線治療

    坂田 耕一, 大内 敦, 永倉 久泰, 染谷 正則, 晴山 雅人

    日本外科系連合学会誌   26 ( 3 )   448 - 448   2001.5

     More details

    Language:Japanese   Publisher:日本外科系連合学会  

    Ichushi

    researchmap

  • Intra-venous Contrast Enhanced Ultrasonography for the Treated Liver Tumors : Comparison With enhanced CT, CT-angiography, and Enhanced MR Imaging

    HIROKAWA N., KOITO K., ICHIMURA T., SHOUNAI T., SOMEYA M., NAKATA K., SATOH T., KAWAI Y.

    28 ( 3 )   J479   2001.4

     More details

    Language:Japanese  

    researchmap

  • Effect of intravenous contrast-enhanced US for hepatic tumors : Comparison with CT/CTA or CO2 contrast-enhanced US

    ICHIMURA T., KOITO K., HIROKAWA N., SHONAI T., SOMEYA M., NAKATA K., HAREYAMA M.

    28 ( 3 )   J492   2001.4

     More details

    Language:Japanese  

    researchmap

  • Percutaneus Ethanol Injection Therapy and/or Percutaneus Microwave Coagulation Therapy under guidance with CO2 Contrast Enhanced Ultrasonography: As a treatment for liver tumors undetected by non-enhanced US.

    HIROKAWA N., KOITO K., ICHIMURA T., SHOUNAI T., SOMEYA M.

    27 ( 4 )   536 - 536   2000.4

     More details

    Language:Japanese  

    researchmap

  • Effect of contrast-enhanced US with intravenous contrast agent (Levovist^R) for hepatic tumors

    ICHIMURA T., KOITO K., HIROKAWA N., SHONAI T., SOMEYA M.

    27 ( 4 )   526 - 526   2000.4

     More details

    Language:Japanese  

    researchmap

  • 進行食道癌に対する化学療法併用放射線治療後に出現した難治性出血性胃炎の1例

    染谷正則

    道南医学会誌   34   352 - 355   1999

     More details

▼display all

Presentations

  • 膵癌における放射線治療の役割:ガイドライン改訂活動から

    染谷 正則

    第71回北日本放射線腫瘍学研究会  2024.10 

     More details

    Event date: 2024.10

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • Relationship between tumor immunity and radiotherapy effects in HPV associated cancer. Invited

    Masanori Someya

    2020.10 

     More details

    Event date: 2020.10

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    researchmap

  • HPV関連癌における腫瘍免疫と放射線治療効果との関係 Invited

    染谷 正則

    第33回日本放射線腫瘍学会学術大会  2020.10 

     More details

    Event date: 2020.10

    Language:English   Presentation type:Symposium, workshop panel (nominated)  

    researchmap

  • 肺癌に対する放射線治療 Invited

    染谷 正則

    日本肺癌学会 市民公開講座  2021.9 

     More details

    Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    researchmap

  • Relationship between tumor immunity and radiotherapy effects in HPV associated cancer. Invited

    Masanori Someya

    2020.10 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    researchmap

  • 放射線治療の最近の話題 Invited

    日本癌治療学会第25回アップデート教育コース  2023.5 

     More details

    Language:Japanese  

    researchmap

  • リキッドバイオプシーを用いた放射線治療効果予測と腫瘍免疫微小環境の非侵襲的なモニタリング Invited

    染谷 正則、土屋 高旭、⻑谷川 智一、福島 悠希、北川 未央、小塚 陽、井戶川 雅史、廣橋 良彦、鳥越 俊彦、坂田 耕一

    第50回放射線による制癌シンポジウム  2022.6 

     More details

    Language:Japanese   Presentation type:Symposium, workshop panel (nominated)  

    researchmap

  • 腫瘍免疫と放射線治療 Invited

    染谷 正則

    高知大学がんプロ生物セミナー  2024.6 

     More details

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    researchmap

  • がん免疫と放射線治療 Invited

    染谷 正則

    第14回日本放射線腫瘍学会生物セミナー  2024.3 

     More details

    Language:Japanese   Presentation type:Public lecture, seminar, tutorial, course, or other speech  

    researchmap

  • 腫瘍免疫と放射線治療の関連 Invited

    染谷 正則

    第10回道南放射線治療研究会  2024.11 

     More details

  • 個別化放射線治療を目指した、リンパ球 RNA 発現解析による有害事象予測 Invited

    染谷正則

    札幌冬季がんセミナー  2017.1 

     More details

▼display all

Awards

  • 生物部会賞受賞

    2016.7   第54回JASTRO生物部会学術大会   前立腺癌放射線治療患者のリンパ細胞を用いた急性期有害事象予測

     More details

  • 放射線影響研究奨励賞受賞

    2009.10   放射線影響協会   DNA二重鎖切断修復酵素と放射線感受性および癌罹患リスクに関する研究

     More details

Research Projects

  • リアルタイム免疫監視放射線治療の実用化を目指した基礎研究

    Grant number:24K10913  2024.4 - 2027.3

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    染谷 正則

      More details

    Grant amount:\4680000 ( Direct Cost: \3600000 、 Indirect Cost:\1080000 )

    researchmap

  • 腫瘍免疫のリアルタイムモニタリングによる個別化放射線治療の確立

    Grant number:23K07161  2023.4 - 2026.3

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    土屋 高旭、染谷 正則

      More details

    Grant amount:\4420000 ( Direct Cost: \3400000 、 Indirect Cost:\1020000 )

    researchmap

  • Practical application of individualized radiotherapy using liquid biopsy

    Grant number:21K07680  2021.4 - 2024.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

      More details

    Grant amount:\4160000 ( Direct Cost: \3200000 、 Indirect Cost:\960000 )

    researchmap

  • 放射線治療に関わるトランスレーショナルリサーチ実施体制構築

    2021.4 - 2024.3

    国立がん研究センター  国立がん研究センター研究開発費 

      More details

    Authorship:Coinvestigator(s) 

    researchmap

  • IMRTを利用した頭髪温存全脳照射

    Grant number:20K08144  2020.4 - 2025.3

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    斉藤 アンネ優子, 大西 洋, 野澤 桂子, 染谷 正則

      More details

    Grant amount:\4420000 ( Direct Cost: \3400000 、 Indirect Cost:\1020000 )

    前半の全脳照射後の頭髪の状況の多施設共同観察研究が進行中である。5施設から、合計44例の登録をいただいた。現状は、頭皮の評価は行わず、症例集積の状況である。
    症例集積が予定より遅い理由として、 COVIDの影響ももちろんあるが、適格条件が厳しすぎること、全脳照射後、頭皮の撮影のために来院する回数が多く、条件を満たせないため参加を躊躇するケースも多いことなどが挙げられ、zoomで3回の会議を行い、照射線量の縛りを外すことで適格条件をゆるめること、また、通院回数は同じままで、ただし、すべての通院を義務化するわけではなく、患者さんが可能な範囲で通院していただく状況に、条件をゆるめた。
    また、当初、80例集積としたが、これは、全脳照射の患者の全身状態が悪いことを踏まえ、半数が脱落することを想定した数である。今までの症例を確認すると脱毛のピークはほとんどの症例で8週目あたりであり、8週目までの経過観察が行えた症例を評価可能と判定することとした。研究実施期間の猶予が少ないことを考えると、当初の予定どおり愚直に80例を蓄積するのではなく、評価可能例が40例になった段階で、次の研究に進む方針へ変更することが得策と思われた。
    これを踏まえて研究実施計画書を書き直し、順天堂浦安病院の倫理委員会に提出した。また、IMRTを利用した頭皮温存についても、実施計画書の作成を開始した。

    researchmap

  • Application of Liquid Biopsy for Personalized Radiation Therapy

    Grant number:18K07760  2018.4 - 2021.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    Someya Masanori

      More details

    Grant amount:\4420000 ( Direct Cost: \3400000 、 Indirect Cost:\1020000 )

    In order to realize "personalized radiotherapy", we used a technique called "liquid biopsy" to examine the nucleic acids and proteins of tumor-derived exosomes in plasma, and applied it to the prediction of radiosensitivity of cancer. Blood samples were collected from a total of 150 patients with cervical, rectal, anal and pancreatic cancers treated with abdominal to pelvic radiotherapy, and plasma and lymphocyte samples were isolated. DNA-PK activity of lymphocytes and radiation-induced gamma H2AX focus was measured, and exosomal microRNA expression analysis in plasma was performed. Based on the results of the treatment outcome and adverse event surveys for each cancer and the results of lymphocyte DNA-PK activity and radiation-induced gamma-H2AX focus measurements, we showed that exosomal microRNAs in plasma are useful for predicting the effects of radiotherapy and that lymphocyte DNA-PK activity may be useful for predicting late adverse events after radiotherapy.

    researchmap

  • Prediction of local tumor control and acute radiation toxicity in pelvic cancer patients using lymphocyte biomarker.

    Grant number:15K10001  2015.4 - 2018.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    Someya Masanori

      More details

    Grant amount:\4810000 ( Direct Cost: \3700000 、 Indirect Cost:\1110000 )

    To predict individual treatment effects and acute toxicity of patients who underwent pelvic radiation therapy, blood lymphocytes were collected from 141 patients who underwent definitive radiation therapy for non metastatic prostate cancer at our hospital, we measured the DNA-dependent protein kinase (DNA-PK) activity, which is considered to be involved in DNA damage repair, and the expression analysis of microRNA-410, 221 and 99a. As a result, we showed that the DNA-PK activity of lymphocytes was a significant predictor of biochemical relapse in prostate cancer patients and that a combination of miRNA-410 and 221 predicted acute gastrointestinal toxicities with higher accuracy than conventional dose-volume histogram analysis.

    researchmap

  • 腹部・骨盤部悪性腫瘍に対する、個別化放射線治療の研究

    2015.4 - 2016.4

    公益信託小野がん研究助成基金 

      More details

    Authorship:Principal investigator 

    researchmap

  • Prediction of late rectal bleeding treated with radiotherapy for prostate cancer using biochemical marker.

    Grant number:24591846  2012.4 - 2015.3

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    SOMEYA Masanori

      More details

    Grant amount:\5330000 ( Direct Cost: \4100000 、 Indirect Cost:\1230000 )

    To predict individual radiosensitivity of normal tissue, we collected and analysed the expressions of Ku80 mRNA and radiation-induced microRNA-99a in peripheral blood lymphocytes treated with radiotherapy for prostate cancer. Peripheral blood lymphocytes were collected from 97 prostate cancer patients with at least 3 year of follow-up after radiotherapy. As a result, a combination of low Ku80 mRNA expression and highly-induced microRNA-99a could precisely detect grade 2 or more of radiation-induced late rectal bleeding. In conclusion, a combination of low Ku80 expression and highly-induced microRNA-99a expression could be a promising marker for predicting rectal bleeding after radiotherapy.

    researchmap

  • Analysis of molecular targeting radiosensitization using DPYD depletion

    Grant number:22791207  2010 - 2011

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Young Scientists (B)

    SOMEYA Masanori

      More details

    Grant amount:\3900000 ( Direct Cost: \3000000 、 Indirect Cost:\900000 )

    Gimeracil, an inhibitor of dihydropyrimidine dehydrogenase(DPYD), partially inhibits homologous recombination(HR) repair and has a radiosensitizing effect. We investigated the mechanisms of sensitization of radiation by DPYD inhibition using DLD-1 cells treated with siRNA for DPYD. DPYD depletion by siRNA significantly restrained the formation of radiation-induced foci of Rad51 and RPA, whereas it increased the number of foci of NBS1. The numbers of colocalization of NBS1 and RPA foci in DPYD-depleted cells after radiation were significantly smaller than in the control cells. The phosphorylation of RPA by irradiation was partially suppressed in DPYD-depleted cells, suggesting that DPYD depletion may partially inhibit DNA repair with HR by suppressing phosphorylation of RPA.

    researchmap

  • Analysis of Molecular mechanisms and radiosensitizing effect of Gimeracil.

    Grant number:20790902  2008 - 2009

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Young Scientists (B)

    MASANORI Someya

      More details

    Grant amount:\4290000 ( Direct Cost: \3300000 、 Indirect Cost:\990000 )

    We analyzed molecular mechanisms of radiosensitizing effect of Gimeracil as a clinically expecting therapeutic drug. By using methods of colony formation assay and radiation-induced foci formation assay, we proved that gimeracil partially inhibits homologous recombination in the DNA double strand break repair mechanism and therefore the radiosensitizing effect can be obtained.

    researchmap

  • DNA二重鎖切断の修復酵素の発現解析による癌罹患リスクの推定法の開発

    Grant number:18710048  2006 - 2007

    日本学術振興会  科学研究費助成事業  若手研究(B)

    染谷 正則

      More details

    Grant amount:\3500000 ( Direct Cost: \3500000 )

    1.乳癌とDNA修復酵素発現の関係を検討
    申請者は,乳癌で乳房温存手術および腋窩リンパ節郭清を行った患者から血液を採取し,末梢リンパ球のDNA-PK(活性およびNBS1フォーカスを測定した所,非浸潤癌に比べて浸潤癌で,またリンパ節転移が陰性例よりも陽性例でDNA-PK活性が低く,フォーカス数が多いことが示された。この事より乳癌罹患リスクの推定だけでなく,発生した癌の臨床的悪性度の予測が可能であり特に腋窩リンパ節郭清を省略できる症例の選別が可能である事を示した。
    (Oncology Reports 2007)
    2.発生する癌の悪性度の推定
    切除された乳癌組織を免疫染色法によってKu70/86タンパクの発現を計測した所,Ku70/86タンパク発現が低いほど組織学的悪性度が高く,腋窩リンパ節転移の要請率が高い傾向にある事が示された。これらの事より,Ku70/86などのDNA修復酵素の発現低下が癌罹患リスクの上昇,発生する癌の組織学的悪性度の上昇に関与している事が示された。
    (Oncology Reports 2007)

    researchmap

▼display all

Other

  • 日本膵臓学会認定指導医

    2023.1

     More details

  • 日本がん治療認定機構 がん治療認定医

    2012.4

     More details

    11100995号

    researchmap

  • Departments of Biochemistry and Molecular Biology and Oncology, University of Calgary

    2009.10

     More details

  • 医学博士取得

    2005.3

     More details

    札幌医科大学 第2272号

    researchmap

  • 日本医学放射線学会 日本放射線腫瘍学会 放射線治療専門医

    2002.8

     More details

    R10194RO

    researchmap

Teaching Experience

  • 放射線治療学

    2022.6 Institution:札幌医科大学医学修士

     More details

  • 放射線物理学

    2020.10 Institution:札幌医科大学医学部医学科

     More details

  • 放射線治療学

    2011.9 Institution:札幌医科大学医学部医学科

     More details